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INTRODUCTION 
Snakebites are a neglected group of diseases in the tropics. There is significant 
variation in geographical distribution of various snake species in India. Hence 
it is essential to be able to identify envenomation syndromes in snakebites 
based on the envenomation pattern, hence making it possible to predict the 
ASV requirements, and expected complications in each syndrome. 
 
Thrombotic Microangiopathy is a phenomenon that has not been well 
described in snake envenomation, and is one of the mechanisms responsible for 
end organ damage in snakebites and implicates serious morbidity and in some 
cases mortality and is grossly under recognized. 
 
Hypothesis and Problem statement 
 
We postulate that thrombotic Microangiopathy is a spectrum ranging from 
isolated thrombocytopenia to thrombocytopenia, schistoytes, MAHA and end 
organ damage.  
In cases where there is a TMA there is a prolonged hospital stay and higher 
degree of morbidity and mortality. 
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AIM AND OBJECTIVES 
Aim 
 
To describe the clinical profile of patients with Thrombotic Microangiopathy in 
snakebites. 
Objectives  
 
1. To find the incidence of TMA spectrum in snake envenomation 
2. To describe the frequency of the TMA spectrum disorder (isolated 
thrombocytopenia, thrombocytopenia with schistocytes, 
microangiopathic hemolytic anemia and HUS/TTP) in syndromes of 
snake envenomation 
3. To describe the relationship between TMA spectrum and Venom 
Induced Consumption Coagulopathy 
4. To describe the clinical course and the outcomes of patients with TMA 
spectrum disorders in snake envenomation  
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REVIEW OF LITERATURE 
 
Snakebites are a major occupational hazard for farmers and daily wage laborers 
in rural India.(1) According to the World Health Organization (WHO) the 
estimated annual mortality which has been attributed to snake bites has been 
projected to be between 35,000 and 50,000 per year; there is likely a gross 
under reporting of snake envenomation, in terms of mortality and late 
presentation to medical facilities. Hence the actual estimated incidence and 
mortality of snakebites may be much higher.(2) 
Therefore snakebites are a major health issue in rural India today, which is 
neglected.   
 
Epidemiology 
According to the WHO, incidence of snakebites worldwide is about 421,00 to 
1,841,000 and mortality is between 20,000 and 94,000 deaths per annum.(3) 
South East Asia is the most heavily affected, which is multifactorial 
(population density, increased farming practices and a large number of 
venomous species of snakes in the regions). 
In India, mortality rates are due to snakebites are the highest in the world, 
estimated to be around 35,000 to 50,000 per anum.(4) In Sri Lanka snakebites 
as a public health problem are of a similar magnitude to India, and studies from 
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these regions have shown that there is a gross misreporting of deaths due to 
snake envenomation.  
Snakebites are an important occupational injury, which affect a multitude of 
workers including farmers, fisherman, herders and plantation workers. Another 
common practice in rural India is open style habitation and sleeping on the 
floor.  
It has been noted that there are spikes of snakebites during rainy seasons and 
during harvesting seasons.(1) There is also increased mortality associated with 
snakebites during natural calamities like floods.  There is a clear male 
preponderance of 2:1, seen most commonly in farmers and bites are usually 
noted on the lower limbs. 
 
Venomous Snakes Species in India  
There are roughly 236 species of snakes in India of which 13 are venomous. In 
India we have the big four, which includes 2 hemotoxic snakes - Russell’s 
viper (Daboia russelii) and Saw scaled Viper (Echis carinatus) and 2 
neurotoxic snakes – Krait (Bangareus caeruleus) and the Indian Cobra (Naja 
naja).(5) However there is a need to broaden this concept, as there are several 
highly venomous snakes, which are widely distributed and many 
geographically distributions which are relevant. An example of this Hump 
nosed viper (Hypnale hypnale) which is seen commonly in Kerala and the 
Monocellate Cobra (Naja kouthia) which is seen predominantly in the North 
East. Similarly there are several more species of venomous snakes belonging 
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mostly to the Elapidae, Viperidae and other Crotalinae, sea snakes (rarely seen 
in India, but few reported cases in coastal regions) all of which we have not 
accounted for with polyvalent ASV.  There is inefficiency of polyvalent Anti 
Snake Venom to neutralize the same.(6)  
 
In a prospective cohort done in Karnataka, which included 76 venomous snake 
bites Saravu et al showed that there was about 73.6% hemotoxic snake bites 
and 19.7% neurotoxic snake bites.(7)  
In retrospective cohort of 200 patients done in Himachal Pradesh, Raina et al 
46% had neurotoxicity and 31% hemotoxicity, hence this shows that in a 
diverse topography like India, it is important to note the difference of 
distribution of envenomation syndromes.(8)  
 
Pathophysiology of Snake Envenomation 
Snake venoms are varied mixture of different proteins and peptides, which vary 
from one species to another and even within species. These toxins are adapted 
to interact with a variety of cellular targets, affecting different organ systems, 
depending on which can cause hemorrhage, disruption of hemostasis, necrosis, 
myolysis, myocarditis, acute kidney injury, neuromuscular paralysis, 
thrombosis and hypovolemic shock.(9) 
The toxic components of venom are classified as enzymes, glycoproteins, 
polypeptides and other compounds with low molecular weight. There are more 
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than 26 different enzymes that are detected in snake venom, 12 of which are 
common to all snake species.  
The different toxins are broadly classified into different components:  
1. Enzymes that clot fibrinogen  
2. Enzymes that degrade fibrinogen  
3. Plasminogen activators  
4. Prothrombin activators  
5. Factor V activators 
6. Factor X activators 
7. Protein C activators 
8. Platelet aggregation inhibitors  
9. Inhibitors of prothrombinase complex, thrombin, phospholipases. (9) 
Different enzymes detected are fibrinogenolytic enzymes, which are of three 
types- alpha/beta/gamma fibrinogenases. Other enzymes include plasminogen 
activator releasers such as Echarin, prothrombin activator, prothrombinase 
complex formation inhibitors such as phosholipase A2, B, C and D, Factor X 
activators, Factor V activators, Factor XI activators, fibrinogenolysin, platelet 
aggregation inducers, either with or without coagulant activity.(10)  
Platelet aggregation inhibitors, such as alpha fibrinogenases or 5-Nucleotidase, 
or ADPase, or fibrinogen receptor antagonists, Von Willebrand factor-
dependent platelet aggregation inducers. Zinc metalloproteases, which disrupt 
the endothelial lining of blood vessels causing spontaneous bleeding, 
hyaluronidases (spreading factor), arginine esterases and, L-amino acid 
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oxidases which is widely found in snake venoms, and is responsible for the 
yellow colouration of snake venom due to the presence of riboflavin as a 
prosthetic group.(11)  
Table 1 showing the Various Venom Proteins and their Mechanism of 
Action   
Type of compound  
 
Action on body  
 
Snake family  
 
Acetyl choline esterases 
AchE  
 
Tetanic paralysis  
 
Colubridae, Elapidae  
 
Arginine esterases  
 
Believed to predigest 
prey  
 
Viperidae  
 
Bradykinin potentiating 
peptides  
 
Pain, hypotension, 
immobilize prey  
 
Viperidae  
 
C- type lectins  
 
Modulate platelet 
activity, prevent clotting  
 
Viperidae  
 
Cysteine rich secretory 
proteins  
 
Believed to induce 
hypothermia and 
immobilize prey  
 
Colubridae, 
Elapidae,Viperidae  
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Disintegrins  
 
Inhibit platelet activity 
and promote 
hemorrhaging  
 
Viperidae  
 
Hyaluronidases  
 
Increase interstitial 
fluidity aiding in the 
dissemination of venom 
proteins  
 
Elapidae, Viperidae  
 
    
L-Amino acid oxidases  
 
Cell damage, apoptosis  
 
Elapidae, Viperidae  
 
Metalloproteinases  
 
Hemorrhage, 
myonecrosis, believed to 
predigest prey  
 
Colubridae, Elapidae, 
Viperidae  
 
Myotoxins  
 
Myonecrosis, analgesia, 
immobilise prey  
 
Viperidae  
 
Phosphodiesterases  
 
Causes hypotension and 
shock  
 
Colubridae, Elapidae, 
Viperidae  
 
Phospholipases Causes myotoxicity, Colubridae, Elapidae, 
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A2(PLA2)  
 
myonecrosis, damage to 
call membranes  
 
Viperidae  
 
PLA2 based presynaptic 
neurotoxins  
 
Immobilises prey  
 
Elapidae, Viperidae  
 
Prothrombin activators  
 
Disseminated 
intravascular coagulation 
(DIC)  
 
Elapidae, Viperidae  
 
Purines and pyrimidines  
 
Hypotension, paralysis, 
apoptosis, necrosis, 
immobilisation of prey  
 
Elapidae, Viperidae  
 
Serine proteases  
 
Disrupts hemostasis, 
hypotension, immobilize 
prey  
 
 
Colubridae, Viperidae  
 
 
Three finger toxins 
(3FTx)  
 
Rapid immobilization of 
prey, paralysis and death  
 
Colubridae, Elapidae  
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Signs and Symptoms of Snake Bites 
Snake venom are complex substances which have protiec and non-protiec 
parts, which produce local and systemic changes. Local changes being part of 
an acute inflammation causing edema, ecchymosis, blistering and skin necrosis 
and may lead on to infection and cellulitis. Systemic changes include 
hemotoxicity, neurotoxicity, rhabdomyolysis and acute kidney injury 
(AKI).(12) 
Local symptoms include: 
• Fang marks 
• Local pain  
• Local bleeding 
• Bruising 
• Lymphangitis 
• Blistering 
• Lymph node enlargement 
• Soft tissue infections – these are a major complication of snakebites 
which have local envenomation. The enzymatic degradation of tissue 
caused by the snake venom causes extensive destruction and 
devitalization, predisposing it to infection with bacteria indigenous to 
the snake’s oral flora.  Atul et al found that the gram positive bacteria 
was more common than gram negative bacteria. Staphylococcus aureus 
followed by coagulase negative Staphylococcus and Streptococcus 
species.(13) 
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Systemic symptoms and signs: 
General Nausea, vomiting, abdominal pain generalized weakness drowsiness 
and prostration 
Cardiovascular visual disturbances, giddiness, collapse, shock, hypotension, 
pulmonary edema, cardiac arrhythmias, myocarditis 
Hemotoxicity excessive bleeding from wounds, spontaneous systemic which 
include minor bleeding like bleeding from gums or epistaxis or could be a 
major bleed such as hematuria, hematemesis, melena, hematochezia, 
hemoptysis, intracranial or intra abdominal bleeds.(14)  
Neurotoxicity Altered sensorium, drowsiness, ptosis, external opthalmoplegia, 
bulbar involvement, diaphragmatic paralysis or generalized flaccid 
paralysis.(15) 
Rhabdomyolysis generalized pain in muscles, stiffness and tenderness of the 
muscles, trismus, dark coloured urine – myoglobinuria/hemoglobinuria, acute 
renal failure, hyperkalemia and cardiac arrest. 
Acute Kidney Injury Loin pain, hematuria, hemoglobinuria/myoglobinuria, 
decreased urine output, and worsening creatinine, pedal edema, anasarca and 
pulmonary edema.(16) 
 
Envenomation Syndrome 
The different clinical syndromes associated with snakebites are as follows: 
1. No envenomation 
2. Local swelling 
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3. Hemotoxicity with/without local swelling 
4. Pure neurotoxicity 
5. Neurotoxicity with local swelling 
6. Hemotoxicity with neurotoxicity 
7. Hemotoxicity/neurotoxicity and renal failure 
 
The use of clinical envenomation syndrome, helps to identify the species in the 
snake bite, which would give a more reasonable idea of what complications to 
expect and how to manage them. 
Species, which are relevant to South India, are: 
Viperidae Bites 
Russell’s Viper(Daboia russelii russelii) bites present with local reaction at the 
bite site with swelling, blistering and necrosis along with coagulopathy. Other 
features frequently encountered are acute kidney injury and neurotoxicity in the 
form of ptosis. (17) Saw scaled viper (Echis carinatus) bites present with local 
reaction and coagulopathy/hemotoxicity.(14) Pit vipers like the hump nosed pit 
viper present with a local reaction, hemotoxicity and can have an acute kidney 
injury.(16) 
Elapidae Bites 
Species like the Indian Cobra (Naja naja) have extensive local reaction in the 
form of swelling, cellulitis, tissue necrosis and gangrene, with a descending 
paralysis which is progressive in nature.(18) 
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Krait Bites 
The common krait (Bungarus caeruleus) is classically a painless bite followed 
by ophthalmoplegia, bulbar weakness and then respiratory distress due to the 
involvement of the diaphragmatic muscles.(19) 
 
According to the WHO algorithm for South East Asia the following syndromes 
were defined to correlate with snake species. 
Syndrome 1: local envenomation with coagulopathy associated with Viperidae 
Syndrome 2: local envenomation with coagulopathy with/without acute kidney 
injury along with neurotoxicity is described with Russell’s viper 
Syndrome 3: local envenomation with paralysis seen with cobra bites 
Syndrome 4: paralysis with minimal or no local envenomation is seen with 
Krait bites 
Syndrome 5: paralysis with acute kidney injury seen with Russell’s viper bites 
 
The algorithm was adapted from data published by Ariaratnam et al as seen in 
the figure below(20): 
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Figure 1 Algorithm for identification of snake responsible for bite 
 
 
Arirathnam et al in a prospective cohort proposed the algorithm to identifying 
the snake bites in Sri Lanka( between August 1993- July 1997). It was noted 
that there was a high specificity in identifying the species with the 
envenomation syndrome as shown in Table 2. (20) 
Table 2 Sensitivity and specificity of species identification with 
Envenomation Syndrome 
Snake Sensitivity (%) Specificity (%)  
Russell’s viper 14 100 
Cobra 78 96 
Common Krait 66 100 
Hump- nosed viper 10 97 
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Snake is brought as definitive evidence in only 25% of cases and once patient 
is transferred to higher centers often the snake is missed out, hence with a 
syndromic approach we are able to identify the culprit snake. 
 
Management of Snake bites 
First Aid 
In a systematic review of first aid in snake bites, the authors looked at evidence 
from 14 studies, and concluded that a practical recommendation is pressure 
immobilization of the limb, as the spread of venom is mostly through the 
venous and lymphatic channels.(21) 
Unnecessary searching for snake, handling and killing of the snake and 
traditional remedies and concoctions are not recommended as it increases risk 
for further envenomation and delay in initiation of ASV. (22) Incision of the 
wound and application of tight tourniquet showed increased incidence of local 
swelling and inflammation.(23) 
Diagnosis 
Importance to the timing and location of the bite, early and intense pain often 
implies significant envenomation. 
Diagnostic Tests include: 
• 20 minute whole blood clotting time, PT/APTT and Fibrinogen 
• Hemoglobin, PCV, platelet counts, peripheral smear 
• Urine test for proteinuria, RBC’s, hemoglobinurua, myoglobinuria 
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• Serum Creatinine, urea, serum electrolytes 
20 Minute Whole Blood Clotting Test(20WBCT) 
This is an informative, easy to perform beside test, which does not require any 
training to perform. Here about 2ml of fresh venous blood is placed in a new 
clean and dry glass test tube and is left at ambient temperature for 20 minutes. 
The mechanism tested here is contact clotting. Use of plastic, polypropelene, 
polystyrene, syringes or glass washed in detergent, which prevents activation 
of Hageman factor, may give rise to false readings. 
Non clotting 20WBCT is predictive of a fibrinogen concentration <0.5g/L with 
a >90% sensitivity and specificity.(24) Hence this is the simplest test that can 
be performed in primary health care facilities and rural areas to distinguish 
Viperidae from Elapid bites. 
Anti Snake Venom (ASV) 
In India, available ASV is polyvalent antisnake venom, which contains 
antibodies against the Russell’s viper; saw scaled viper, common krait and the 
Indian cobra, which is isolated from horse serum after injecting snake venom 
by fractionation of plasma. 
Monovalent Antivenom is considered the more efficacious, identification of the 
species may not be possible, hence across the country the polyvalent ASV is 
being used. 
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Dosing of ASV 
There is no consensus on the number of vials of ASV which is to be initiated. 
Usual practice is a high dose initial dose of 10 vials with monitoring for 
anaphylaxis and hypersensitivity. (25) The patients should be monitored for 
resolution of coagulopathy and other manifestations every 4-6 hours and dose 
to be repeated if necessary. There have been multiple trials comparing low dose 
to high dose ASV (6 vials vs. 12 vials), which did not show any statistical 
difference in the resolution of envenomation in the two groups.(26)  However 
these results are limited by small sample size and had not taken into 
consideration the species. A larger trial done in Nepal compared slow 
administration of ASV over 12 hours to initial 10 vial dosing at initial 
presentation. Here also there was no difference in both arms of the trial with 
regard to envenomation resolution and ASV anaphylaxis.(27)  
A systematic review published in 2015 on low and high dose ASV concluded 
that there were no differences in resolution of envenomation syndromes and 
incidence of adverse reactions with ASV. However there was significant cost 
effectiveness of low dose regimens.(28)  
There is stillroom for well conducted studies to get establish a standard 
protocol for ASV administration in India.  
There are still several limitations to the polyvalent ASV available in India. 
There is an insufficient supply of ASV and costs are also high. In the Indian 
setting most snakebite victims are from a low socioeconomic strata. 
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There is a geographical variation in the distribution of the snakebites seen in 
India, several venomous species are not accounted for with the polyvalent 
ASV, and example of this is the Hump nosed viper, where the polyvalent ASV 
is inefficient.  
Specific Management: 
Local Envenomation 
According to the WHO guidelines, immobilization of the limbs should be done 
early. ASV should be administered if there is increase in swelling and pain of 
more than half the limb in 48 hours or rapid increase in swelling. Antibiotics 
should be administered for cellulitis/necrotizing fasciitis. Surgical debridement 
should be offered early for source control. 
Hemotoxicity 
The indication for ASV administration include spontaneous systemic bleeding 
manifestations, coagulopathy defined as positive non clotting whole blood 
clotting time more than 20 minutes or INR >1.2 or prothrombin time 4-5 
seconds longer than the control time.  The parameters are repeated every 6 
hours and if there is persistence of coagulopathy or systemic bleeding, then 
ASV further dose of ASV is given.  
Neurotoxicity 
Any neurotoxic manifestation at admission, bilateral ptosis, external 
ophthalmoplegia and paralysis requires ASV at admission and the patient has 
to be reassessed every 6 hours for resolution of signs and symptoms. Evidence 
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of respiratory muscle weakness like diaphragmatic and intercostal muscle 
weakness will require mechanical ventilation.  
Acute Kidney injury 
The patient may have oliguria, anuria, hemoglobinuria, myoglobinuria, rising 
creatinine/urea levels, evidence of rhabdomyolysis and intravascular 
haemolysis. ASV has to be administered for these situations and the patient 
needs to be monitored for the need for renal replacement therapy. 
 
Venom Induced Consumption Coagulopathy 
 
VICC- pathogenesis and clinical features: 
 
Venom-induced consumption coagulopathy is the most common entity in 
haemotoxic snake bites, notably Russell’s viper, Saw-scaled viper and Hump-
nosed pit viper. 
The most common derangements seen are prolonged INR, prolonged aPTT, 
low fibrinogen and low factor V, VIII and X levels.  
Venom contains Factor V and X activators, which leads to formation of 
Prothrombinase complex (Xa/Va complex) thereby subsequently activating the 
coagulation cascade and leading to consumptive coagulopathy. It also contains 
thrombin-like enzymes, which lyse either alpha or beta chain of fibrinogen, 
giving rise to fibrinopeptide A or B causing consumption of fibrinogen without 
the formation of fibrin. The risk of bleeding in VICC appears to be associated 
with presence of Prothrombin activators- metalloproteinases in snake venom 
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which not only activate the coagulation cascade but also damage vessel wall 
integrity predisposing to bleeding. VICC can co-exist with HUS-TMA, leading 
to the popular mistaken belief that VICC is a form of DIC. 
 
VICC usually presents with local bleeding manifestations- from the bite site/ 
cannula site. However, gum bleeding, gastrointestinal or genitourinary bleeding 
and intracerebral haemorrhage are also seen. The more serious bleeding 
manifestations are seen in bites with Echis spp – due to substances called 
haemorrhagins. 
 
A cohort study involving 146 patients with Russell’s viper envenomation done 
in a tertiary care hospital at Sri Lanka using Enzyme immunoabsorbent assay 
for venom detection to assess dynamic relationship between Russell’s viper 
antivenom and clotting factor levels showed that haemotoxic envenomation by 
Russell’s Viper is associated with an elevated PT/INR and aPTT, low 
fibrinogen, Factor V, VIII and X levels. Coagulation profile trends showed that 
aPTT normalized by 24 hours; PT/INR, Fibrinogen, Factors V and X 
normalized by 48 hours. There was a non-significant statistical association 
between pre-ASV venom concentration and INR (p=0.02), aPTT (p=0.03).  
This study also showed that PT/ INR was still elevated at 6 hours post-ASV 
administration, stating that 6 hours maybe early for reassessment of 
coagulation status.(29)  
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Are VICC and DIC the same?   
 
Recent studies have shown that pathogenesis of Venom-induced consumption 
coagulopathy is unique and dissimilar to DIC. Isbister et al, in 2010 showed 
that VICC is not the same as DIC. VICC is not characterized by systemic 
microthrombi and end-organ damage due to the thrombi. DIC is mediated via 
the tissue factor/ VIIa pathway. Initiation of VICC is at any point in the 
coagulation cascade upstream from thrombin. The time course in VICC is 
rapid- occurring within a few hours of envenomation and resolution within 24-
48 hours.(30) 
Diagnostic criteria proposed by Isbister et al.  
 
 
Thrombotic Microangiopathy 
 
Thrombotic Microangiopathy (TMA) is a set of diverse syndromes. Clinical 
features include microangiopathic hemolytic anemia, thrombocytopenia and 
end organ damage. They have characteristic pathological features of vascular 
damage, which is manifested by arteriolar and capillary thrombosis, with 
abnormalities of the endothelium and the vessel wall.(31)  
Thrombotic microangiopathies were previously categorized as Hemolytic 
Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP). 
HUS being characterized by thrombocytopenia, microangiopathic hemolytic 
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anemia and renal failure. TTP classically described as a pentad of 
thrombocytopenia, microangiopathic hemolytic anemia, neurological deficits, 
renal dysfunction and fever. However, about 60% of patients diagnosed with 
TTP lack one or more of these criteria, while 30% of those receiving a 
diagnosis of HUS exhibit subtle neurological symptoms and fever, this shows 
the difficulty to differentiate the two. Hence have been broadly classified as 
Thrombotic Microangiopathies.(32) 
A recent revision has been made in the classification of TM, due to this 
difficulty in differentiating the syndromes and the pathophysiology.  
Currently being classified as Hereditary and Acquired Thrombotic 
Microangiopathies. 
 
Primary TMA syndromes are: 
• Thrombotic Thrombocytopenic purpura (TTP)  
• Shiga Toxin Mediated Hemolytic Uremic syndrome (ST-HUS)  
• Complement Mediated TMA  
• Drug Induced TMA  
• Metabolism Mediated TMA  
• Coagulation mediated TMA  
Acute episodes of thrombotic microangiopathies have been observed in 
association with viral and bacterial infections, toxins, pregnancy, HELLP 
syndrome, bone marrow transplantation, drug (mitomycin, cyclosporin A, 
ticlopidine) therapy, and cancer, and have been variously referred to as TTP, 
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HUS, TTP/HUS, TTP‐like disease or secondary TTP. (31) 
Classification and Pathophysiology: 
Thrombotic thrombocytopenic purpura (TTP) 
This is a severe deficiency of ADAMTS13 (activity <10%), but the diagnosis 
of TTP is based on clinical judgment, as ADAMTS level measurement results 
are usually not available for several days. 
ADAMTS is a metalloprotease, which cleaves von Willebrand  factor 
multimers, which are secreted from the vascular endothelium. Deficiency of 
ADAMTS13 results in the unusually large multimers to cause platelet thrombi 
in the small vessel causing TTP. Hereditary TTP (Upshaw-Schulman 
syndrome) is a homo/heterozygous mutation of ADAMTS13. Antibodies 
directed against ADAMTS13 cause acquired TTP. (32)(33) 
Treatment of TTP is ADAMTS13 replacement with plasma infusion/plasma 
exchange. Before the use of plasma exchange for TTP, survival was only 10%. 
Glucocorticoids are considered the standard treatment in conjunction with 
Plasma exchange. Other treatment options are Rituximab and IVIG.(31) 
 
Complement- Mediated TMA(Acquired and Hereditary) 
These are syndromes with predominant renal failure. This results due to 
uncontrolled activation of the alternative complement pathway on the cell 
membranes including the vascular endothelium and kidneys. This can be due to 
hereditary deficiency of regulatory proteins like complement factor H [CFH], 
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complement factor H related proteins [CFHRs] CFI, membrane cofactor 
protein [MCP, CD46]), or a hereditary abnormality of proteins that accelerate 
activation of this pathway (eg, CFB, C3). 
Deficiency of complement factor H (CFH) or complement factor I (CFI) can 
also be acquired caused by an autoantibody that inhibits CFH or CFI 
activity.(34) 
The only available anticomplement agent available is ecluzimab, the high cost 
and limited availability limit its use.(31) 
 
Drug-induced TMA  
Some agents can cause immune-mediated TMA due to drug-dependent 
antibodies that react with platelets, neutrophils, endothelial cells, and/or other 
cells. (29) is the most common and best-described etiology of immune-
mediated DITMA. Gemcitabine, oxaliplatin, and quetiapine may also cause 
acute episodes of TMA that appear to be immune-mediated. Acute kidney 
injury in quinine-induced, immune-mediated TMA is typically severe.(31) 
 
Metabolism mediated TMAs: 
Hereditary metabolism-mediated or coagulation-mediated TMAs typically 
occur in infants but can occur in adults; these disorders do not have specific 
presenting symptoms. Patients may describe symptoms related to progressive 
kidney failure, such as weakness and fatigue.(31) 
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Coagulation-mediated TMA: 
Hereditary deficiency of proteins involved in coagulation can cause TMA. 
These syndromes differ from the abnormalities associated with hereditary 
thrombophilia, which cause thromboembolism in large vessels rather than 
systemic microvascular thrombosis. Mutations in genes encoding 
thrombomodulin (TM), plasminogen, and diacylglycerol kinase epsilon 
(DGKE) have been reported to be associated with TMA.(31) 
 
 
Figure 2 Approach to Thrombotic Microangiopathies(35) 
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Thrombotic Microangiopathy in Snake Envenomation 
 
Multiple publications from Australia and Sri Lanka have shown case reports 
of TMA in snakebites with the Brown Snake, Russell’s viper and Humped 
nose viper bites.(30,36,37) Many of these studies have limitations of 
ADAMTS13 and complements not being included in the study.  
 
Venom induced consumptive coagulation (VICC) is a well-known 
consequence of viper bites. It is also known that some viper venoms, such as 
those of hump nosed viper and Russell’s viper, can precipitate renal failure. 
The common tendency is to view both these manifestations as a part of a same 
syndrome. VICC is characterized by rapid onset coagulopathy within hours 
after the snake bite with elevated D-dimer levels, prolonged prothrombin time, 
and low fibrinogen levels which at times is associated with thrombocytopenia. 
This resolves within 24 to 48 hours. It is not associated with systemic 
microthrombi and end organ failure. (30,38) Hence the pathophysiology of the 
end organ damage remains a question and is likely contributed to Thrombotic 
Microangiopathy which is an under recognized entity. 
 
Hence it has been postulated that the end organ damage is due to a venom 
induced thrombotic Microangiopathy, and that VICC and TMA are exclusive. 
Most case reports have shown an HUS like syndrome, and not shown much of 
a TTP spectrum, which is likely due to TTP being so rare. 
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Hence TMA could present as TTP or a complement mediated Thrombotic 
Microangiopathy in Snake envenomation. In all of these case reports the 
investigators have not been able to substantiate findings with investigations 
like complements or ADAMTS13. 
 
Myint / Warrel et al showed that out of 123 Russell’s viper bites they had an 
almost 26% subset who had thrombocytopenia and about 44% had oliguria 
and these patients had a prolonged hospital stay. (39) 
In a study done in Kerala, Joseph K Joseph et al showed that low platelets, 
drop in Hemoglobin, rising creatinine and proteinuria showed a poor outcome 
and prolonged hospitalization. (40) Which shows that patients with 
thrombocytopenia may fall into a spectrum of TMA, which would explain the 
poorer prognosis in this subset. 
Hence it could be postulated that the spectrum of Thrombotic 
Microangiopathy extends from thrombocytopenia only to thrombocytopenia, 
MAHA, and end – organ damage. There is also a significant overlap of TMA 
and VICC, and these patients often have a poorer prognosis. 
 
Role of Plasma Exchange in TMA secondary to Snakebite 
 
The proposed mechanism is that the venom or endothelial toxins act on von 
Willebrand factor activators and initiate TMA by inducing endothelial damage. 
(41)The role of ADAMTS 13 in still unclear as there is no studies, which have 
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evaluated ADAMTS13. Hence it is unclear if these patients would improve 
with plasma exchange, as this is a secondary TMA, which should resolve 
without replacement of factors. Data on plasma exchange in snakebites is 
limited as shown below in figure 3. Most citations have shown good/modest 
improvement in hospital stay and outcome. 
 The clinical efficacy of plasma exchange in snake envenomation is not clear, 
even though immune complex and toxin removal may be augmented, studies 
have not shown difference in renal recovery, anemia or platelet count with or 
without plasma exchange.(41) 
American society for Apharesis has put role of plasma exchange in 
envenomation as Grade 2C, Category 3, which is a weak recommendation.(42)  
 
Figure 3Thrombotic Microangiopathy in snakebites and Plasma 
Exchange/Hemodialysis(37) 
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There are no well-conducted studies, which have been done looking at 
Thrombotic Microangiopathy looking at diagnostic methods like 
ADAMTS13/ von Willebrand factor assays or therapeutic role of plasma 
exchange. Hence there is an urgent need for such studies for optimizing 
therapy in such patients. 
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MATERIALS AND METHODS 
 
Setting 
 
All patients admitted to Christian Medical College, Hospital, Vellore with 
suspected/ confirmed snakebite from April 2017 to July 2018, would receive 
standard-of-care treatment. During hospital admission patients will be observed 
both clinically and with appropriate investigations daily till discharge. 
Observations seen within the groups will be recorded for comparison. 
In addition data will be retrieved from past records of the last 5 years to add a 
retrospective analysis for the last 5 years (5 years retrospective and 1 year 
prospective). 
 
Participants 
 
All patients above the age of 18 years, admitted with suspected or confirmed 
snake envenomation from April 2017 to July 2018 were recruited to the study 
with informed consent, which was be taken in the Department of Emergency 
Medicine, prior to admission for prospective analysis, if patients had a platelet 
count less than 1, 50,000  they were closely monitored for features suggestive 
of Thrombotic Microangiopathy and were included in the study population. 
 
For the retrospective analysis all patients above the age of 18 years, admitted 
with suspected or confirmed snake envenomation from April 2012 to March 
2017 was recruited.  
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Inclusion criteria  
 
• All consenting adult patients presenting to CMC Hospital with 
suspected snake bite within 24 hours 
• Patients with a thrombocytopenia of less than 1,50,000 (in the 
first 3 days of hospitalization). 
• Patients that have presented with snakebites with a 
thrombocytopenia less than 1,50,000, during a hospital admission 
in Christian Medical College over the last 5 years (Information 
obtained through Clinical workstation and hospital records of the 
same). 
 
Case definitions 
 
Thrombotic Microangiopathy – Thrombocytopenia (platelets<1,50,000), 
Microangiopathic haemolytic anemia(drop in Hemoglobin/fragmented red cells 
evidenced by schistocytes, elevated LDH) with : 
Acute renal impairment, including oliguria/anuria, elevated creatinine 
(>1.5mg/dl) 
And/or 
Acute neurological features (reduced consciousness, seizures, cerebrovascular 
accident, and coma)  
Cases are categorized as follows: 
1. Thrombocytopenia only 
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2. Thrombocytopenia with evidence of schistocytes 
3. Thrombocytopenia with evidence of schistocytes and 
microangiopathic haemolytic anaemia (anaemia, retriculocytosis, 
indirect hyperbilirubinemia and elevated LDH) 
4. Thrombocytopenia with evidence of schistocytes and 
Neurological dysfunction: altered sensorium, focal neurological 
with or without Renal dysfunction: elevated creatinine  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  44 
Detailed diagrammatic Algorithm of the Prospective Part of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Snake bite suspected/confirmed 
To be given supportive care in Accident and 
Emergency (Local dressings, pain relief, 
hydration) 
 
Full dose of ASV according to requirement 
  Recruit for study 
Admit and observe during hospital admission 
 2. Classify into TMA spectrum 
 3. Analysis of collected Data 
If consenting (Consent to be taken in 
Casualty) 
adults>18 years of age 
Presence of envenomation 
Platelet count < 1,50,000/ml within 3 
days of admission 
1. Classify into Envenomation Syndrome 
Daily Clinical monitoring: 
• Epistaxis, bruising, 
petechiae, gingival bleeding, 
hematuria, GI bleeding, 
hemoptysis, retinal hge. 
(Thrombocytopenia) 
• Confusion, headache, 
paresis, dysarthria, visual 
problems, encephalopathy, 
coma. (Fluctuating 
neurological symptoms) 
• Fever(>37.5 C) 
• Jaundice(MAHA( 
• Frothy urine, hematuria, 
facial puffiness, pedal 
edema. (Renal impairment) 
Daily Laboratory investigations: 
Hb, Platelets, Peripheral smear 
(schiztocytes),Creatinine, Bilirubin, 
Retics, LDH( to be done daily) ( 
Treatment: 
ASV dose 
Dialysis 
Blood transfusion: product, 
quantum 
Plasmapheresis 
ICU care 
Duration of hospitalization 
Death/discharged alive 
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Detailed Diagrammatic Algorithm of Retrospective Part of Study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Snake bite suspected/confirmed from 
Hospital records( last 5 years 2012-2017) 
If Platelets count <1,50,000/ml to be included 
in study 
  Recruit for study 
 2. Classify into TMA spectrum 
 3. Analysis of collected Data 
1. Classify into Envenomation Syndrome 
Clinical Data Available during 
admission: 
• Epistaxis, bruising, 
petechiae, gingival bleeding, 
hematuria, GI bleeding, 
hemoptysis, retinal hge. 
(Thrombocytopenia) 
• Confusion, headache, 
paresis, dysarthria, visual 
problems, encephalopathy, 
coma. (Fluctuating 
neurological symptoms) 
• Fever(>37.5 C) 
• Jaundice(MAHA( 
• Frothy urine, hematuria, 
facial puffiness, pedal 
edema. (Renal impairment) Daily Laboratory investigations: 
Hb, Platelets, Peripheral smear 
(schiztocytes),Creatinine, Bilirubin, 
Retics, LDH( to be done daily) ( 
Treatment: 
ASV dose 
Dialysis 
Blood transfusion: product, 
quantum 
Plasmapheresis 
ICU care 
Duration of hospitalization 
Death/discharged alive 
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Variables 
 
Admission characteristics:  Characteristics of bite, symptoms and 
signs, pre hospital management 
 
Clinical syndrome (envenomation) : local swelling only, pure 
haemotoxicity, haemotoxicity and neurotoxicity and/or AKI, 
neurotoxicity with or without local swelling, pure AKI 
 
Clinical findings: 
o Epistaxis, bruising, petechiae, gingival bleeding, hematuria, 
gastrointestinal bleeding, hemoptysis, retinal bleeding. 
(Thrombocytopenia) 
 
o Confusion, headache, paresis, aphasia, dysarthria, visual 
problems, encephalopathy, coma. 
o Fever >37.5 C 
o Jaundice. (Microangiopathic haemolytic anemia) 
o Frothy urine, hematuria. (Renal Impairment) 
o Respiratory distress, single breath count, ptosis, neck holding 
time. 
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Laboratory abnormalities: CBC, clotting screen (PT/aPTT, 
Fibrinogen), platelets, Peripheral smear for schistoytes, reticulocyte 
count, LDH, bilirubin (Total/Direct), creatinine. 
 
Treatment 
ICU care, mechanical ventilation, dialysis, plasma exchange, 
surgical treatment, antibiotics, anti snake venom dose, allergy 
and anaphylaxis, blood transfusion 
 
Time course of TMA 
Temporal profile of platelet count, schistoytes, hemoglobin and 
organ dysfunction. 
 
Outcomes 
Clinical outcome of snake bite in different snake bite syndromes 
in patients with TMA and without TMA, in relation to death, 
duration of hospitalization, need for dialysis and blood products 
 
Data Sources/measurement 
 
Admission characteristics, clinical syndromes and outcomes- From Patient 
Emergency and IP records, Clinical workstation 
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a. Progress notes, transfusion records, treatment records- 
dialysis/plasma exchange, surgical intervention, antibiotics based 
on ward and ICU records and details from Clinical workstation. 
 
b. Comparability of assessment: association between envenomation 
syndromes and TMA spectrum, Association of VICC and TMA, 
clinical outcomes in patients with TMA and without. 
 
Follow up 
   
Follow up of the patients was done during hospital stay, from admission to 
discharge. Patients were monitored daily both clinically and with 
investigations. Information was obtained from progress notes, transfusion 
records, treatment records from Wards/ICU and the Clinical workstation. 
 
Bias  
 
All consecutive patients with snake envenomation were included in the study to 
avoid any form of bias. 
 
Sample size 
 
Using the data from the thesis published in the previous year, the prevalence 
was about 66% (Dr. George’s thesis) and another article from Lancet (both 
references given below), the required sample size to show an incidence of 
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spectrum of TMA among snake bites was found to be 61 subjects with 12.5% 
precision and 95% confidence limit with an anticipated prevalence of about 
46% (obtained as an average of 66 and 26 from the quoted studies below).  
References:  
A Descriptive study on the Clinical Profile of Snake Envenomation in a 
Tertiary Care Center in Tamil Nadu and the Diagnostic and Prognostic Utility 
of Serum Phospholipase A2 in Various Envenomation Syndromes  
Lancet. 1985 Dec 7;2(8467):1259-64. Bites by Russell's viper 
(Viperarussellisiamensis) in Burma: haemostatic, vascular, and renal 
disturbances and response to treatment. Myint-Lwin, Warrell DA, Phillips RE, 
Tin-Nu-Swe, Tun-Pe, Maung-Maung-Lay. 
 
Formula: 
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Reference for the above formula:Lemeshow S, Hosmer DW, Klar J, Lwanga 
SK.  Adequacy of Sample Size in Health Studies.  John Wiley and Sons, 1990.  
Single Proportion - Absolute Precision 
Expected  incidence (proportion) 0.46 0.26 0.66 0.46 0.46 0.46 
 
Precision (%) 5 5 5 10 12.5 15 
 
Desired confidence level  (1- alpha) % 95 95 95 95 95 95 
 
Required sample size 382 296 345 95 61 42 
 
 
 
Statistical methods 
 
Descriptive statistics were used such as mean, standard deviation, Median and 
Inter quartile range for the Haemoglobin level, Platelets, Creatinine and ASV 
total, ICU stay etc., Frequency and Percentage were reported for Gender, TMA 
spectrum, Dialysis, Plasmapharesis and VICC etc., If the TMA spectrum 
groups follows normal distribution across Haemoglobin level and Baseline 
creatinine. If across the group does not follows normal distribution, Kruskal 
Wallis test was used across the TMA spectrum with Platelets, Creatinine, ASV 
total, ICU stay, Duration of hospitalization etc.,. Categorical variables (such as 
clinical syndromes) and the outcomes such as death, VICC etc., was compared 
across the groups, Fisher’s exact test was used. P value < 0.05 was considered 
as a statistical significance. The analysis was carried out using SPSS 21.0 
version.  
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STROBE FIGURE: Prospective Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
216 Suspected snake bites/unknown bite 
presented to Accident and Emergency (June 
2017 – July 2018) 
114 Patients provisionally recruited for study 
54 Patients, with hemotoxic snakebites 
recruited for study  
 19 Patients recruited for final analysis 
32 Patients - Refused consent 
30 Patients - Not snakebites 
8 Patients - Dry bites 
32 Patients - Presented after 24 
hours 
 
 
 57 Patients – Pure Neurotoxic 
Snakebites 
3 Patients – withdrew consent 
 
 
 
35 Patients had a platelet count 
>1,50,000/cumm 
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STROBE FIGURE: Retrospective Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
284 Hemotoxic Snakebites admitted from June 
2012 – May 2017  
102 Patients provisionally recruited for study 
182 Patients – Platelet count > 
1,50,000/cumm 
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RESULTS 
 
Prevalence of TMA spectrum Disorder and Full Spectrum Disorder 
121 patients were included in this study, 19 in the prospective cohort and 102 in 
the retrospective cohort. 
The prevalence of TMA spectrum in hemotoxic snakebites in the prospective arm 
was 51.35% (19 cases out of 37 hemotoxic snake bites) and 21.6% with the full 
spectrum disorder (8 cases out of 37 hemotoxic snake bite). In the prospective 
and retrospective arms together, the prevalence of TMA spectrum was 35.9% 
(102 cases out of 284 hemotoxic snake bites) and 7.74 % with the full spectrum 
disorder (22 cases out of 284 hemotoxic snake bite). 
 
Table 3 Baseline Characteristics 
Variable Prospective(n=19) Retrospective(n=102) Total(n=121) 
n(%) n(%) n(%) 
Gender 
Male 
Female 
 
14(73.7) 
5(26.3) 
 
75(73.5) 
27(26.5) 
 
89(73.6) 
32(26.4) 
Age (Mean ± SD) 38.58 ± 12.10 46.46 ± 14.21 45.22 ± 14.15 
Site of Bite 
Upper Limb 
Lower Limb 
Trunk 
Face 
 
4(21.1) 
14(73.7) 
- 
1(5.3) 
 
11(10.8) 
89(87.3) 
1(1.0) 
1(1.0) 
 
15(12.4) 
103(85.1) 
1(0.8) 
2(1.7) 
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Baseline Characteristics (Refer to Table 1) 
Baseline characteristics of the prospective and retrospective arm were matched. 
The majority of the patients was male (73.6%), with a mean age of 45.22 years of 
age and had a lower limb bite (85.1%). 
In the retrospective cohort it was noted that patient geographical distribution 
was mainly from Vellore, Tamil Nadu (56.9%) whereas in the prospective cohort 
the population was mostly from Chittoor, Andhra Pradesh (42.1%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Locality 
Chittoor 
Thiruvanmallai 
Vellore 
Others 
 
8(42.1) 
2(10.5) 
7(36.8) 
2(10.6) 
 
23(23.5) 
19(18.6) 
58(56.9) 
2(2.0) 
 
31(25.6) 
21(17.4) 
65(53.7) 
4(3.3) 
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Table 4 Laboratory Parameters 
 
Variable Prospective(n=19) Retrospective(n=102) Total(n=121) 
n(%) n(%) n(%) 
WBCT 
<20 min 
>20 min 
 
6(31.6) 
13(68.4) 
 
5(4.9) 
97(95.1) 
 
11(9.1) 
110(90.9) 
Hemoglobin 
(g/dL) (Mean ± 
SD) 
13.18 ± 2.63 13.51 ± 2.45 13.45 ± 2.47 
Total Counts 
(/dL) (Mean ± 
SD) 
16852.06 ± 7124.71 19110.87 ± 10352.06 18756.27 ± 
9924.32 
Platelets 
(/cumm) 
(Mean ± SD) 
Mild (>1,00,000) 
Moderate (50,000 
– 1,00,000) 
Severe (<50,000) 
 
 
14(73.7) 
2(10.5) 
 
3(15.7) 
 
 
52(51.0) 
23(22.5) 
 
27(26.5) 
 
 
66(54.5) 
25(20.7) 
 
30(24.8) 
Creatinine 
(mg/dL) 
(Mean ± SD) 
2.03 ± 1.66s 1.44 ± 0.82 1.53 ± 1.01 
INR (Mean ± SD) 2.96 ± 2.64 4.81 ± 3.73 4.52 ± 3.64  
APTT(s) (Mean ± 
SD) 
48.54 ± 35.08 86.22 ± 66.57 80.30 ± 64.06 
CPK(IU/dL) 
(Mean ± SD) 
2060.79 ± 3068.09 3258.63 ± 7550.14 2478.06 ± 
4588.46 
 
 
Laboratory Parameters (refer to Table 2) 
The degree of VICC was more severe in the retrospective arm. WBCT was 
prolonged in 68.4% of patient’s in the prospective cohort as compared to 95.1% 
in the retrospective cohort. The mean INR in the prospective cohort was 2.96 as 
compared to 4.81 in the retrospective cohort. The mean aPTT in the prospective 
cohort was 48.54 as compared to 86.22 in the retrospective cohort. 24.8% of the 
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retrospective cohort and 15.7% of the prospective cohort had severe 
thrombocytopenia (<50,000/cumm). There was elevation of CPK in both the 
prospective and retrospective cohorts. 
 
Table 5 Thrombotic microangiopathy spectrum 
TMA Spectrum 
 
Prospective(n=19) Retrospective(n=102) Total(n=121) 
n(%) n(%) n(%) 
Thrombocytopenia  
only 
 
6(31.6) 
 
 
57(55.9) 
 
 
63(52.1) 
 
 
Thrombocytopenia 
+ MAHA  
 
Thrombocytopenia 
+ MAHA + 
Schistocytes  
 
1(5.3) 
 
 
1(5.3) 
 
 
 
4(3.9) 
 
 
3(2.9) 
 
 
 
5(4.1) 
 
 
4(3.3) 
 
 
 
Total MAHA 
 
2(10.6) 7(6.8) 9(7.4) 
Thrombocytopenia 
+ MAHA + 
Schistocytes +Renal 
Failure 
 
Thrombocytopenia 
+ Renal Failure 
 
8(42.1) 
 
 
 
 
3(15.8) 
22(21.6) 
 
 
 
 
16(15.7) 
30(24.8) 
 
 
 
 
19(15.7) 
 
Total Renal Failure 
+ 
Thrombocytopenia 
 
 
 
11(57.9) 
 
 
38(37.3) 
 
 
49(40.5) 
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Thrombotic microangiopathy spectrum (refer to Table 3) 
In the prospective cohort, 31.6 % had isolated thrombocytopenia, 10.6 % had 
thrombocytopenia and MAHA and 57.9 % had thrombocytopenia with renal 
failure. 42.1 % had thrombocytopenia, MAHA, renal failure and schistocytes.  
In the retrospective arm, 55.9% had isolated thrombocytopenia, 6.8% had 
thrombocytopenia and MAHA and 37.3% had thrombocytopenia with renal 
failure. 21.6% had thrombocytopenia, MAHA, renal failure and schistocytes.  
  
In the prospective arm, 47.4% had schistocytes compared to 24.5% in the 
retrospective arm. Recently the Department of Transfusion Medicine has 
included microspherocytes in the reporting of schistocytes. This is likely to have 
increased the schistocytes percentage in the prospective arm as compared to the 
retrospective arm. 
 
Overall of the 121 cases, 52.1% had isolated thrombocytopenia, 40.5% had 
thrombocytopenia with renal failure, 7.4% had thrombocytopenia with MAHA 
and 24.8% had thrombocytopenia, renal failure and MAHA (see Figure 3) 61.2% 
of patients with renal failure had schistocytes.  
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Figure 3 Broad Classification of TMA 
 
 
 
 
  
 
 
 
 
 
A: Isolated Thrombocytopenia 
B: Thrombocytopenia +Microangiopathic Hemolytic Anemia 
C: Thrombocytopenia + MAHA + Renal Failure 
D: Thrombocytopenia and Renal Failure 
 
A(52.1%) B(7.4%) C(24.8%) D(40.5%) 
(3.3% 
sch.) 
 (24.8% 
sch.) 
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Table 6 Envenomation Syndrome 
 
Envenomation 
Syndrome 
Prospective(n=19) Retrospective(n=102) Total(n=121) 
n(%) n(%) n(%) 
 
Local Reaction + 
Hemotoxicity 
 
Pure Hemotoxicity 
 
5(26.3) 
 
 
1(5.3) 
 
27(26.4) 
 
 
4(3.9) 
 
32(26.5) 
 
 
5(4.1) 
 
Total isolated 
hemotoxicity 
 
 
6(31.6) 
 
31(30.3) 
 
37(30.6) 
 
Hemotoxicity + AKI 
 
Hemotoxicity + 
Neurotoxicity 
 
Hemotoxicity + 
Neurotoxicity + AKI 
 
 
4(21.1) 
 
6(31.6) 
 
 
3(15.8) 
 
 
 
5(4.9) 
 
45(44.1) 
 
 
21(20.6) 
 
 
 
9(7.4) 
 
51(42.1) 
 
 
24(19.8) 
 
 
 
Total Hemotoxicity 
±  Neurotoxicity ±  
AKI  
 
 
 
 
 
13(68.5) 
 
 
71(69.7) 
 
 
84(69.3) 
 
Envenomation syndrome (refer to Table 4) 
Majority of the patient population in both the prospective and retrospective 
cohorts presented with an envenomation syndrome of hemotoxicity with 
neurotoxicity and/or AKI suggestive of Russell’s viper like syndrome in 
84(69.4%) of the patients and 37(30.6%) presented with a pure hemotoxic 
envenomation syndrome (see figure 2)
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Figure 4 Envenomation Syndrome 
 
 
69%
31%
(n=121)
Russell's Viper Envenomation Syndrome Pure Hemotoxic Envenomation
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Table 7 VICC 
 
VICC  Prospective(n=19) Retrospective(n=102) Total(n=121) 
n(%) n(%) n(%) 
Yes 
 
 
No 
12(63.2) 
 
 
7(36.8) 
86(84.3) 
 
 
16(15.7) 
98(81) 
 
 
23(19) 
 
Table 8 TMA, VICC and Baseline Platelets 
 
 
VICC 
 
Platelets Baseline  
n(%) 
 
Mild 
(>1,00,00/cumm) 
Moderate 
(50,000-
1,00,00/cumm) 
Severe 
(<50,000/cumm) 
P value 
 
Yes 
(n=98) 
 
 
 
No 
(n=23) 
 
 
55(56.1) 
 
 
 
 
11(47.1) 
 
 
 
20(20.4) 
 
 
 
 
5(21.7) 
 
 
 
23(23.5) 
 
 
 
 
7(30.4) 
 
 
 
0.258 
 
 
 
 
 
 
 
Total 
(n=121) 
66(54.5) 
 
 
25(20.7) 
 
 
30(24.8) 
 
 
 
 
 
 
VICC, TMA and correlation with platelets (refer to Table 5 and 6) 
 
VICC was seen in 63.2% of the prospective cohort as compared to 84.3% of 
subjects in the retrospective cohort.It was noted that 30.4% patients without 
VICC, had a severe thrombocytopenia as compared to 23.5% with VICC. Overall 
54.5% of TMA spectrum had mild thrombocytopenia, 20.7% moderate and 
24.8% severe thrombocytopenia. 
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Figure 5 VICC (Prospective and Retrospective) 
 
 
Figure 6 VICC(Total) 
 
 
 
 
In about 19% patient population, there is thrombocytopenia without VICC, which 
shows that there is isolated microangiopathy occurring without VICC
Yes
63%
No
37%
VICC (Prospective)
Yes
84%
No
16%
VICC (Retrospective)
81%
19%
VICC (Total)
Yes No
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Table 9 Envenomation syndrome with stratified TMA groups 
 
 
Envenomation 
Syndrome 
Stratified groups 
Isolated 
Thrombocytopenia 
n(%) 
Thrombocytopenia 
with Schistocytes and 
Renal Failure 
n(%) 
 
Thrombocytopenia with Renal 
Failure 
n(%) 
P Value 
Pure 
Hemotoxic 
Envenomation 
(n=35) 
31(88.6) 0(0) 4(11.4)) <0.001* 
Russell’s Viper 
like 
Envenomation 
(n=76) 
34(44.7) 30(39.5) 12(15.8)  
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Envenomation Syndrome and TMA (refer to Table 7) 
In patients with an a pure hemotoxic envenomation syndrome, it was noted that 
they had less severe manifestations, with isolated thrombocytopenia which was 
seen in 88.6 %, thrombocytopenia with MAHA and renal failure was 0% and 
thrombocytopenia with renal failure in 11.4%. In contrast in the Russell’s viper 
envenomation syndrome isolated thrombocytopenia occurred in 44.7%, 
Thrombocytopenia with MAHA and renal failure 39.5% and thrombocytopenia 
with renal failure in 15.8%. (See Figure 5, detailed Table of Envenomation 
Syndrome and TMA, Table 17 given in Annexure 6). The difference in TMA 
spectrum according to envenomation syndrome was statistically significant 
(p=0.001) 
 
Figure 7 Snake Envenomation Syndrome and TMA Spectrum 
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Table 10 VICC correlation with TMA Spectrum 
 
 
 
 
VICC 
TMA Spectrum (Prospective n=19, Retrospective n=102, Total n=121) 
Thrombocytopenia 
only 
 
Thrombocytopenia + 
MAHA  
 
Thrombocytopenia 
+ MAHA + 
Scistocytes  
 
Thrombocytopenia + 
MAHA + Scistocytes 
+Renal Failure 
 
Thrombocytopenia + 
Renal Failure 
 
 
P(n=8) 
n(%) 
R(n=57) 
n(%) 
T(n=65) 
n(%) 
P(n=1) 
n(%) 
R(n=4) 
n(%) 
T(n=5) 
n(%) 
P(n=1) 
n(%) 
R(n=3) 
n(%) 
T(n=4) 
n(%) 
P(n=8) 
n(%) 
R(n=22) 
n(%) 
T(n=30) 
n(%) 
P(n=3) 
n(%) 
R(n=13) 
n(%) 
T(n=16) 
n(%) 
Yes 
(n=98) 
 
No 
(n=23) 
8(100) 
 
 
 
- 
51(89.5) 
 
 
 
6(10.5) 
59(90.5) 
 
 
 
6(9.5) 
- 
 
 
 
1(100) 
4(100) 
 
 
 
- 
4(80) 
 
 
 
1(20) 
1(100) 
 
 
 
- 
 
 
 
 
3(100) 
 
 
 
- 
4(100) 
 
 
 
- 
2(25) 
 
 
 
6(75) 
14(63.6) 
 
 
 
8(36.4) 
16(53.3) 
 
 
 
14(46.7) 
3(100) 
 
 
 
- 
11(84.6) 
 
 
 
2(18.18) 
14(89.5) 
 
 
 
2(10.5) 
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Table 11 VICC in relation to TMA spectrum 
VICC Stratified groups (n=111) 
Isolated 
Thrombocytopenia 
(n=65)  
n(%) 
Thrombocytopenia 
with Schistocytes and 
Renal Failure (n=30) 
n(%) 
 
Thrombocytopenia with Renal 
Failure (n=16) 
n(%) 
P Value 
Yes 
(n=89) 
59(66.3) 16(18.0) 14(15.7) <0.001 
No 
(n=22) 
6(27.3) 14(63.6) 2(9.1) 
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Figure 8 VICC correlation with TMA Spectrum 
 
 
 
 
 
 
From this data we are able to see that in patients that present with VICC (81.1%), 
most subjects had less severe manifestations, with isolated thrombocytopenia 
which was seen in 66.3%, thrombocytopenia with MAHA in 18% and 
thrombocytopenia with renal failure in 15.7%. In contrast to the patients 
without VICC, isolated thrombocytopenia occurred in 27.3%, Thrombocytopenia 
with MAHA and renal failure 63.6% and thrombocytopenia with renal failure in 
9.1%. 
Therefore there is a group of patients with snake bite induced TMA without 
VICC. This group of patients had more severe manifestations than TMA without 
VICC.
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Table 12 Treatment Outcomes 
 
Variable Prospective 
(n=19) 
Retrospective 
(n=102) 
Total(n=121)  
n(%) n(%) n(%) P value 
Time to ASV 
(Mean ± SD) 
 
ASV (Outside) 
(Mean ± SD) 
 
ASV (CMCH) 
(Mean ± SD) 
 
ASV (Total) 
(Mean ± SD) 
 
Need for 
Transfusion 
Yes 
No 
 
Days of 
Admission 
(Mean ± SD) 
 
Need for ICU 
Admission 
Yes 
No 
 
ICU Days  
(Mean ± SD) 
 
Dialysis 
Yes 
No 
 
Plasmapharesi
s 
Yes  
No 
 
Final Outcome 
Discharge 
DAMA/Death 
4:06:40 ± 3:40:20 
 
 
7.53 ± 8.72 
 
 
9.58 ± 7.07 
 
 
17.11 ± 8.36 
 
 
 
 
6(31.6) 
13(68.4) 
 
 
7.79 ± 6.08 
 
 
 
 
5(26.3) 
14(73.7) 
 
1.21 ± 1.93 
 
 
 
6(31.6) 
13(68.4) 
 
 
3(15.8) 
16(84.2) 
 
 
19(100) 
- 
3:48:17 ± 4:13:25 
 
 
7.02 ± 10.30 
 
 
11.11 ± 5.10 
 
 
18.13 ± 9.94 
 
 
 
 
18(17.6) 
84(82.4) 
 
 
4.89 ± 4.39 
 
 
 
 
14(13.7) 
88(86.3) 
 
0.49 ± 1.57 
 
 
 
17(16.7) 
85(83.3) 
 
 
3(2.9) 
99(97.1) 
 
 
92(90.2) 
10(9.8) 
3:51:02 ± 4:07:58 
 
 
7.10 ± 10.04 
 
 
10.87 ± 5.45 
 
 
17.97 ± 5.45 
 
 
 
 
24(19.8) 
97(80.2) 
 
 
5.35 ± 4.79 
 
 
 
 
19(15.7) 
102(84.3) 
 
0.60 ± 1.61 
 
 
 
23(19.0) 
98(81.0) 
 
 
6(4.95) 
115(95.05) 
 
 
111(91.7) 
10(8.2) 
0.407 
 
 
0.799 
 
 
0.460 
 
 
0.926 
 
 
 
 
0.208 
 
 
 
0.02 
 
 
 
 
0.260 
 
 
0.198 
 
 
 
0.198 
 
 
 
0.049 
 
 
 
- 
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Treatment outcomes (refer to Table 10) 
Subjects in the prospective and retrospective cohort both had similar treatment 
outcomes. The mean total ASV requirements in the prospective and 
retrospective cohort were 17.1 and 18.1 vials of ASV, respectively. 
In the prospective cohort patients had a significantly longer duration hospital 
admission as compared to the retrospective cohort (7.79 days as compared to 
4.89 days, p=0.02). 26.3% of patients in the prospective arm required ICU care, 
compared to 13.7% in the retrospective cohort. The mean ICU stay in the 
prospective cohort, was 1.21 days compared to 0.49 days in the retrospective 
arm. 31.6% of the prospective cohort patients required dialysis compared to 
16.7% in the retrospective cohort. There was significantly higher requirement of 
plasmapharesis in prospective arm of 15.8% as compared to 2.9% in the 
retrospective arm (p=0.049) and may be attributed to a higher incidence of TMA 
with renal failure, thrombocytopenia and schistocytes in the prospective cohort 
as compared to retrospective cohort (42.1% versus 21.6%) 
As treatment approaches have evolved, the use of plasmapharesis has increased 
and may have led to a longer hospital stay. 
The final outcome of patients in both the prospective arm and retrospective arm 
both were good (91.7% of the patients were discharged) and death occurred in 
only 4.9% of patients, which was noted in the retrospective cohort. There were 
no deaths or discharge against medical advice in the prospective arm suggesting 
the outcome of patients with full spectrum of TMA had improved in the recent 
period. 
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Table 13 Severity of TMA Spectrum: Admission Laboratory Values 
 
 
 
 
 
TMA Spectrum(Stratified groups) 
Thrombocytopenia only 
(n=65) 
 
Thrombocytopenia + MAHA + 
Scistocytes +Renal Failure 
(n=30) 
Thrombocytopenia + Renal 
Failure 
(n=16) 
 
P value 
B D3 D6 B D3 D6 B D3 D6 
Hemoglobin 
(g%) 
(Mean ± SD) 
 
Platelets 
(/cumm) (Mean 
± SD) 
 
Creatinine 
(mg/dL) (Mean 
± SD) 
 
LDH (IU/dL) 
(Mean ± SD) 
 
INR (Mean ± 
SD) 
 
 
aPTT (s) (Mean 
± SD) 
 
 
13.57 ± 
2.51 
 
1,15,295.
38 ± 
1,20,424.
18 
 
1.03 ± 
0.23  
 
 
997.1 ± 
527.2 
 
 
5.03 ± 
3.65  
 
 
82.42 ± 
63.77 
 
11.18 ± 
2.02 
 
1,52,795.
38 ± 
1,20,424.
18 
 
0.84 ± 
0.27 
 
 
626.0 ± 
527.3 
 
11.00 ± 
2.44 
 
1,56,166.6
7 ± 
62,496.13 
 
 
0.80 ± 0.26 
 
 
 
589.3 ± 
205.2 
 
12.83 ± 
2.59 
 
85,446.67 
± 
55,493.63 
 
 
2.70 ± 
1.38 
 
 
5,466.33 
± 
11,777.1 
 
 
2.85 ± 
2.97 
 
 
64.94 ± 
56.34 
 
9.22 ± 1.70 
 
 
55,344.83 ± 
46,121.94 
 
 
 
4.64 ± 2.32 
 
 
 
3,194.0 ± 
2,370.8 
 
7.75 ± 1.32 
 
 
86,772.73 ± 
90,307.90 
 
 
 
6.55 ± 2.17 
 
 
 
1830.5 ± 
1,208.5 
 
13.93 ± 
2.44 
 
1,3612.50 
± 
1,42,070.5
0 
 
 
 
1.58 ± 0.28 
 
 
 
926.3 ± 
94.7 
 
 
5.24 ± 4.08 
 
 
 
89.21 ± 
72.98 
 
11.68 ± 
1.41 
 
1,36,812.5
0 ± 
1,42,070.5 
 
 
1.93 ± 1.76 
 
 
 
1265 ± 
430.6 
 
12.10 ± 
1.55 
 
1,66,000.
00 ± 
4,242.64 
 
 
3.60 ± 
2.67 
 
 
 
- 
 
<o.280 
 
 
<0.239 
 
 
 
 
<0.001 
 
 
0.002 
 
 
0.001 
 
 
 
0.694 
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Table 14 Severity of TMA Spectrum: Treatment and Outcomes 
 
 
 
 
 
TMA Spectrum(Stratified groups) 
Thrombocytopenia only 
(n=65) 
 
Thrombocytopenia + MAHA + 
Scistocytes +Renal Failure 
(n=30) 
 
Thrombocytopenia + Renal Failure 
(n=16) 
 
 
P Value 
ASV 
Total(Vials) 
(Mean ± SD) 
 
Hospital Stay 
(Days) 
(Median) 
 
ICU Stay (Days) 
(Mean ± SD) 
 
Dialysis 
Yes 
No 
 
Plasmapharesis 
Yes 
No 
 
Final Outcome 
Discharge 
DAMA/Death 
 
16.41 ± 8.56 
  
 
2(2,4) 
 
 
 
0(0,0) 
 
 
- 
65(100) 
 
 
- 
65(100) 
 
 
63((96.9) 
2(3.1) 
 
 
21.63 ± 8.56 
 
 
12(7.75,13.25) 
 
 
 
1.83 ± 2.78 
 
 
22(73.3) 
8(26.7) 
 
 
6(20) 
24(80) 
 
 
24(80) 
6(20) 
 
16.62 ± 8.56 
 
 
3(2,4.75) 
 
 
 
0.50 ± 1.15 
 
 
1(6.25) 
15(93.75) 
 
 
- 
16(100) 
 
 
14(87.5) 
2(12.5) 
 
0.051 
 
 
<0.001 
 
 
 
<0.001 
 
 
<0.001 
 
 
 
- 
 
 
 
0.015 
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Severity of TMA Spectrum: Admission Laboratory Values (Refer to Table 12) 
Out of the TMA groups, the laboratory values at admission were comparable 
except in the TMA group with full spectrum, in which there were the lowest 
Hemoglobin (12.83 g/dL), platelets (85,446/cumm), with the highest creatinine 
(2.07 mg/dL) and LDH (5,466 IU/dL) values. Coagulopathy was least in this 
group with mean INR of 2.85 and aPTT of 64.85s.  
 
Severity of TMA Spectrum: Treatment and Outcomes (Refer to Table 13) 
In comparison of treatment of the TMA spectrum, the full TMA spectrum 
required more ASV (21.63 vials, p=0.051) and had longer hospital and ICU stay 
(11.3 days and 1.83 days respectively, p<0.001) and 73.3% of patients required 
dialysis (p=<0.001).  
The final outcomes were significantly different in the groups. 6 patients (20%) of 
the full TMA spectrum had death/DAMA compared to 12.5% in the 
thrombocytopenia with renal failure group and 3.1% in the isolated 
thrombocytopenia group (p=0.015). There were 3(10%) deaths in the full 
spectrum TMA disorder and 2 deaths (12.5%) in the thrombocytopenia and 
renal failure group.  
 
This data shows that patients who develop the full TMA spectrum have a more 
severe disease, as compared to isolated thrombocytopenia, which is a more 
benign disease process.
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Detailed clinical case descriptions of full spectrum TMA disorder in prospective 
cohort (8 patients) 
 
Patient 1: 
18 year old male, student, from Chittoor, presented to CMCH, 18hours after 
snake bite. Initial symptoms developed within 30 minutes, with bleeding from 
site and some minimal gum bleeding, following which he developed ptosis. 
He had received first aid from local hospital and first ASV was administered at 
approximately 4 hours and 30 minutes (10 vials).  
He was referred to CMCH as he developed decreased urine output.  
 
At time of admission he was noted to have a severe thrombocytopenia, falling 
hemoglobin with MAHA evidenced by high LDH, mild indirect bilirubinemia, and 
presence of schistocytes on a peripheral smear, also noted to have an oliguric 
renal failure. 
During hospital stay he developed a cellulitis requiring fasciotomy, and was 
initiated on hemodialysis in view of worsening renal failure, requiring 8 sessions 
of hemodialysis.  
 
Snake Envenomation syndrome: Hemotoxic with Neurotoxicity and Acute 
Kidney injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
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 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
12.4 
 
9,000 
 
7.46 
 
 
1 
 
14749 
 
1.35 
 
51 
7.1 
 
8,000 
 
5.9 
 
 
4 
 
9541 
7.3 
 
53,000 
 
9.5 
 
 
3.2 
 
3462 
8.6 
 
4,83,000 
 
4.99 
 
 
nil 
 
 
12.0 
 
3,42,000 
 
2.54 
 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
26 
 
- 
 
8 
 
- 
 
Fasciotomy  
 
 
4 
- 
- 
- 
 
Discharged 
 
 
Patient was discharged in a stable condition, persisted to have a non oliguric 
renal failure, not requiring further dialysis, follow up at 3 months showed that he 
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had a persistently elevated creatinine but had decreased significantly hence 
renal biopsy was done which showed: 
Renal Biopsy( at 3 months): Mesangioproliferative glomerulonephritis with 
focal segmental and diffuse global glomerulosclerosis 
Concomitant Interstitial nephritis with focal tubular injury 
IF: Granular mesangial and focal capillary deposits of IgM, IgG and C3 
 
End organ damage in this patient was likely due to Thrombotic Microangiopathy 
and Toxin related glomerulonephritis. 
 
Patient 2: 
36 year old house-wife, from Vellore, presented to CMCH, 36 hours after snake 
bite. She did not have any hemotoxic/neurotoxic snakebites at presentation and 
hence was discharged, told to have a dry bite. At 36 hours she developed oliguric 
renal failure and was noted to have pulmonary edema. 
She did not receive ASV at presentation or at time of admission.  
 
At time of admission he was noted to have a moderate thrombocytopenia, falling 
hemoglobin with MAHA evidenced by markedly increased LDH, mild indirect 
bilirubinemia, and presence of schistocytes on a peripheral smear, also noted to 
have an oliguric renal failure. 
 
During hospital stay he developed a cellulitis, which was treated conservatively 
with antibiotics. She was intiated on early plasmapheresis and hemodialysis in 
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view of probable Thrombotic Microangiopathy and worsening renal failure, 
requiring 4 sessions of plasmapharesis and 2 sessions of hemodialysis.  
 
Snake Envenomation syndrome: Pure Thrombotic Microangipathy 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
 
 
 
 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
12.9 
 
2,43,000 
 
4.02 
 
 
0.8 
 
5225 
 
0.97 
 
24.6 
11.1 
 
46,000 
 
4.99 
 
 
1 
 
3014 
8.6 
 
19,000 
 
5.7 
 
 
1.2 
 
1320 
9.0 
 
1,76,000 
 
10.55 
 
 
nil 
 
 
10.0 
 
2,28,000 
 
0.90 
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Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate/supernatant 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
10 
 
- 
 
2 
 
4 
 
- 
 
 
- 
40 
- 
- 
 
Discharged 
 
 
 
Patient was discharged in a stable condition, persisted to have a non oliguric 
renal failure, not requiring further dialysis, follow up at 3 months showed 
resolved Acute kidney injury with a normal creatinine. 
Initial End organ damage likely caused by a Thrombotic Microangiopathy. 
 
Patient 3: 
36 year old male, vegetable vendor from Vellore, presented to CMCH, 11 hours 
after snake bite. He had initial symptoms of severe pain and bleeding from bite 
site. He did not seek medical attention and at 8 hours post bite he developed 
bleeding from gums with hematuria. At presentation he was noted to have a 
deranged WBCT and hence was given a total of 20 vials of ASV.  
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At time of admission he was noted to have a mild thrombocytopenia, falling 
hemoglobin with MAHA evidenced by markedly increased LDH, indirect 
bilirubinemia, and presence of schistocytes on a peripheral smear, also noted to 
have an oliguric renal failure. 
 
During hospital stay he developed a cellulitis, which was treated conservatively 
with antibiotics. He was intiated on early plasmapheresis and hemodialysis in 
view of probable Thrombotic Microangiopathy and worsening renal failure, after 
1st session of plasmapharesis, he developed fever and worsening cellulitis and 
hence was only continued on cryosupernatant and 14 sessions of hemodialysis.  
 
Snake Envenomation syndrome: Hemotoxic with Acute Kidney injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
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 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
13.4 
 
1,72,000 
 
2.89 
 
 
0.5 
 
8892 
 
2.16 
 
39.7 
11.1 
 
46,000 
 
7.40 
 
 
1.2 
 
6832 
9.3 
 
19,000 
 
7.25 
 
 
4 
 
1810 
8.6 
 
1,76,000 
 
7.39 
 
 
nil 
 
 
10.7 
 
7,17,000 
 
1.56 
 
 
 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate/supernatant 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
18 
 
- 
 
14 
 
1 
 
- 
 
 
2 
16 
- 
- 
 
Discharged 
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Patient was discharged in a stable condition, persisted to have a non oliguric 
renal failure, not requiring further dialysis, follow up at 3 months showed 
resolving Acute kidney injury with persistently elevated creatinine. 
Initial End organ damage, was caused by a Thrombotic Microangiopathy. 
 
Patient 4: 
37 year old house-wife from Chittoor, presented to CMCH, 12 hours after snake 
bite. Initial symptoms developed within 30 minutes, with bleeding from site and 
some minimal gum bleeding.  
She had received first aid from local hospital and first ASV was administered at 
approximately 6 hours and 30 minutes (18 vials). At 8 hours she noticed that she 
was having gross hematuria and decreased urine output. 
 
At time of admission he was noted to have a severe thrombocytopenia, falling 
hemoglobin with MAHA evidenced by high LDH, mild indirect bilirubinemia, and 
presence of schistocytes on a peripheral smear, also noted to have an oliguric 
renal failure. 
During hospital stay she developed a cellulitis, which was treated conservatively 
with antibiotics. She was initiated on early plasmapharesis with 
cryosupernatants, receiving 4 sessions in view of a likely Thrombotic 
Microangiopathy.   
 
Snake Envenomation syndrome: Hemotoxic and Acute Kidney injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
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 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
11.6 
 
72,000 
 
2.00 
 
 
5 
 
3780 
 
2.5 
 
42.9 
9.2 
 
32,000 
 
3.51 
 
 
2 
 
2006 
6.8 
 
75,000 
 
2.58 
 
 
3.5 
 
810 
6.7 
 
1,93,000 
 
0.65 
 
 
4 
 
 
Lost to follow up 
 
 
 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
11 
 
- 
 
- 
 
4 
 
- 
 
 
- 
- 
16 
4 
 
Discharged 
 
 
Patient was discharged in a stable condition, with a completely resolved Acute 
Kidney injury and normal creatinine. 
End organ damage in this patient was due to Thrombotic Microangiopathy. 
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Patient 5: 
30 year old house-wife, from Gudiyatham, presented to CMCH, 12 hours after 
snake bite. Initial symptoms developed within 15 minutes, with pain and 
bleeding from bite site. She had received first aid from local hospital and first 
ASV was administered at approximately 45 minutes (18 vials).  
She was referred to CMCH as he developed gross hematuria decreased urine 
output.  
At time of admission she was noted to have a severe thrombocytopenia, falling 
hemoglobin with MAHA evidenced by high LDH, mild indirect bilirubinemia, and 
presence of schistocytes on a peripheral smear, also noted to have an oliguric 
renal failure. 
In hospital she developed worsening breathlessness, and 3 episodes of 
hemoptysis, requiring NIV and subsequently was started on mechanical 
ventilation for 2 days. During hospital stay she developed a cellulitis, which was 
treated conservatively. She was initiated on hemodialysis in view of worsening 
renal failure, requiring 5 sessions of hemodialysis. As she had a probable 
Thrombotic Microangiopathy she was given 10 units of cryosupernatant. 
Snake Envenomation syndrome: Hemotoxic with Neurotoxicity and Acute 
Kidney injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
9.2 
 
35,000 
 
3.79 
 
 
7.5 
 
21,000 
 
3.59 
 
 
7.3 
 
66,000 
 
4.49 
 
 
9.1 
 
4,45,000 
 
7.26 
 
 
9.4 
 
2,90,000 
 
0.74 
  83 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
0.9 
 
4371 
 
1.12 
 
33.7 
2 
 
2331 
1 
 
1477 
nil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
12 
 
8 
 
5 
 
- 
 
- 
 
 
- 
10 
- 
2 
 
Discharged 
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Patient was discharged in a stable condition, persisted to have a non oliguric 
renal failure, not requiring further dialysis, follow up at 3 months showed a 
completely resolved Acute Kidney Injury, with normal creatinine.  
 
Patient 6: 
42 year old house-wife, from Vellore, presented to CMCH, 2 hour after snake bite. 
Initial symptoms developed within 15 minutes, with pain and bleeding from bite 
site. She had received first aid from local hospital and first ASV was administered 
at approximately 1 hour (20 vials).  
She was referred to CMCH for further management.  
At time of admission she was noted to have a mild thrombocytopenia, falling 
hemoglobin with MAHA evidenced by high LDH, mild indirect bilirubinemia, and 
presence of schistocytes on a peripheral smear, also noted to have an oliguric 
renal failure. 
In hospital she developed worsening breathlessness and fluid overload, hence 
was admitted to ICU for NIV and monitoring. During hospital stay she developed 
a cellulitis, which was treated conservatively. She was initiated on hemodialysis 
in view of worsening renal failure, requiring multiple sessions of hemodialysis. 
Snake Envenomation syndrome: Hemotoxic with Neurotoxicity and Acute 
Kidney injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
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 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
6.0 
 
1,01,000 
 
3.13 
 
 
1.8 
 
2956 
 
1.18 
 
45.9 
7.9 
 
33,000 
 
3.02 
 
 
0.5 
 
4685 
8.3 
 
77,000 
 
5.39 
 
 
1 
 
4572 
6.5 
 
2,61,000 
 
7.27 
 
 
nil 
 
 
7.8 
 
2,62,000 
 
9.79 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
13 
 
4 
 
7 
 
- 
 
- 
 
 
3 
- 
12 
- 
 
Discharged 
 
 
Patient was discharged in a stable condition, persisted to have a non oliguric 
renal failure, but persisted to require further dialysis, follow up at 3 months 
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showed that he had a persistently elevated creatinine but had decreased 
significantly hence renal biopsy was done which showed: 
Renal Biopsy( at 3 months): Cortical parenchymal necrosis with confluent 
glomerular, tubular, arteriolar and arterial necrosis.  
IF: Focal segmental trapping of IgM and C3 in sclerosed tufts. 
 
End organ damage in this patient was likely due to Thrombotic Microangiopathy 
and Acute Tubular Necrosis. 
 
 
 
Patient 7: 
20 year old, male student from Villupuram, presented to CMCH, 12 hours after 
snakebite. Initial symptoms developed within 30 minutes, with bleeding from 
site and some minimal gum bleeding.  
He had received first aid from local hospital and first ASV was administered at 
approximately 6 hours (30 vials). At 8 hours it was noticed that he was having 
gum bleeding, gross hematuria and ptosis. 
 
At time of admission he was noted to have a mild thrombocytopenia, falling 
hemoglobin with MAHA evidenced by elevated LDH, mild indirect bilirubinemia, 
and presence of schistocytes on a peripheral smear, also noted to have a non 
oliguric renal failure. 
During hospital stay he developed a cellulitis, which was treated conservatively 
with antibiotics. He was treated conservatively for the renal failure.   
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Snake Envenomation syndrome: Hemotoxic, Neurotoxicity and Acute Kidney 
injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
 
 
 
 
 
 
 
 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
12.6 
 
1,29,000 
 
3.25 
 
 
0.3 
 
1514 
 
1.22 
 
31.5 
12.0 
 
1,86,000 
 
10.76 
 
 
0.5 
 
1210 
10.5 
 
3,10,000 
 
10.94 
 
 
0.8 
 
980 
10.4 
 
3,81,000 
 
2.06 
 
 
nil 
 
 
 
11.5 
 
3,80,00 
 
1.07 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
13 
 
- 
 
- 
 
- 
 
- 
 
 
- 
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   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
- 
4 
- 
 
Discharged 
 
 
Patient was discharged in a stable condition, with a completely resolved Acute 
Kidney injury and normal creatinine. 
End organ damage in this patient was due to Thrombotic Microangiopathy/ 
Pigment nephropathy. 
 
Patient 8: 
41 year old, male farmer from Chittoor, presented to CMCH, 8 hours after 
snakebite. Initial symptoms developed within 30 minutes, with bleeding from 
site. After about 4 hours he noticed that he was having ptosis. 
He had received first aid from local hospital and first ASV was administered at 
approximately 2 hours (2 vials). He was shifted for further management to 
CMCH. In CMCH he was noticed to have a deranged WBCT, hence was given 10 
vials of ASV. 
 
At time of admission he was noted to have a mild thrombocytopenia, falling 
hemoglobin with MAHA evidenced by elevated LDH, mild indirect bilirubinemia, 
and presence of schistocytes on a peripheral smear, also noted to have a non 
oliguric renal failure. 
During hospital stay he developed a cellulitis, which was treated conservatively 
with antibiotics. He was treated conservatively for the renal failure.   
 
  89 
Snake Envenomation syndrome: Hemotoxic, Neurotoxicity and Acute Kidney 
injury 
TMA Spectrum: Thrombocytopenia, MAHA, schistocytes and End organ damage. 
 
 
 
 0 3 6 Discharge 3 months 
Hb (g%) 
 
Platelets (cumm) 
 
Creatinine 
(mg/dL) 
 
Schistocytes (%) 
 
LDH(IU/dL) 
 
PT/INR 
 
aPTT(s) 
 
 
 
15.7 
 
1,00,000 
 
1.31 
 
 
Nil 
 
1310 
 
>10 
 
48.9 
11.9 
 
89,000 
 
1.64 
 
 
0.5 
 
960 
 13.5 
 
1,10,000 
 
0.83 
 
 
nil 
 
 
 
Lost to follow up 
 
 
Treatment  Requirement 
Hospital Stay (days) 
 
ICU Stay (days) 
 
Dialysis (sessions) 
 
Plasmapharesis (sessions) 
 
Surgical intervention 
 
Transfusion 
   Packed Red cells 
   Cryoprecipitate 
   Fresh Frozen Plasma 
   Platelets 
 
Outcome 
5 
 
- 
 
- 
 
- 
 
- 
 
 
- 
- 
- 
- 
 
Discharged 
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Patient was discharged in a stable condition, with a completely resolved Acute 
Kidney injury and normal creatinine. 
End organ damage, though transient was likely due to Thrombotic 
Microangiopathy/ Acute Tubular Necrosis. 
 
Summary of cases with full spectrum TMA disorder in Prospective cohort(8 
cases) 
The following tables below show summary of 8 patients with full spectrum of 
thrombotic microangiopathy, laboratory values during the course of hospital 
stay with treatment and outcomes. 
In the clinical profile of the patients who had developed a full spectrum of 
thrombotic microangiopathy disorder, patients were identified with the 
presence of fall in hemoglobin, platelets and presence of microangiopathy which 
was evidenced by high LDH, and mild indirect bilirubinemia and schistocytes. 
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Table 15 Profiles of Patients who had Thrombotic Microangiopathy (Prospective): Laboratory Values during admission 
 
 Hb (g%) Plt (cumm) Creatinine 
(mg/dL) 
Sch (%)* LDH (IU/dL) INR aPTT 
(s) 
Time for 
Normalisa
tion of 
INR to 1.4 
0 3 6 D 0 3 6 D 0 3 6 D 3m 0 3 6 D 0 3 6 D 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
12.4 
 
 
12.9 
 
 
13.4 
 
 
11.6 
 
 
9.2 
 
 
6.0 
 
 
12.6 
 
 
15.7 
 
 
 
7.1 
 
 
11.1 
 
 
11.1 
 
 
9.2 
 
 
7.5 
 
 
7.9 
 
 
12.0 
 
 
11.9 
7.3 
 
 
8.6 
 
 
9.3 
 
 
6.8 
 
 
7.3 
 
 
8.3 
 
 
10.5 
 
 
- 
8.6 
 
 
9.0 
 
 
8.6 
 
 
6.7 
 
 
9.1 
 
 
6.5 
 
 
10.4 
 
 
13.5 
0.09 
 
 
2.43 
 
 
1.72 
 
 
0.72 
 
 
0.35 
 
 
1.01 
 
 
1.29 
 
 
1.00 
0.08 
 
 
0.46 
 
 
0.46 
 
 
0.32 
 
 
0.21 
 
 
0.33 
 
 
1.86 
 
 
0.89 
0.53 
 
 
0.19 
 
 
0.19 
 
 
0.75 
 
 
0.66 
 
 
0.77 
 
 
3.10 
 
 
- 
4.83 
 
 
1.76 
 
 
1.76 
 
 
1.93 
 
 
4.45 
 
 
2.61 
 
 
3.81 
 
 
1.10 
7.46 
 
 
4.02 
 
 
2.89 
 
 
2.00 
 
 
3.79 
 
 
3.13 
 
 
3.25 
 
 
1.31 
5.9 
 
 
4.99 
 
 
7.40 
 
 
3.51 
 
 
3.59 
 
 
3.02 
 
 
10.7 
 
 
1.64 
9.5 
 
 
5.7 
 
 
7.25 
 
 
2.58 
 
 
4.49 
 
 
5.39 
 
 
10.9 
 
 
- 
4.99 
 
 
10.5 
 
 
7.39 
 
 
0.65 
 
 
7.26 
 
 
7.27 
 
 
2.06 
 
 
0.83 
2.54 
 
 
0.9 
 
 
1.56 
 
 
- 
 
 
0.74 
 
 
9.79 
 
 
1.07 
 
 
- 
1 
 
 
1 
 
 
1 
 
 
5 
 
 
1 
 
 
2 
 
 
0 
 
 
0 
4 
 
 
1 
 
 
1 
 
 
2 
 
 
2 
 
 
1 
 
 
1 
 
 
1 
3 
 
 
1 
 
 
4 
 
 
4 
 
 
1 
 
 
1 
 
 
1 
 
 
- 
0 
 
 
0 
 
 
0 
 
 
4 
 
 
0 
 
 
0 
 
 
0 
 
 
- 
1474
9 
 
 
5225 
 
 
8892 
 
 
3780 
 
 
4371 
 
 
2956 
 
 
1514 
 
 
1310 
9541 
 
 
3014 
 
 
6832 
 
 
2006 
 
 
2331 
 
 
4685 
 
 
1210 
 
 
960 
3462 
 
 
1320 
 
 
1810 
 
 
810 
 
 
1477 
 
 
4572 
 
 
980 
 
 
- 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
1.35 
 
 
0.97 
 
 
2.16 
 
 
2.5 
 
 
1.12 
 
 
1.18 
 
 
1.22 
 
 
>10 
51 
 
 
24.6 
 
 
39.7 
 
 
42.9 
 
 
33.7 
 
 
45.9 
 
 
31.5 
 
 
48.9 
- 
 
 
- 
 
 
12h 
 
 
18h 
 
 
- 
 
 
-/ 
 
 
- 
 
 
24h 
* Schistocyte figures have been rounded of to the nearest whole number
  92 
Table 16 Profiles of patients who had Thrombotic Microangiopathy: Treatment and Outcomes 
 Hospital 
Stay (days) 
ICU Stay 
(days) 
Dialysis 
(sessions) 
Plasmapharesis 
(sessions) 
Surgical 
Intervention 
Transfusion Outcome 
PRBC Cryo* FFP PRC 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
26 
 
 
10 
 
 
18 
 
 
11 
 
 
12 
 
 
13 
 
 
13 
 
 
5 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
8 
 
 
4 
 
 
- 
 
 
- 
 
8 
 
 
2 
 
 
14 
 
 
- 
 
 
5 
 
 
7 
 
 
- 
 
 
- 
 
- 
 
 
4 
 
 
1 
 
 
4 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
Fasciotomy 
 
 
Conservative 
 
 
Conservative 
 
 
Conservative 
 
 
Conservative 
 
 
Conservative 
 
 
Conservative 
 
 
Conservative 
 
4 
 
 
- 
 
 
2 
 
 
- 
 
 
- 
 
 
3 
 
 
- 
 
 
- 
 
- 
 
 
40 
 
 
16 
 
 
- 
 
 
10 
 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
 
16 
 
 
- 
 
 
12 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
 
4 
 
 
2 
 
 
- 
 
 
- 
 
 
- 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
 
 
Discharged 
* Cryosupernatant
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Temporal profiles of Laboratory values in patients with TMA: 
 
Figure 9 Temporal profile of Hemoglobin 
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Figure 10 Temporal profile of Platelets 
9000 8000
53000
483000
243000
46000
19000
176000172000
8
29000
168000
72000
32000
75000
193000
35000
21000
66000
445000
101000
3
7
261000
129000
186000
310000
381000
89000 89000
108000 110000
0
100000
200000
300000
400000
500000
600000
0 3 6 Discharge
P
la
te
le
ts
(/
cu
m
m
)
Days
Platelet count(/cumm)
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
  95 
 
Figure 11 Temporal profile of Creatinine 
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Figure 12 Temporal profile of LDH
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Clinical picture of patients with full spectrum TMA disorder in the prospective 
cohort (8 patients) 
The clinical syndrome in 8 patients were:  
All the 8 patients had Russell’s viper envenomation syndrome. 7 patients 
developed cellulitis. 7 patients had clinical bleeding, (VICC present in 3 patients): 
all had minor bleeding from bite site or mucosal bleeding, 4 patients had gross 
hematuria. There was not major systemic bleeding in any of the cases. 
Laboratory Values of patients who had full spectrum TMA in the prospective 
cohort (Refer to table 13) 
Patients were noted to have a fall in hemoglobin and platelets between 6th day, 
with nadir between day 3-6, after which there was a gradual improvement. 
Similar findings were noted in the platelet count, where it was noted that the 
maximal fall in platelet count occured till the 3rd day after which there was a 
plateau till the 6th day, after which there was steady improvement. Renal 
functions worsened from the first day of admission till the 3rd day after which 
there was improvement. Most patients had achieved nadir creatinine by 
discharge and 75% of patients achieved this by 3 months. 2 patients persisted to 
have renal dysfunction, hence renal biopsies were done, which showed cortical 
necrosis in one patient and glomerulonephritis in the other patient. 
LDH reached peak on day 0 after which there was a gradual decline. However the 
LDH was elevated even at discharge. In 7 out of 8 patients schistocytes were 
present till day 6. The peak schistocyte percentage was between day 3-6. In one 
patient schistocytes were present even at discharge. 3 patients had an abnormal 
INR, which normalized by between 12 -24 hours in all patients. 
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Treatment and outcomes of patients who had full spectrum TMA in the 
prospective cohort (Refer to table 13) 
3(37.5%) received early plasmapharesis. Six patients required transfusion 
therapy, cryosupernatant (3 patients), FFP (2 patients), PRC (2 patients) and 
packed cells (3 patients). In all these patients transfusion was for TMA and not 
for clinical bleeding. 5 patients required dialysis. 1 patient required fasciotomy. 
All patients had improvement of renal functions and at 3 months they had 
normalized creatinine levels. In all the patients in the prospective cohort, the 
final outcomes were good and all patients were discharged from hospital. 
The overall clnical picture suggests that VICC resolved within 48 hours. However 
the TMA picture evolved over 3-6 days with worsening hemoglobin, platelet 
count, creatinine and persisting schistocytes which gradually improved after 6 
days and a proportion of patients having persisting renal dysfunction. 
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Salient Findings of the study: 
1. Spectrum disorder:  
The thrombotic microangiopathy is spectrum disorder ranging from isolated 
thrombocytopenia (52.1%), thrombocytopenia with microangiopathic hemolytic 
anemia (MAHA) (7.4%), thrombocytopenia with microangiopathic hemolytic 
anemia and renal failure (40.5%).  
There were no cases with neurological involvement suggestive of thrombotic 
thrombocytopenic pupura (TTP) or TTP/hemolytic uremic syndrome (HUS) 
overlap. 
Patients who had full spectrum disorder TMA with thrombocytopenia, MAHA, 
renal failure and schistocytes had the most severe form of disorder. 
Patients with renal failure without schistocytes were not as severe as the full 
spectrum disorder.  
 
2. Association with envenomation syndrome: 
TMA spectrum is strongly associated only with Russell’s viper envenomation 
syndrome (69.3%). Pure hemotoxicity is associated with milder forms of the 
disorder (81% had thrombocytopenia). There were no cases of full spectrum 
disorder with pure hemotoxicity. 
Typical Russell’s viper envenomation syndrome is associated with full spectrum 
TMA disorder (full spectrum disorder in Russell’s viper envenomation 39.5%). 
 
3. TMA association with VICC:  
The majority of patients had VICC (81%). About 19 % of TMA picture did not 
have VICC. TMA picture with VICC had milder forms of the TMA spectrum. 
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TMA picture without VICC had more severe forms of the TMA spectrum. 
The severity of the thrombocytopenia did not correlate to the presence of VICC 
suggesting that it was not the VICC process that was inducing the 
thrombocytopenia. 
In the majority of patients TMA and VICC occur together. However TMA can also 
occur independently of VICC.  
However the VICC resolves within 24 hours and TMA process progresses over 3-
6 days. Therefore VICC precedes the onset of TMA. 
 
4. Outcome of TMA:  
The full spectrum disorder was associated with higher ASV dose, blood products, 
dialysis and plasmapharesis, requirement of ICU care, longer duration of ICU 
admission and hospitalization and more mortality. 
 
5. Comparison of prospective and retrospective arms of study: 
There was a difference in the clinical profile, treatment and outcome of TMA 
spectrum in the retrospective and prospective study groups. 
The full TMA spectrum disorder frequency was higher in the prospective study 
suggesting that there was higher index of suspicion for diagnosis 
The proportion of patients with full spectrum disorder without VICC was also 
greater. 
The proportion of patients dialysed, required blood transfusion, who underwent 
plasmapharesis, ICU admission and duration of hospitalization and ICU care was 
greater in the prospective study.   
  101 
The clinical outcome of full spectrum disorder had significantly improved in the 
prospective arm compared to the retrospective arm.  
 
6. Descriptive study of full spectrum disorder in prospective arm 
The descriptive study of 8 cases of full spectrum disorder in the prospective 
study showed that: 
Nearly all the cases except one had VICC/bleeding which resolved in <24 hours 
and was associated with minor bleeding. The syndrome was associated with 
worsening hemoglobin, platelet count and renal functions and presence of 
schistocytes, all of which peaked over 3-6 days and then improved by discharge. 
Five patients required dialysis, blood or blood product transfusion and 3 
required plasmapharesis. The most common products used were packed cells 
and cryosupernatant. 
 
Overall the full TMA spectrum disorder had a good clinical outcome. 
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DISCUSSION 
 
This study was designed to determine the prevalence of TMA in hemotoxic 
snakebites and its correlation to envenomation syndromes and venom induced 
consumption coagulopathy. 
1. Prevalence of TMA spectrum and full spectrum disorder 
The study determined that the overall prevalence of TMA spectrum was 51.35% 
in the prospective cohort and full spectrum TMA disorder was 21.6%. The 
prevalence of TMA spectrum in the retrospective cohort was 35.9% and full 
spectrum TMA disorder was 7.74%. 
2. TMA as a spectrum Disorder 
The study confirmed that the disorder of TMA in hemotoxic snake bites is a 
spectrum disorder which varies from isolated thrombocytopenia, 
thrombocytopenia with MAHA and thrombocytopenia, MAHA and renal failure 
(see figure below) 
 
Figure 13 TMA spectrum Disorder 
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3. Thrombotic microangiopathy relationship with envenomation syndrome 
It was noted that a majority of the hemotoxic snakebites had a Russell’s viper 
like envenomation syndrome (69.4%). More importantly all the patients (30 
subjects) who had full spectrum TMA had presented with Russell’s viper 
envenomation syndrome. We are unable to identify the exact species of biting 
snake, as the snake was not brought to hospital, and venom detection assays 
were not performed. Based on envenomation syndromes, Russell’s viper is likely 
to have been the biting species in all the patients with the full spectrum disorder. 
4. Relationship between VICC and TMA 
When we looked at Venom induced consumption coagulopathy it was clear that a 
majority of hemotoxic snakebites presented with VICC (81%). In correlation to 
TMA, we noted that there was a patient group who did not have VICC, but 
presented with Thrombocytopenia (19%). Subjects, who had presented with 
VICC, had a less severe form of TMA and most patients had isolated 
thrombocytopenia (58.1%) with less number of patients having the full 
spectrum of TMA. Majority of the patients had a mild thrombocytopenia (56.1%). 
Where as in the patients without VICC there was a higher incidence of the full 
spectrum (60.9%) and these patients had more severe thrombocytopenia 
(30.4% as compared to 23.5%). The group of patients with TMA spectrum 
without VICC, had more severe manifestations and outcomes. 
The results suggest that VICC and TMA are co-existing and overlapping 
conditions. The majority of patients with TMA have VICC (80%). However TMA 
can occur independently of VICC in 20% of cases. VICC resolves in 24 hours and 
TMA evolves over 3-6 days. Therefore it is possible that VICC is the initiating 
factor for TMA. 
  104 
5. Severity and outcomes of TMA 
The coagulopathy, which is attributed to venom induced consumption 
coagulopathy (VICC), resolves rapidly and there is a transient fall in the platelet 
count. In patients who have a TMA, there is a persistent thrombocytopenia, 
which in our patients started resolving around the 6th day of admission. In 
patients who had renal failure, the renal injury usually resolves in about 1-6 
weeks. Most patients had almost complete resolution of acute kidney injury. In 
our patients we have not done renal biopsies unless there was a persistent renal 
failure at 12 weeks. Of the patients who had a TMA, only 2 patients persisted to 
have renal dysfunction and renal biopsy was performed on them. The first 
patient had glomerulonephritis, with C3 and IgM deposition and the second 
showed a cortical necrosis.  
In the prospective cohort it was noted that the patients who had developed TMA 
had a delay in administration of ASV although it was not statistically significant. 
In most cases, the ASV was administered more than four hours after 
envenomation. This finding is similar to Isbister et al, in case of Australian tiger 
snake TMA (reference).  
We additionally looked at severity and outcomes of illness in patients with TMA. 
Here we have shown that patients who had a full spectrum of thrombotic 
microangiopathy with renal failure had a more severe illness, based on the 
clinical and laboratory values, compared to the other groups in the spectrum. 
Patients in this group had lower hemoglobin, platelets counts and had the 
highest creatinine values, which was inversely proportional to the coagulopathy, 
where PT/INR and aPTT was lower as compared to the other groups. Treatment 
outcomes were also noted to be worse in the TMA spectrum with renal failure, 
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requiring higher doses of ASV with longer hospital/ICU stay, and with 73.3% of 
these patients requiring dialysis. Hence it is clear that patients who developed a 
TMA full spectrum disorder have a more severe illness with worse outcomes.  
6. Pathogenesis of TMA 
Based on the clinical data we suggest a two-step process in occurrence of 
thrombotic microangiopathy.  
Step 1 
1. The VICC process of activation of Factor V and X in Russell’s viper 
envenomation may lead to thrombin activation and formation of fibrin 
clot which may induce intra-vascular thrombosis. 
2.  In addition to this Russell’s viper venom may induced endothelial 
injury and injury to the basement membrane which may cause platelet 
aggregation and activation of coagulation cascade through VII 
activation.  
Step 2 
The intravascular thrombosis, which occurs in step 1, could lead to 
microangiopathy with thrombocytopenia, haemolytic anaemia and renal failure. 
 (See diagram of pathogenesis of TMA and relationship to VICC) 
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Figure 14 Hypothesis for pathogenesis of TMA and relationship to VICC 
 
 
 
7. Differences and similarities of TMA spectrum in snake envenomation from 
other TMA disorders 
The TMA spectrum of snake envenomation is probably unrelated to the primary 
TMA disorders where the thrombi consist of platelets and vWF and not red cells 
and fibrin. The TMA disorder is probably unlike Shiga toxin induced HUS, drug 
induced TMA, autoimmune disease with inhibitors to ADAMTS13 activity or 
inherited deficiency of ADMTS 13. In the primary TMA the deficiency of activity 
of ADMTS 13 is important in the formation of vWF multimers that induce 
formation of microthrombi. Primary TMAs have prominent neurological 
manifestations. The TMA spectrum of snake envenomation is probably similar to 
the secondary TMA with severe infections and DIC, malignancies and abruption 
placenta, where there is prolongation of PT INR, APTT and there is activation of 
the coagulation cascade. The paucity of neurological manifestations and 
prominent coagulopathy suggest that the pathogenesis is through activation of 
the coagulation cascade.  
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8. Comparison of the results of the study with other studies of snake bite induced 
TMA 
A study of HUS in snake bite from Christian Medical College in 1986 of 24 
patients showed a similar clinical picture to the present study. Seven cases were 
identified as Russell’s viper envenomation. A kidney biopsy was performed in 15 
cases which showed acute tubular necrosis in 13 cases and acute cortical 
necrosis in 2 cases. (43) 
A case report from Sri Lanka of Russell’s viper envenomation with thrombotic 
microangiopathy, showed a similar clinical picture to our study.  They suggested 
that the TMA combined with VICC to produce a DIC picture. Plasmapharesis may 
be beneficial only if the ADAMTS 13 activity is deficient. Therefore the role of 
plasmapharesis in snake bite envenomation induced TMA is unclear. (44) 
A case report of two patients with viper induced TMA were treated with with 
hemodialysis and plasmapheresis. Renal biopsy showed thrombi within 
glomeruli and arterioles and cortical necrosis. One patient developed end stage 
renal disease. (37) 
In a study of 103 patients with snake bite induced renal failure, 18.5% developed 
TMA. All patients required dialysis and patients who developed TMA required 
higher doses of ASV and longer hospitalisation. There was no difference in 
outcome of those who were treated with plasmapheresis and those who were 
not. (38) 
The clinical profile in these studies is very similar to that which we observed in 
this study. 
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Thrombotic manifestations of Russell’s viper bite have been described such as 
the presence of strokes. However in this study we could not demonstrate any 
such large vessel thrombotic manifestations. The clinical picture was that of 
arteriolar Microangiopathy. 
9. Treatment of TMA 
Treatment modalities that were used in patients with TMA in our study were: 
plasmapharesis, transfusion of blood products, and dialysis. Compared to the 
retrospective cohort, more patients were treated with plasmapharesis (15.8% 
compared to 2.9%), in the prospective cohort patients. Those who were treated 
with plasmapharesis had good outcomes and all of the patients had resolved 
acute kidney injury at the end of 3 months, as compared to the retrospective 
cohort where 3 patients had received plasmapharesis, in which 1 patient died 
and the other persisted to have elevated creatinine and had non oliguric chronic 
kidney disease at follow up. Therefore it is still unclear whether plasmapharesis 
should be used as a standard treatment for TMA. Surprisingly patients who had 
received cryosupernatant/cryoprecipitate had similar outcomes to those who 
underwent plasmapharesis. In the prospective cohort, 1 patient received 
cryosupernatant and had a complete resolution of acute kidney injury and TMA. 
In the retrospective cohort 2 patients received cryoprecipitate/cryosupernatant, 
out of which 1 patient died and the other had improvement in acute kidney 
injury and TMA, but persisted to have a non oliguric chronic kidney disease at 
follow up. There did not appear to be difference in the outcome between 
cryosupernatant/cryoprecipitate. Since cryosupernatant transfusion is cheaper, 
it can be used in the treatment of patients thrombotic microangiopathy, 
especially in hospitals, which do not have facilities to carry out plasmapharesis. 
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Further well-designed studies are required to validate these findings and to 
prove benefit of plasmapharesis and cryosupernatant transfusions in TMA. The 
mechanism whereby blood products benefit the management of snakebite 
induced TMA is unclear. It could replace ADAMTS 13 or enable the creation of 
equilibrium between the pro-coagulant and fibrinolytic system. 
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LIMITATIONS 
 
1. ADAMTS/ Complements have not been looked at, and a consumption of 
ADAMTS 13, may be the reason for Thrombotic Microangiopathy in snakebites. 
2. Study was not designed to examine the effects of different treatment 
modalities and compare benefits in these patients. 
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CONCLUSION 
 
1. The TMA disorder is a spectrum disorder consisting of isolated 
thrombocytopenia, thrombocytopenia with MAHA, Thrombocytopenia with 
MAHA and renal failure. The most severe form of the disorder is the full 
spectrum disorder, with thrombocytopenia and MAHA, schistocytes and renal 
failure, associated with a mortality of 20%. 
2. The TMA spectrum disorder is probably due to Russell’s viper envenomation. 
The full spectrum disorder occurs only in Russell’s viper envenomation. 
3. The TMA disorder and VICC are usually coexistent and closely related. VICC 
resolves in the first 24 hours followed by TMA spectrum which evolves over 3rd 
to 6th day. In one-fifth of patients TMA can occur independent of VICC.  VICC may 
play a role in initiating the TMA spectrum. 
4. The TMA spectrum disorder affects predominantly the hematological and 
renal system sparing the central nervous system. 
5. The quality of care for full spectrum disorder has improved with greater 
recognition of the TMA syndrome, use of product transfusions, plasmapharesis 
and overall improvements of care, which have led to reduction of mortality. 
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CLINICAL IMPLICATIONS 
 
1. Clinicians need to have a high index of suspicion of TMA in hemotoxic 
envenomation. 
2. Simple tests including peripheral blood smear for schistocytes, platelet count, 
hemoglobin, LDH and serum creatinine should be monitored for the first few 
days after hemotoxic snake bites. 
3. Early appropriate antivenom therapy in hemotoxic snake bite may play a role 
in preventing TMA.  
4. Patients with full spectrum disorder should be managed with good supportive 
care and individualized management including product support, dialysis and 
plasmapheresis where required. Cryosupernatant therapy may be considered as 
the product of choice for cost-effective transfusion therapy.
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ANNEXURE 2: Consent Forms 
 
Thrombocytopenia, Microangiopathy and End Organ damage 
in Snake Bites 
 
Investigator: Dr.Anil Mathew Philip 
 
 
Please initial each box & sign at bottom 
 
 
1.  
I confirm that I have read and understood the ‘Patient 
Information Sheet’ for the above study. I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2.  
I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason and 
without my medical care or legal rights being affected 
 
3.  
I understand that relevant sections of any of my medical 
notes and data collected during the study may be looked at 
by responsible individuals from CMC Hospital. I give 
permission for these individuals to have access to my 
records. 
 
4.  
I consent to my data being retained if I withdraw from the 
study 
 
5.  I agree to take part in the above study. 
 
 
 
 
……………………………… ……………… ……………………… 
Name of patient/ Date / Signature 
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……………………………… ……………… ……………………… 
Researcher Name/ Date / Signature 
                                   సమ్మ తి ఫారం 
 
1. Thrombocytopenia, Microangiopathy and End Organ damage in 
Snake Bites 
2. Characterisation of Venom Induced Consumption Coagulopathy 
(VICC) in patients with Haemotoxic Snake Bite and the effects of 
Blood Products on Coagulation Parameters 
3. Clinical profile and transfusion requirements in VICC 
 
పరిశోధకులుగా: Dr. ఫిలిప్, Dr. జెస్ ఎలిజబెత్ రసలం, Dr. రాచన 
షెనోయ్ 
  
దయచేసి దిగువ ప్రతి పెట్టనెు & సైన్ని  తన్నఖీ చేయండి 
1.  1. పై అధ్య నాల కోసం 'పేషంట్ ఇన్ఫ ర్మే షన్ షీట్' ను నేను చదివాను 
మరియు అర్ థం చేసుకునిా న్న్న నేను న్నరా్ధరిసుునిా ను. నేను సమాచార్ధన్ని  
రరిశీలి 0 చే అవకాశ 0 ఉ 0 ది, ప్రశి లను అడగాలి, ఈ ప్రశి లకు స 0 
తృప్తుకర్మైన్ జవాబు లభి 0 చి 0 ది. 
 
2.  నా పాలొ్గన్డం సవ చఛ ందమన్న నేను అర్ థం చేసుకునిా ను మరియు 
ఎటువంటి కార్ణం లేకుండా, నా వైదయ  సంర్క్షణ లేదా చట్రెర్మైన్ 
హకుు లు లేకుండానే ఏ సమయంలోనైనైనా ఉరసంహరించుకోవడం నాకు 
ఉచితం. నేను అధ్య న్ం కోసం పూరిు చేసిన్ ఏ అదన్పు రరీక్షల కోసం 
చెలిలంచవలసిన్ అవసర్ం లేదన్న కూడా నేను అర్ థం చేసుకునిా ను. 
 
3.  ఈ అధ్య న్ంలో సేకరించిన్ నా వైదయ  గమన్నకలు మరియు 
సమాచార్ంలోన్న సంబంధిత సెక్షనుల CMC హాసిి ట్ల్ నుండి బాధ్యయ లైన్ 
వయ కుులు చూస్తు ర్న్న నేను అర్ థం చేసుకునిా ను. ఈ వయ కుులు నా రికార్డులను 
ప్పాప్తు చేయడాన్నకి నేను అనుమతిన్నసుునిా ను. 
 
4.  2. నేను అధ్య న్ం నుండి ఉరసంహరించుకుంటే నా డేటాను 
న్నలుపుకోవటాన్నకి నేను అంగీకరిసుునిా ను 
 
5.  3. పై అధ్య న్ంలో పాలొ్గన్డాన్నకి నేను అంగీకరిసుునిా ను. 
4.  
 
 
………………………………            ………………            
……………………… 
రోగి పేరు                            తేదీ             సంతకం 
 
………………………………             ………………            
……………………… 
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పరిశోధకుడు               తేదీ  సంతకం 
 
ஒப்புதல் படிவம் 
  
1.Thrombocytopenia, Microangiopathy and End Organ damage in 
Snake Bites 
2.Characterisation of Venom Induced Consumption Coagulopathy 
(VICC) in patients with Haemotoxic Snake Bite and the effects of Blood 
Products on Coagulation Parameters 
3.Clinical profile and transfusion requirements in VICC 
 
விசாரணை: மருத்துவர். பிலிப்,  
மருத்துவர். ரஸலம்,  
மருத்துவர். ஷென ா 
  
 கீழே ஒவ்வ ொரு வெட்டியை டிக் வெய்ைவும் 
6.  5. னமற்கூறிய ஆராய்ச்சிக்கு 'ன ாயாளி தகவல் தாள்' என்பணத  ான் படித்து புரிந்து 
ஷகாண்னேன் என்பணத உறுதிப்படுத்துகினேன். இந்த தகவணலக் கருத்தில் 
ஷகாள்ளவும், னகள்விகணளக் னகட்டு, திருப்திகரமாக பதிலளித்திருந்னதன். 
 
7.  என் பங்களிப்பு முழுவதும் என் சுய முடிவு  என்பணத  ான் புரிந்துஷகாள்கினேன், 
எப்னபாது னவண்டுமா ாலும் விடுதணலணயத் தவிர்த்னதன், என் மருத்துவ கவனிப்பு 
அல்லது சட்ே உரிணமகள் இல்லாமல் பாதிக்கப்போமல் விடுகினேன். ஆய்வின் 
ன ாக்கத்திற்காக ஷசய்யப்படும் கூடுதல் பரினசாதண களுக்கு  ான் பைம் ஷசலுத்த 
னவண்டியதில்ணல எ வும் எ க்குப் புரிகிேது. 
 
 
8.  ஆய்வின் னபாது னசகரிக்கப்பட்ே எ து மருத்துவ குறிப்புகள் மற்றும் தரவுகளின் 
எந்த பகுதியும் சம்பந்தப்பட்ே பிரிவுகணள CMC ணவத்தியசாணலயிலிருந்து 
ஷபாறுப்புள்ள தனி பர்கள் பார்த்துக் ஷகாள்ளலாம் என்பணத  ான் புரிந்து 
ஷகாள்கினேன். எ து பதிவுகணள உபனயாகிப்பதற்கு  இந்த  பர்களுக்கு அனுமதி 
தருகினேன். 
 
9.  6.  ான் படிப்பிலிருந்து விலகி இருந்தால் என் தரவு தக்கணவத்துக்ஷகாள்ள 
ஒப்புக்ஷகாள்கினேன் 
 
10.  7. னமற்கண்ே ஆய்வுகளில் பங்னகற்க  ான் ஒப்புக்ஷகாள்கினேன்.  
 
………………………………            ………………            
……………………… 
ன ாயாளியின் ஷபயர்                 னததி   ணகஷயாப்பம் 
 
………………………………            ………………            
……………………… 
ஆராய்ச்சியாளர்                     னததி              ணகஷயாப்பம் 
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ANNEXURE 3: Patient Information Sheet 
 
Thrombocytopenia, Microangiopathy and End Organ damage 
in Snake Bites 
 
 
You are being invited to take part in a research study. Before you decide 
whether to takepart, it is important for you to understand why the research is 
being done and what it willinvolve. Feel free to discuss the study with others if 
you wish. Please take time to decidewhether or not you wish to take part. 
 
 
………………………………………………. 
 
 
1. What is the purpose of this study? 
The aim of this study is to collect information on patients such as yourself who 
have had a snake bite to determine what effects snake venom has on the blood 
vessels and blood. 
 
The study will follow patients with snakebite admitted to CMC Hospital over a 
period oftime to see how well they do. The type of treatment patients receive 
will not be altered bytaking part in this study. 
 
The results from this study will enable clinicians to make a more informed 
decision aboutwhich treatment option will be best for individual patients. 
 
We aim to analyse all the information collected in order to: 
a. Understand the effects of snake bite on the blood clotting mechanisms. 
b. Try to understand and study different methods to assess the severity of 
snakebite 
c. Understand how different people recover from the snake bite and what the 
clinical 
course is. 
 
 
2. Why have I been invited? 
You have been invited to take part in this study because you have been 
diagnosed with asnake bite and have admitted to CMC Hospital, Vellore. Your 
doctor will have identified youas a patient who is eligible for the study, and 
your treatment remains the same. 
 
 
  127 
3. Do I have to take part? 
No. Your participation in this study is entirely voluntary. If you decide to take 
part you willbe asked to sign a consent form. You are under no pressure to take 
part and may withdrawfrom the study if you wish at any time, without having 
to explain why. If you decide not totake part, the quality of medical and 
nursing care you receive will not be affected. With yourpermission we will 
keep the information we have already collected about you. You will notbe 
contacted again about the study. 
 
 
4. What will happen to me if I take part? 
If you agree to take part you will be observed from the time you agree to take 
part until youleave the hospital. No additional tests will be undertaken as part 
of the study, but you willbe asked to give permission for your medical records 
to be examined in detail, in order tocollect information about your health status 
and any treatments that you have throughoutyour hospital stay. 
Your treatment options will not be altered in any way by taking part in this 
study. Yourdoctor will decide on the best treatment for you. Participation in the 
study does not restrictyour ability to change from one treatment option to 
another. 
There will be no additional visits as part of the study. 
 
 
5. What are the possible disadvantages and risks of taking part? 
There are no anticipated disadvantages or risks involved in this study as it is an 
observational study of the routine care for patients with snake bite. 
 
 
6. What are the benefits of taking part? 
There are no direct benefits to yourself from taking part in this study but the 
informationwe get may help to improve the treatment of other people with 
snake bite in the future. 
 
 
7. What if there is a problem? 
If you have a concern about any aspect of this study, you can speak with the 
researcherswho will do their best to answer your questions. If you remain 
unhappy and wish tocomplain formally, you can do this through the CMC 
Hospital Complaints Procedure. Detailscan be obtained from your doctor. 
 
 
8. Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of this study will 
be kept 
strictly confidential. Paper records regarding your case and your study number 
will be heldsecurely. Electronic information will be kept on computers that are 
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protected by passwords. 
The electronic data stored for this study will be kept on a database, but we will 
not keepany identifiable information.When the study is reported it will not be 
possible to identify you personally.Confidentiality will be maintained at all 
times. 
 
 
9. What will happen to the results of the research study? 
The results of the study will be written up and published in scientific journals 
and presentedat scientific meetings. You will not be identified in any 
report/publication. 
 
 
10 . Who is organising and funding the research? 
The study is being organised and run by the Departments of Accident and 
Emergency, 
Internal Medicine, Medical Intensive Care Unit and Transfusion Medicine and 
Immunohaematology at CMC Hospital Vellore.The doctor and the research 
team conducting the research are not receiving additionalpayments for 
including you in this study. 
 
 
11. Who has reviewed the study? 
This study was reviewed and approved by the Institutional Review Board and 
Ethics 
Committee of Christian Medical College Hospital Vellore. 
 
 
 
Contact details: 
In the first instance please contact Dr. Anil Mathew Philip at Department of 
Medicine Unit I (2nd Floor, OPD building, CMC Hospital, Vellore-632002, 
Mobile Number-9567263773) 
 
Alternatively, you can speak to one of the supervising Consultants – 
Dr. Anand Zachariah, Department of Internal Medicine Tel: 04162282089 
 
 
Thank you for taking time to read this sheet and for considering taking part in 
this study. 
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Thrombocytopenia, Microangiopathy and End Organ damage 
in Snake Bites (Telugu) 
 
 
మీర్డ రరిశోధ్నా అధ్య న్ంలో పాలొ్గన్డాన్నకి ఆహావ న్నంచబడాు ర్డ. మీర్డ 
తీసుకునే న్నర్ ణయం తీసుకునే మందు, రరిశోధ్న్ ఎందుకు జర్డగుతందో 
అర్ థం చేసుకోవడం మరియు అది ఏమయందో అర్ థం చేసుకోవడం చాలా 
మఖ్య ం. మీర్డ కోర్డకుంటే, ఇతర్డలతో అధ్య న్ం గురించి 
చరిచ ంచండి. మీర్డ పాలొ్గన్డాన్నకి కోర్డకునాి రో లేదో న్నర్ ణయంచుకోవడాన్నకి 
సమయం రడుతంది. 
....................................................... 
1. ఈ అధ్య న్ం యొకు  ఉదే్దశయ ం ఏమిటి? 
ఈ అధ్య న్ం యొకు  లక్షయ ం ఏమిట్ంటే పామ విషం ర్క ు నాళాలు 
మరియు ర్క ుం మీద ఏ ప్రభావాలను కలిగి ఉందో తెలుసుకోవడాన్నకి ఒక 
పామ కాటు కలిగి ఉన్ి  మీ వంటి రోగులపై సమాచార్ధన్ని  సేకరించడం. 
 
ఈ అధ్య న్ంలో సిఎంసి ఆసురప్తికి చికితస  చేసుున్ి  రోగులను వార్డ 
ఎంత బాగా చేస్తు రో చూడడాన్నకి కంతకాలం పాటు తీసుకుంటార్డ. చికితస  
పందిన్ రోగుల ర్కాన్ని  ఈ అధ్య న్ంలో భాగమైన్ మార్డి ను 
మార్చ లేర్డ. 
 
ఈ అధ్య న్ం యొకు  ఫలితాలు వైదయ  న్నపుణులు మరింత సమాచార్ం 
తీసుకునే న్నర్ ణయం తీసుకునేలా చేసుుంది, ఇది ఏమైనా రోగులకు ఉతుమ 
చికితస గా ఉంటుంది. 
 
మేమ సేకరించిన్ మొతుం సమాచార్ం విశ్ల లషంచడాన్నకి మేమ లక్షయ ంగా 
పెటెుకునిా మ: 
ఒక. ర్క ుం గడు కటే ెవిధానాలపై పామ కాటు యొకు  ప్రభావాలను అర్ థం 
చేసుకోండి. 
బి. పామబైట్ యొకు  తీప్వతను అంచనా వేసేందుకు వివిధ్ రదాతలను 
అర్ థం చేసుకోవడాన్నకి మరియు అధ్య న్ం చేయడాన్నకి ప్రయతిి ంచండి 
సి. పామ కాటు నుండి ఎలాంటి వేర్మవ ర్డ వయ కుులు తిరిగి ర్ధవాలో మరియు 
క్లకి లన్నకల్ ను ఎలా అర్ థం చేసుకోవచ్చచ  అర్ థం చేసుకోండి 
కోర్డస  ఉంది. 
 
2. నేను ఎందుకు ఆహావ న్నంచబడాును? 
మీర్డ ఈ అధ్య న్ంలో పాలొ్గన్డాన్నకి ఆహావ న్నంచబడాు ర్డ ఎందుకంటే 
మీర్డ ఎర్డపు కాటుతో బాధ్రడుతనాి ర్డ మరియు CMC హాసిి ట్ల్, 
వెల్లల రోల చేరిన్ందున్. మీ డాకరె్ మిమే లిి  గురిుంచి, అధ్య న్ం కోసం 
అర్డులైన్ రోగిన్న గురిుంచి, మీ చికితస  అద్ద విధ్ంగా ఉంటుంది. 
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3. నేను పాలొ్గనాలా? 
ఈ అధ్య న్ంలో మీర్డ పాలొ్గన్డం పూరిుగా సవ చఛ ందంగా ఉంది. మీర్డ 
పాలొ్గన్డాన్నకి న్నర్ ణయంచుకుంటే మీర్డ ఒక సమే తి రూరంలో సంతకం 
చేయమన్న కోర్ధర్డ. మీర్డ ఎపిు డైనా కోర్డకుంటే, ఎందుకు పాలొ్గన్డాన్నకి 
ఒతిుడి చేయకుండా మరియు అధ్య న్ం నుండి 
ఉరసంహరించుకోవచుచ . మీర్డ పాలొ్గన్డాన్నకి న్నర్ ణయంచకపోతే, మీర్డ 
పందిన్ వైదయ  మరియు న్రిస ంగ్ సంర్క్షణ నాణయ త ప్రభావితం కాదు. మీ 
ట్టసిమెోషన్ తో మేమ మీ గురించి ఇరి టికే సేకరించిన్ సమాచార్ం 
ఉంచుతామ. మీర్డ ఈ అధ్య న్ం గురించి మళ్లల సంప్రదించలేర్డ. 
 
 
4. నేను పాలొ్గంటే, నాకు ఏమవుతంది? 
మీర్డ పాలొ్గన్డాన్నకి అంగీకరిసేు, మీర్డ ఆసురప్తిలో చేర్డం వర్కు 
పాలొ్గన్డాన్నకి అంగీకరిసుున్ి  సమయంలో మీర్డ గమన్నంచవచుచ . 
అధ్య న్ంలో భాగంగా అదన్పు రరీక్షలు జర్డగుతాయ, కానీ అదన్పు 
ఛారీలీు తీసుకోవు. 
మీ ఆరోగయ  క్లసిథతి గురించి మరియు మీ ఆసురప్తిలో న్నవసించే అన్ని  
చికితస ల గురించి సమాచార్ధన్ని  సేకరించేందుకు మీ మెడికల్ రికార్డులను 
వివర్ంగా రరిశీలించడాన్నకి అనుమతి ఇవావ లన్న మీర్డ కోర్డతార్డ. 
మీ చికితస  ఎంప్తకలు ఈ అధ్య న్ంలో పాలొ్గన్డం దావ ర్ధ ఎలాంటి 
మార్డి లు చేయబడవు. మీ డాకరె్ మీ కోసం ఉతుమ చికితస ను న్నర్ ణయస్తుర్డ. 
ఈ అధ్య న్ంలో పాలొ్గన్డం అనేది ఒక చికితాస  ఎంప్తక నుండి 
మరొకదాన్నకి మార్చ డాన్నకి రరిమితం కాదు. 
అధ్య న్ంలో భాగంగా అదన్పు సందర్శ న్ల ఉండదు. 
 
5. స్తధ్య ం న్షె్టలు మరియు పాలొ్గనే ప్రమాదాలు ఏమిటి? 
ఈ అధ్య న్ంలో ఎటువంటి ఊహంచన్న న్షె్టలు లేదా ప్రమాదాలు లేవు 
ఎందుకంటే ఇది ఒక 
పామ కాటు రోగులకు స్తధార్ణ సంర్క్షణ యొకు  రరిశీలన్ అధ్య న్ం. 
 
6. పాలొ్గనే ప్రయోజనాలు ఏమిటి? 
ఈ అధ్య న్ంలో పాలొ్గన్డం నుండి మీకు ఎటువంటి ప్రతయ క్ష 
ప్రయోజనాలు లేవు కాన్న భవిషయ తులో ఇతర్ వయ కుుల చికితస ను 
మెర్డగురర్చ డాన్నకి సమాచార్ం అందుతంది. 
 
7. సమసయ  ఉంటే ఏమి చేయాలి? 
మీర్డ ఈ అధ్య న్ం యొకు  ఏ అంశంపై ఒక ఆందోళన్ కలిగి ఉంటే, 
మీర్డ రరిశోధ్కులతో మాటాల డగలర్డ: మీ ప్రశి లకు సమాధానాలు 
ఇవవ టాన్నకి వార్డ ఉతుమంగా ఉంటార్డ. మీర్డ సంతోషంగా ఉండి, 
అధికారికంగా అభయ ర్నా్ చేయాలనుకుంటే, మీర్డ CMC హాసిి ట్ల్ 
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ఫిర్ధయ దుల విధాన్ంలో దీన్నన్న చేయవచుచ . వివర్ధలు మీ డాకరె్ నుండి 
పందవచుచ . 
 
8. ఈ అధ్య న్ంలో పాలొ్గన్డం ర్హసయ ంగా ఉంచబడుతందా? 
ఈ అధ్య న్ వయ వధిలో మీ గురించి సేకరించిన్ సమాచార్ం 
ఉంచబడుతంది 
ఖ్చిచ తంగా ర్హసయ ంగా. మీ కేసు మరియు మీ అధ్య న్ం సంఖ్య కు 
సంబంధించి పేరర్ రికార్డులు సుర్క్షితంగా జర్డగుతాయ. ఎలక్ట్కెాన్నక్ 
సమాచార్ం పాసవ ర్ ుల దావ ర్ధ ర్క్షించబడిన్ కంపూయ ట్ర్ లపై 
ఉంచబడుతంది. 
ఈ అధ్య న్ంలో న్నలవ  చేయబడిన్ ఎలక్ట్కెాన్నక్ డేటా ఒక డేటాబేస్లల  
ఉంచబడుతంది, కాన్న మేమ గురిుంచదగిన్ సమాచార్ధన్ని  ఉంచదు. 
అధ్య న్ం న్నవేదించిన్పుి డు మీర్డ వయ కి ుగతంగా గురిుంచడాన్నకి 
స్తధ్య రడదు. అన్ని  స్తర్డల ఎపుి డైనా కాపాడుకోవచుచ . 
 
9. రరిశోధ్న్ అధ్య న్ం యొకు  ఫలితాలకు ఏం జర్డగుతంది? 
అధ్య న్ం యొకు  ఫలితాలు శాక్ట్రుయ రప్తికలలో ప్వాయబడి, శాక్ట్రుయ 
సమావేశాలలో ప్రచురించబడతాయ. మీర్డ ఏ న్నవేదిక / ప్రచుర్ణలో 
గురిుంచబడర్డ. 
 
10. రరిశోధ్న్ను ఎవర్డ న్నర్వ హసుునాి ర్డ మరియు న్నధ్యలు 
సమకూర్డసుునాి ర్డ? 
ఈ విభాగం అధ్య న్ం మరియు న్నర్వ హంచబడుతోంది మరియు 
డిపార్టెే ంట్ ఆఫ్ యాకిస డంట్ అండ్ ఎమర్టనీీస , 
ఇంట్ర్ి ల్ మెడిసిన్, మెడికల్ ఇంట్టన్నస వ్ కేర్ యూన్నట్ మరియు 
ప్టాన్స్ఫస ఫ య షన్ మెడిసిన్ మరియు 
CMC హాసిి ట్ల్ వెల్లల ర్ వద ేఇమయ నోహెమటోటాలజీ. డాకరె్ మరియు 
రరిశోధ్నా బృందం ఈ అధ్య న్ం లో పాలొ్గన్డాన్నకి అదన్పు చెలిలంపులు 
పందడం లేదు. 
 
11. ఈ అధయ యనాన్ని  ఎవరు సమీక్షంచారు? 
ఈ అధయ యనం ఇన్నట ిట్యయ షనల్ రివ్యయ  బోర్డ ్అండ్ ఎథిక్సట  దా్వ రా 
సమీక్షంచబడంది మ్రియు ఆమోదించబడంది 
క్రిస్టయిన్ మెడకల్ కాలేజీ హాస్టి టల్ వెల్లూ ర్డ కమిటీ. 
 
సంక్రపదింపు వివరాలు: 
మొదట్లూ  డాకరి్డ అన్నల్ మాథ్యయ  ఫిలిపుి  మెడకల్ డపార్టిమ ంట్ ఆఫ్ 
డపార్టిమ ంట్ ఆఫ్ I. (2 వ అంతస్తు, OPD భవనం, CMC హాస్టి టల్, 
వెల్లూ రు -632002, మొబైల్ నంబర్డ -9567263773) సంక్రపదించండ. 
 
క్రపత్యయ మాి యంగా, మీరు పరయ వేక్షంచే కనట ల్ింటూలో ఒకద్వన్ని 
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మాట్లూ డగలరు - 
డా. ఆనంద్ జఖారియా, అంతరగత వైదయ  విభాగము టెల్: 04162282089 
 
 
ఈ షీట్ చదవడాన్ని మ్రియు ఈ అధయ యనంలో పాల్గగనడాన్ని 
ఆలోచిస్తుని ందుకు సమ్యం తీస్తకుని ందుకు ధనయ వాద్వలు. 
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Thrombocytopenia, Microangiopathy and End Organ damage 
in Snake Bites (Tamil) 
 
ஆரொய்ச்சியில் ெங்கு வெறு தற்கு நீங்கள் அயேக்கப்ெடுகிறீர்கள். எடுத்துக் 
வகொள்ளலொமொ என்ெயதத் தீர்மொனிக்கும் முன், ஆரொய்ச்சியை ஏன் வெய்ை 
ழ ண்டும், அது என்னவ ன்ெயத புரிந்து வகொள் து முக்கிைம். நீங்கள் 
விரும்பினொல் மற்ற ர்களுடன் இந்த ஆய்வு ெற்றி வி ொதிக்கலொம். நீங்கள் 
ெங்ழகற்க விரும்புகிறீர்களொ இல்யலைொ என்ெயத முடிவு வெய்ை ழேரம் 
எடுத்துக்வகொள்ளுங்கள். 
....................................................... 
1. இந்த ஆய்வின் ழேொக்கம் என்ன? 
இந்த ஆய்வின் ழேொக்கம் என்னவ ன்றொல், ெொம்பு விஷம் இரத்த ேொளங்கள் 
மற்றும் இரத்தத்தின் மீது என்ன வியளவுகயள ஏற்ெடுத்துகிறது என்ெயத 
நிர்ணயிக்க ெொம்பு கடித்தொல் உங்கயளப் ழெொன்ற ழேொைொளிகளுக்கு தக ல் 
ழெகரிக்க ழ ண்டும். 
 
இந்த ஆய்வில், சி.எம்.சி ய த்திைெொயலயில் உள்ள ழேொைொளிகளில் 
சிகிச்யெயினொல் எவ் ொறு ெைனயடகிறொர்கள் என்ெது ெொர்க்கப்ெடும் .  
ழேொைொளிகளின் சிகிச்யெ  மொற்றிையமக்கெடொது. 
 
இந்த ஆய்வின்  முடிவுகள் மருத்து த் தக ல்கள் வதரிந்தொல், ழேொைொளிகளுக்கு 
சிறந்த சிகிச்யெ அளிக்க முடியும் . 
 
ஆய்வு  குறிக்ழகொள்கள்: 
அ. இரத்தம் உயறயும் ழிமுயறகள் மீது ெொம்பின் விஷம் ஏற்ெடுத்தும்  
வியளவுகயள புரிந்து வகொள்ளுங்கள். 
ஆ. ெொம்பின் விஷத்தின்  தீவிரத்யத மதிப்பிடு தற்கு ெல்ழ று முயறகயள 
புரிந்துவகொண்டு ெடிக்கவும் 
இ. ெொம்பு கடியினொல் வ வ்ழ று விதமொக மக்கள் குணமொகும் முயறகள் . 
 
2. ேொன் ஏன் அயேக்கப்ெட்ழடன்? 
இந்த ஆய்வில் கலந்து வகொள்ள நீங்கள் அயேக்கப்ெட்டுள்ளீர்கள், ஏவனன்றொல் 
நீங்கள் ெொம்பு  கடித்ததொக கண்டறிைப்ெட்டு, CMC ய த்திைெொயலயில் 
அனுமதிக்கப்ெட்டுள்ளீர்கள், ழ லூர். ஆய்வில் தகுதியுயடை ஒரு ழேொைொளி  
என்று உங்கயள உங்கள் மருத்து ர் அயடைொளம் கண்டுவகொள் ொர், உங்கள் 
சிகிச்யெயில் மொற்றம் எதுவும் இருக்கொது . 
 
3. ேொன் கண்டிப்ெொக  ெங்ழகற்க ழ ண்டுமொ? 
இல்யல. இந்த ஆய்வில் நீங்கள் கலந்துவகொள் து முற்றிலும் உங்கள் விருப்ெம் . 
நீங்கள் ெங்ழகற்க முடிவு வெய்தொல் நீங்கள் ஒரு ஒப்புதல் ெடி த்தில் 
யகவைொப்ெமிட ழ ண்டும். நீங்கள் கலந்துவகொள்ள எந்தவ ொரு அ சிைமும்  
இல்யல, நீங்கள் எப்ழெொது ழ ண்டுமொனொலும் 
விரும்பினொல்,விளக்கமளிக்கொமல் ஆய்விலிருந்து விலகி வகொள்ளலொம்  நீங்கள் 
ெங்ழகற்கவில்யல  எனில், உங்களுக்கு மருத்து  மற்றும் மருத்து  ெரொமரிப்பு 
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தரத்யத ெொதிக்கொது. உங்கள் விருப்ெத்துடன்  ேொங்கள் உங்களிடம் ஏற்கனழ  
ழெகரித்த தக யல ய த்திருப்ழெொம். ஆய்விற்கு  நீங்கள் மீண்டும் வதொடர்பு 
வகொள்ளெட மொட்டீர்கள். 
 
 
4. ேொன் ெங்ழகற்றொல் எனக்கு என்ன ொகும்? 
நீங்கள் ெங்ழகற்க ஒப்புக்வகொள்கிறீர்கள் என்றொல் நீங்கள் மருத்து மயனயில் 
அனுமதிக்க ெட்டிருக்கும்  யர நீங்கள் ஆய்வில் . ஆய்வின் 
ெகுதிைொகவெர்கெடுவீர்கள்  கூடுதல் ழெொதயனகள் ழமற்வகொள்ளப்ெடும், ஆனொல் 
அதற்கொன கூடுதல் கட்டணங்களும் எடுக்கப்ெடொது. 
உங்களுயடை மருத்து  ெதிவுகள் உங்கள் ஆழரொக்கிை நியல ெற்றிை 
தக ல்கயளயும் உங்கள் மருத்து மயனயில் தங்கியிருக்கும் எந்தவ ொரு 
சிகிச்யெயும் ெற்றிை தக யல ழெகரிப்ெதற்கொக, உங்கள் மருத்து  ெதிழ டுகயள 
விரி ொக ஆய்வு வெய்ை அனுமதியுங்கள். 
இந்த சிகிச்யெயில் ெங்ழகற்ெதன் மூலம் உங்கள் சிகிச்யெ விருப்ெங்கள் எந்த 
விதத்திலும் மொற்றப்ெடொது. உங்களுக்கொன சிறந்த சிகிச்யெ ெற்றி உங்கள் 
மருத்து ர் தீர்மொனிப்ெொர். ஆய்வில் ெங்ழகற்ெது,  சிகிச்யெக்கு  எந்த ஒரு 
மொற்றத்யதயும் ஏற்ெடுத்தொது . 
ஆய்வின் ெகுதிைொக கூடுதல் ருயககள் ழதய  இல்யல. 
 
5. ெொத்திைமொன தீயமகள் மற்றும் ெங்ழகற்பின் அெொைங்கள் ைொய ? 
இந்த ஆய்வில் எந்தவ ொரு எதிர்ெொர்க்கப்ெடொத குயறெொடுகளும் அல்லது 
அெொைங்களும் ஏதும் இல்யல 
ெொம்பு கடித்த ழேொைொளிகளுக்கு ேக்கமொன ெரொமரிப்பு ெற்றிை ஆய்வு . 
 
6. ெங்கு வெறும் ேன்யம என்ன? 
இந்த ஆய்வில் ெங்வகடுப்ெதில் இருந்து ழேரடிைொன ேன்யமகள் எதுவும் இல்யல 
ஆனொல் எதிர்கொலத்தில் ெொம்பு கடி வகொண்டு மற்ற ர்களின் சிகிச்யெயை 
ழமம்ெடுத்து தற்கு தக ல் வெறலொம். 
 
7. ஒரு பிரச்ெயன என்றொல் என்ன? 
இந்த ஆய்வின் எந்தவ ொரு அம்ெத்யதயும் ெற்றி நீங்கள் க யலயைப் 
வெற்றிருந்தொல், ஆரொய்ச்சிைொளருடன் நீங்கள் ழெெலொம். நீங்கள் 
மகிழ்ச்சிைற்ற ரொகவும், முயறைொகக் ழகொரு திலும் விரும்பினொல், நீங்கள் CMC 
ய த்திைெொயலயின் புகொர் அளிக்கும்  ேயடமுயற மூலம் வெய்ைலொம். 
வி ரங்கள் உங்கள் மருத்து ரிடம் இருந்து வெற்றுக்வகொள்ளலொம். 
 
8. ஆய்வில் ெங்ழகற்ப் பு ரகசிைமொக ய க்கப்ெடுமொ? 
இந்த ஆய்வின் ழெொது நீங்கள் ழெகரிக்கப்ெட்டுள்ள அயனத்து தக ல்களும் 
கண்டிப்ெொக ரகசிைமகொ  ய க்கப்ெடும். உங்கள் ஆ ணங்கள்  மற்றும் உங்கள் 
ஆய்வு எண்யணப் ெற்றிை கொகிதப்ெதிவுகள். கடவுச்வெொற்கள் மூலம் 
ெொதுகொக்கப்ெடும் கணினிகளில் மின்னணு தக ளில் ய க்கப்ெடும். 
இந்த ஆய்விற்கொக ழெமிக்கப்ெட்டிருக்கும் மின்னணு தக ல்கள் ஒரு 
தரவுத்தளத்தில் ய க்கப்ெடும், ஆனொல் ேொங்கள் அயடைொளம் கொணக்கூடிை 
தக யல ய த்திருக்க மொட்ழடொம். ஆய் றிக்யக வ ளியிடப்ெட்டொல், அது 
உங்கயள தனிப்ெட்ட முயறயில் அயடைொளப்ெடுத்த முடிைொது 
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9. ஆரொய்ச்சியின் முடிவுகளுக்கு என்ன ேடக்கும்? 
ஆய்வின் முடிவுகள் விஞ்ஞொன ெத்திரியககளில் வ ளியிடப்ெட்டு, விஞ்ஞொனக் 
கூட்டங்ளில் முன்ய க்கெடும். எந்த அறிக்யகயிலும் வ ளியீட்டிலும் நீங்கள் 
அயடைொளம் கொணப்ெடமொட்டீர்கள். 
 
10. ஆரொய்ச்சி ஏற்ெொடு வெய் து மற்றும் நிதிைளிப்ெது ைொர்? 
இந்த ஆய் ொனது விெத்து மற்றும் அ ெரநியல தியணக்களங்களொல் ஏற்ெொடு 
வெய்ைப்ெட்டு, 
உள் மருத்து ம், மருத்து  தீவிர ெரொமரிப்பு அலகு மற்றும் மொற்று மருத்து ம் 
மற்றும் 
சி.எம்.சி மருத்து மயனயிலுள்ள இம்முழனொவெமொமொட்டொலஜி வ ல்லூர். 
இந்த ஆய்வில் நீங்கள் ழெர்த்துக் வகொள்ளும் மருத்து ர் மற்றும் ஆரொய்ச்சிக் 
குழு ொனது கூடுதலொன ெரிழெொதயனகள் வெறவில்யல. 
 
11. ஆய்வுக்கு மதிப்ெளித்த ர் ைொர்? 
இந்த ஆய்வு நிறு ன மதிப்ெொய்வு ொரிைம் மற்றும் ஒழுக்கவிைல் மூலம் 
மதிப்ெொய்வு வெய்ைப்ெட்டது 
கிறிஸ்த  மருத்து க் கல்லூரி மருத்து மயன ழ லூர் 
 
ஷதாேர்பு விபரங்கள்: 
முதல் ஆய்வாளர்   
ோக்ேர் அனில் னமத்யூ பிலிப்  
மருத்துவப் பிரிவு I- ல் 
 (2 வது மாடி, OPD கட்டிேம், CMC மருத்துவமண , னவலூர் -632002, 
ஷமாணபல் எண்- 9567263773) 
 
மாற்ோக, கண்காணிப்பு ஆனலாசகர்களில் ஒருவனராடு நீங்கள் னபசலாம் - 
ோக்ேர் ஆ ந்த் ஜகாரியா, உள் மருத்துவத் துணே ஷதாணலனபசி: 04162282089 
 
 
இந்தத் தாள்கணளப் படிக்கவும், இந்த ஆய்வில் பங்னகற்கவும் ன ரம் 
எடுத்துக்ஷகாண்ேத்தற்கு  ன்றி. 
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ANNEXURE 4: Case Report Form 
 
Snake Envenomation Proforma 
 
Name:         Date: 
 
         
 (dd/mm/yy) 
 
H.No:     Age (years):    Serial No:  
 
 
Sex: Male (0)         
        Female (1) 
 
 
 
Occupation: 
Locality: 
 
 
Time of presentation to CMCH:  (24-hour scale) 
 
 
Time of snakebite: (24-hour scale) 
 
 
 
Site of bite: Upper limb (0) 
 Lower limb (1) 
 Face (2) 
 Other (3) 
 
 
Time to onset of symptoms:  (24-hour scale) 
 
 
First aid:            Yes (0) 
                            No (1) 
 
 
Time to first dose of ASV administration:(24-hour scale) 
 
 Within 1 hour                           
 1- 6 hours 
 6-12 hours 
 12-24 hours 
  After 24 hours 
Number of ASV vials given outside:      Less than 
10    (0) 
1
1
1
1
1 1
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           10   
(1) 
          More than 
10 (2) 
 
 
Type of product transfused: (if any)       FFP 
(0) 
       
 Cryo (1) 
          
 PRC (2) 
       
 Platelets (3) 
 
 
Number of products transfused outside: 
 
 
Time to first bleeding manifestation:(24-hour scale) 
 
 
Envenomation Syndrome: 
 
 
LOCAL:       HEMOTOXIC: 
 
Fang marks    Bleeding from bite site 
Bruising       Minor bleed- 
epistaxis/gum bleed 
Local necrosis      Major bleed- 
hematuria/hematemesis/melena 
Cellulitis     
 hematochezia/hemoptysis/intracerebral/ 
intrabdominal 
 
 
 
 
NEUROTOXICITY:                                         NON-SPECIFIC: 
 
Altered sensorium      Nausea/Vomiting 
Ptosis       Pain abdomen 
Diplopia/ blurring of vision    Loose stools 
Limb paralysis      Headache 
Respiratory failure     Diaphoresis 
       Sudden collapse/ Shock 
Seizure 
Cardiac arrest 
 
 
 
Whole blood clotting time:  <20min  (0) 
     >20min  (1) 
1
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Number of ASV vials given at CMCH:      Less than 
10 (0)           
 10(1) 
      More than 
10  (2) 
 
 
Laboratory parameters: 
 
 
 At presentation 
Hemoglobin (g/dL) 
 
 
Total count  
<4,000 or >11,000 
4,000-11,000 
 
Platelets 
>1,50,000 
<1,50,000 
 
PT/INR 
>1.4 
<1.4 
 
aPTT  
Fibrinogen 
>100 
<100 
 
Urea/Creatinine 
AKI 
No AKI 
 
Electrolytes  
CPK 
Normal 
Elevated 
 
  
 
 
Daily Lab parameters: 
Time 
Test 
1 
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 Peripheral 
Smear for 
schiztocyte
s 
Hb Platelets Creatinine LDH TB/DB Retics 
Day 1        
Day 2        
Day 3        
Day 4        
Day 5        
Day 6        
Day 7        
Day 8        
Day 9        
Day 10        
Day 11        
Day 12        
 
 
Daily clinical assessment: 
 
 
Post-bite day 
Test 
Post-bite day 
System 
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 Local 
reaction 
CNS Renal Coagulation 
Day 1     
Day 2     
Day 3     
Day 4     
Day 5     
Day 6     
Day 7     
Day 8     
Day 9     
Day 10     
Day 11     
Day 12     
 
 
 
CNS: 
Sensorium- Alert/ Drowsy/ Stuporous/ Comatose 
Cranial nerve palsy- Ptosis/ Diplopia/ Facial deviation/ Absent gag 
Limb palsy- Power in all limbs 
Respiratory effort - single breath count 
 
Renal: 
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Urine output- >0.5mL/kg/hour or <0.5mL/kg/hour 
Puffiness of face/ Pedal edema/ Anasarca 
 
Coagulation: 
Bleeding manifestations 
 
Local reaction: 
Cellulitis/local necrosis/ bruising 
 
 
 
Outcome: 
 
• TMA Spectrum 
     Thrombocytopenia only 
     Thrombocytopenia + MAHA    
     Thrombocytopenia + MAHA + schiztocytes 
     Thrombocytopenia + MAHA + Schiztocytes + End organ damage 
 
• Snake Envenomation Syndrome 
No envenomation 
Local envenomation 
Pure Hemotoxicity 
Hemotoxicity with AKI 
Hemotoxicity with Neurotoxicity 
 
 
 
• Need for product transfusion  Yes (0) 
 No (1) 
 
• VICC Yes(0) 
 No(1) 
 
• Amount of product required 
                    Cryoprecipitate <6 units 
 6-12 units 
 >12 units 
                    FFP  
 </=4 units 
 >4 units 
 
               Packed red cells  </=2 unit 
  >2 units 
 
              Platelet Rich Concentrate  </=4unit 
  >4 units 
 
 
• Requirement of dialysis 
Yes  
No 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
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• Requirement of Plasmapheresis      
 Yes 
No 
 
 
• Duration of Hospital Stay 
 
<5 
day
s 
>5 
day
s 
 
• Duration of ICU Stay        Yes 
No 
 
 
 
 
 
• Final outcome 
Discharge 
(0) 
Death (1) 
DAMA(2) 
 
1 
1 
1 
1 
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ANNEXURE 5: Thesis Data
 
Sno datead hospno age sex occupation Bitetime Presentation site firstaid firstasv
ASVn
umO
Prodstra
nsout
Local
sym
Hemo
toxic
Neuro
tox WBCT ASVCMCHHbb INRb TCb APTTb
1 25-Jul-2018 "026325 61 0 1 00:30:00 13:00:00 1 1 08:00:00 0 1 2 1  1 10 14.4 1.69 14,800 31.0
2 16-Jul-2018 "189400 18 0 3 08:00:00 16:00:00 1 0 01:00:00 2 1 0 0 1 1 12 16.7 3.35 18,300 36.9
3 27-Jun-2017 "566813 48 0 1 06:00:00 10:00:00 1 1 04:00:00 0 1 0 2  1 20 17.8 3.65 19,300 39.4
5 21-Aug-2017 "933944 38 0 2 12:00:00 00:00:00 1 1 12:00:00 0 1 0 1  1 10 15.0 4.36 14,000 43.6
6 28-Aug-2017 "934715 25 0 2 12:30:00 03:00:00 1 0 01:00:00 4 1 2 0 1 1 10 13.8 1.96 19,800 44.9
7 02-Apr-2018 "180008 48 0 1 05:30:00 01:30:00 1 0 01:00:00 20 1 0 0 2 0 0 13.9 2.52 15,300 34.5
8 13-Jul-2017 "930146 47 0 1 06:00:00 15:00:00 1 0 02:00:00 6 0 2 1  1 10 14.5 10.00 21,800 180.0
9 24-Oct-2017 "576567 50 1 4 12:00:00 21:00:00 1 0 02:00:00 10 1 2 2  1 10 12.7 2.81 17,300 34.8
1 19-Jun-2014 "910326 48 0 1 04:45:00 16:30:00 1 0 00:30:00 6 1 2 0 1 1 20 15.8 2.69 24,100 92.0
2 05-Jun-2012 "218619 54 1 2 04:00:00 12:00:00 1 0 00:30:00 6 1 2 0 1 1 4 15.0 1.78 21,800 25.4
3 12-May-2012 "200454 52 1 2 19:30:00 07:30:00 1 0 00:30:00 10 1 2 2 1 1 18 11.1 2.11 20,400 36.1
4 02-Mar-2012 "139412 46 0 1 20:00:00 20:30:00 1 0 00:30:00 0 1 2 0  1 9 15.3 10.00 8,800 180.0
5 01-Apr-2012 "170009 72 0 1 09:00:00 09:30:00 1 0 00:30:00 4 1 2 2 1 1 14 13.0 8.03 26,800 180.0
6 21-Sep-2012 "304412 23 0 2 17:30:00 20:30:00 1 1 03:00:00 6 1 2 0 1 1 21 15.1 10.00 18,100 160.0
9 03-Jul-2016 "514132 47 1 4 04:00:00 16:00:00 1 0 00:45:00 6 1 2 2 1 1 18 13.0 6.37 24,000 47.8
11 22-Oct-2016 "531107 38 0 1 10:00:00 18:00:00 1 0 01:00:00 10 1 2 0 1 1 10 15.6 1.27 11,300 24.5
13 11-Oct-2016 "530298 41 1 4 10:00:00 18:00:00 1 0 00:30:00 50 1 2 2 1 1 20 8.4 2.39 22,800 99.7
14 19-Sep-2016 "526385 59 0 1 11:00:00 16:00:00 0 0 01:00:00 4 1 2 0  1 20 13.4 10.00 15,700 180.0
15 20-Aug-2016 "521590 55 0 1 07:30:00 18:30:00 0 0 02:00:00 6 1 2 0  1 6 17.1 10.00 10,900 180.0
16 15-Aug-2016 "521031 60 0 1 13:00:00 09:00:00 0 0 01:00:00 10 1 2 0 0 1 10 13.4 10.00 14,100 180.0
17 29-Jun-2016 "518430 63 0 1 03:15:00 15:30:00 1 0 01:00:00 4 1 0 2 0 1 10 15.0 1.06 11,200 35.8
18 30-Sep-2018 "527316 66 0 1 04:30:00 16:00:00 1 0 00:30:00 4 1 2 0 1 1 10 15.0 1.63 17,500 29.3
19 10-Jun-2016 "511947 40 1 4 18:30:00 08:00:00 0 0 01:00:00 14 1 2 2 1 1 10 10.0 1.92 14,600 108.5
20 20-May-2016 "508345 59 1 2 16:00:00 20:00:00 1 0 00:30:00 4 1 2 0 1 1 14 15.6 3.78 18,800 23.5
21 25-Feb-2014 "756616 49 0 2 04:00:00 17:00:00 1 0 04:00:00 0 1 2 0 1 1 10 8.8 10.00 12,100 180.0
23 29-Sep-2012 "295943 51 0 1 18:30:00 23:30:00 1 1 08:00:00 0 1 2 0 1 1 12 13.0 10.00 18,600 180.0
25 06-Jan-2016 "995152 19 0 3 19:30:00 23:00:00 1 0 03:00:00 8 1 2 0 1 1 10 14.9 2.10 17,500 35.0
27 03-Mar-2016 "108055 68 1 2 19:00:00 23:00:00 1 0 00:30:00 8 1 2 0 1 1 10 12.0 1.39 25,500 68.0
28 22-Jun-2012 "227618 35 1 4 20:30:00 21:30:00 0 1 02:00:00 0 1 2 2  1 10 10.0 10.00 8,200 180.0
29 15-Feb-2012 "133312 34 1 4 12:00:00 19:00:00 1 0 00:30:00 5 1 2 0  1 12 10.5 2.44 26,800 61.0
30 22-Jan-2014 "753456 53 0 1 09:00:00 18:00:00 1 0 00:30:00 4 0 2 0 1 1 20 14.1 2.70 19,320 33.2
31 15-Nov-2013 "713926 19 0 3 19:00:00 23:00:00 1 0 01:30:00 2 1 2 0  1 10 15.7 2.68 26,000 35.5
32 25-Nov-2015 "988201 40 0 2 11:00:00 12:30:00 1 1 01:30:00 0 1 2 2 0 1 20 15.0 2.54 13,200 68.0
33 12-Jun-2014 "909400 35 0 2 07:30:00 20:00:00 1 0 00:15:00 2 1 2 0 1 1 10 13.0 10.00 23,500 180.0
34 26-Feb-2014 "756616 54 0 1 04:00:00 16:00:00 1 0 01:30:00 2 0 0 1 2 1 13 8.8 10.00 12,100 180.0
38 24-Dec-2013 "406667 71 0 2 11:00:00 21:00:00 1 0 02:00:00 0 1 0 0 1 1 18 15.6 2.36 11,700 27.6
39 15-Oct-2013 "696213 60 0 1 18:30:00 03:00:00 1 0 05:00:00 0 1 2 0 1 1 20 12.0 10.00 9,600 160.0
41 25-Sep-2012 "304640 31 0 1 05:00:00 22:00:00 2 0 08:00:00 8 1 2 0  1 10 13.8 1.62 17,800 26.2
42 18-Nov-2014 "931102 23 1 3 09:00:00 21:30:00 1 0 05:00:00 8 1 2 2 1 1 10 11.2 1.40 41,900 51.2
43 01-Aug-2012 "261148 66 1 2 21:00:00 01:00:00 1 0 04:30:00 0 1 2 1  1 8 6.5 10.00 11,300 180.0
45 16-Oct-2014 "355127 58 0 2 09:30:00 15:00:00 1 0 03:00:00 16 1 0 1  1 8 13.0 1.66 2,000 35.5
46 04-Jan-2013 "379990 60 0 1 08:00:00 15:00:00 1 0 15:00:00 0 1 2 0  1 10 13.0 4.98 11,700 24.0
47 31-Jul-2012 "252963 31 1 4 02:15:00 17:00:00 1 0 17:00:00 0 1 2 2  1 12 6.3 2.03 16,100 33.3
48 16-Feb-2014 "914052 25 1 3 15:00:00 20:00:00 0 0 05:00:00 12 1 2 0  0 0 10.1 1.74 24,900 37.0
51 14-Jul-2014 "912898 29 1 4 16:00:00 01:00:00 0 0 02:00:00 10 1 2 0  1 7 11.9 1.96 3,700 25.4
55 24-Sep-2012 "309481 30 0 2 05:30:00 09:00:00 1 0 04:00:00 0 1 0 0  1 6 17.3 2.59 16,900 36.0
55 19-Oct-2014 "926501 49 0 1 14:00:00 10:00:00 1 0 20:00:00 0 1 2 0 1 1 12 15.9 10.00 29,000 31.0
57 02-Oct-2012 "309765 64 0 1 05:00:00 07:00:00 1 0 03:00:00 0 1 1 0 1 1 10 15.6 10.00 14,100 180.0
58 21-May-2015 "958027 33 0 1 13:00:00 02:00:00 1 0 20:00:00 0 1 2 0 1 1 10 16.3 3.15 21,000 30.1
59 15-Apr-2016 "687126 53 0 2 02:00:00 07:00:00 1 0 02:00:00 6 1 2 0 1 1 10 15.8 1.71 5,900 66.3
60 11-Jun-2014 "909854 39 0 2 10:00:00 02:00:00 1 0 04:00:00 8 1 2 2 1 1 10 11.9 1.81 41,150 111.0
61 13-Oct-2013 "696050 23 0 3 14:00:00 17:00:00 1 0 02:00:00 0 1 1 2 2 1 10 14.8 2.14 14,300 33.4
80 12-May-2015 "965724 63 0 1 11:00:00 16:00:00 0 0 01:00:00 0 1 0 1  1 10 13.8 10.00 11,300 64.8
81 24-May-2014 "907618 54 0 1 15:00:00 20:00:00 1 0 01:00:00 2 1 0 0  1 8 16.0 1.23 4,200 25.4
83 16-Feb-2012 "137776 30 0 1 19:00:00 23:00:00 1 0 02:00:00 6 1 2 1  1 9 14.4 1.78 26,500 27.2
84 22-Aug-2015 "973188 59 0 1 18:30:00 23:00:00 1 0 01:00:00 10 1 0 0  1 0 11.5 10.00 6,600 38.1
86 06-Aug-2013 "630773 57 0 1 08:30:00 12:00:00 1 0 04:00:00 0 1 2 0 1 1 12 16.1 6.08 13,800 28.0
87 05-Oct-2015 "978288 53 0 1 18:30:00 23:00:00 1 0 01:00:00 10 1 0 0  1 10 14.4 10.00 14,700 125.0
95 12-Aug-2014 "915771 52 0 1 07:30:00 18:00:00 1 0 01:30:00 4 1 1 1  1 9 14.4 10.00 18,200 110.0
96 12-Apr-2012 "180010 28 0 2 14:00:00 02:00:00 1 0 04:00:00 0 1 0 2 1 1 12 15.7 1.43 29,300 25.7
97 17-Mar-2016 "500264 42 0 1 04:00:00 10:20:00 1 0 02:00:00 6 1 2 0  1 15 14.5 3.15 15,200 32.0
99 26-Sep-2013 "675287 51 0 2 08:30:00 12:00:00 1 0 03:30:00 0 1 2 0  1 10 12.2 10.00 11,100 180.0
100 23-Aug-2015 "973303 45 0 1 20:30:00 23:10:00 1 0 00:30:00 10 1 0 1 1 1 4 16.8 2.84 14,500 25.0
101 27-Sep-2015 "977432 62 0 2 04:00:00 20:45:00 1 1 16:00:00 0 1 2 1  1 10 13.0 4.24 19,500 180.0
102 17-Jul-2015 "967533 58 1 4 08:00:00 20:10:00 1 0 04:00:00 6 1 2 0  1 15 12.0 10.00 12,500 180.0
10 29-Jun-2017 "567147 35 0 1 18:00:00 08:00:00 1 0 03:00:00 10 1 2 2 1 1 10 13.6 1.25 13,800 36.7
11 11-Jul-2017 "930013 51 0 1 21:20:00 19:00:00 1 0 02:00:00 5 1 2 2 1 1 20 11.0 2.63 24,100 94.8
10 17-Sep-2015 "975406 20 0 2 10:00:00 17:00:00 1 0 01:00:00 5 1 2 0 1 1 12 13.3 10.00 14,700 180.0
53 27-Sep-2015 "977579 48 0 1 04:00:00 08:00:00 1 0 04:00:00 0 1 2 2  1 10 14.6 10.00 14,000 180.0
54 24-Jul-2015 "967756 49 0 2 05:00:00 03:00:00 1 0 02:00:00 6 1 2 2 1 1 20 14.4 10.00 3,400 180.0
90 18-Sep-2013 "671443 45 1 2 15:00:00 01:00:00 1 0 01:00:00 0 1 2 0 2 1 16 12.0 3.05 35,100 25.9
4 12-Oct-2017 "939581 48 0 2 16:00:00 18:00:00 0 0 02:00:00 0 1 2 0  1 10 13.7 1.63 6,900 27.6
35 28-Jun-2014 "910944 67 0 1 06:00:00 19:00:00 1 0 02:00:00 8 1 2 0 1 1 18 13.1 4.71 3,300 38.3
49 18-Sep-2012 "299455 48 1 4 10:00:00 13:30:00 1 0 01:00:00 8 1 0 2 1 1 14 16.0 2.71 27,200 180.0
68 26-Jul-2012 "252354 38 0 2 10:45:00 19:45:00 1 0 01:00:00 8 1 2 0 1 1 12 16.5 4.56 28,900 40.1
12 13-Jul-2018 "189068 42 1 4 21:00:00 20:00:00 1 0 01:00:00 20 1 0 0  0 0 6.0 1.18 21,500 45.9
13 03-Jul-2018 "188283 30 1 4 06:00:00 18:00:00 0 0 03:00:00 18 1 2 2  0 0 9.2 1.12 21,000 33.7
14 02-Jul-2018 "188210 42 1 4 11:30:00 05:00:00 0 0 06:30:00 6 1 2 2  1 20 11.6 2.50 12,700 42.9
15 30-May-2018 "185278 41 0 1 05:30:00 13:30:00 1 0 02:00:00 2 1 2 1 2 1 10 15.7 10.00 4,300 48.9
16 12-Jul-2017 "930106 20 0 3 03:00:00 11:00:00 3 0 06:00:00 30 0 0 2 1 0 10 12.6 1.22 15,700 31.5
17 25-Jul-2018 "350167 35 0 1 23:00:00 11:00:00 0 1 13:00:00 0 0 2 2  1 20 13.4 2.16 18,900 39.7
18 18-Aug-2018 "352170 36 1 4 08:00:00 07:00:00 1 0  0 1 2 0  0 0 12.9 0.97 5,300 24.6
19 23-Mar-2018 "599184 18 0 3 13:30:00 12:30:00 1 0 04:30:00 10 1 2 1 1 0 0 12.0 1.35 35,400 51.0
7 07-Apr-2016 "501890 55 0 1 04:30:00 16:00:00 1 0 04:30:00 10 1 2 0 1 1 10 13.9 1.15 13,000 164.0
12 16-Jan-2016 "530620 36 1 4 16:00:00 05:30:00 1 0 06:30:00 10 1 2 0  1 6 14.0 1.27 29,800 32.8
37 05-Aug-2014 "710941 44 1 4 11:00:00 18:00:00 0 0 07:00:00 0 0 0 0 1 1 6 12.6 1.70 20,400 26.0
62 07-Feb-2012 "130885 29 0 2 04:00:00 12:00:00 1 0 06:00:00 4 1 2 1 1 1 22 16.9 10.00 20,500 180.0
63 11-Jul-2014 "514924 52 0 1 07:00:00 16:00:00 1 0 05:00:00 20 1 2 1 1 1 6 12.6 5.50 27,000 180.0
64 23-May-2015 "949208 35 0 1 19:00:00 23:00:00 1 0 04:30:00 12 0 2 2 1 1 18 15.5 1.74 4,000 49.3
65 04-Apr-2013 "429574 70 0 1 20:30:00 21:30:00 1 0 04:30:00 0 1 2 0 1 1 10 6.6 1.29 7,400 25.0
66 10-Jul-2014 "912627 48 0 2 03:00:00 12:00:00 1 0 01:30:00 18 1 2 1 1 1 6 17.0 1.72 30,950 56.9
67 11-Feb-2016 "105317 31 0 1 18:00:00 07:00:00 1 0 05:20:00 47 1 2 2 1 0 0 16.8 1.35 26,800 35.5
69 05-Mar-2014 "759027 45 1 4 18:00:00 22:00:00 1 0 04:00:00 0 1 2 1 1 1 20 12.9 10.00 16,700 180.0
70 16-Sep-2015 "950294 36 0 2 23:30:00 09:00:00 1 0 06:00:00 10 1 2 2 1 1 10 10.8 1.09 35,700 38.0
71 12-Apr-2016 "028405 71 0 1 12:30:00 16:30:00 1 0 02:00:00 0 1  1  1 20 15.5 3.05 5,800 41.0
72 06-Apr-2013 "441221 20 0 3 14:00:00 19:00:00 1 0 03:00:00 5 1 2 2 1 1 10 12.5 2.05 38,800 46.7
73 16-Apr-2014 "902269 50 0 2 18:00:00 10:00:00 1 1 04:00:00 6 1 2 1  1 10 11.2 1.26 19,700 31.3
74 16-Oct-2016 "530620 36 1 4 16:30:00 05:30:00 1 0 04:00:00 10 1 2 0  1 6 14.0 1.27 29,800 32.8
75 07-Apr-2016 "501890 55 0 1 04:30:00 16:00:00 1 0 03:45:00 10 1 2 0 1 1 10 13.9 1.15 57,400 164.0
76 17-Apr-2012 "180040 42 1 2 21:00:00 10:00:00 1 0 04:00:00 3 1 1 1 2 1 18 13.3 2.26 45,700 48.6
77 10-Jan-2012 "110128 62 0 2 21:00:00 11:00:00 1 0 13:00:00 0 1 2 2 1 1 14 14.2 10.00 29,800 180.0
78 10-Mar-2013 "422596 30 1 4 05:00:00 09:00:00 1 0 04:00:00 17 1 2 2 1 1 12 10.7 1.96 24,900 31.4
79 26-Mar-2016 "500932 73 0 1 10:00:00 09:00:00 1 0 04:00:00 19 1 2 0 1 0 0 12.6 1.78 20,700 26.0
82 14-Jul-2013 "611889 70 0 1 19:10:00 12:00:00 0 0 04:45:00 72 0 2 0 2 0 0 10.9 1.52 33,500 26.0
88 10-Dec-2014 "932900 59 0 1 18:20:00 16:00:00 1 0 06:30:00 6 1 1 2 2 1 10 12.9 2.11 53,500 34.8
8 04-Oct-2015 "647473 55 0 1 13:30:00 18:00:00 1 0 01:00:00 6 0 2 0 1 1 10 19.0 3.72 16,600 22.6
22 29-May-2015 "934094 51 0 2 04:30:00 10:30:00 1 0 07:00:00 0 1 2 1 1 1 10 15.2 10.00 20,100 180.0
24 16-Jun-2014 "910171 46 0 2 02:30:00 20:00:00 0 1 07:00:00 15 1 2 0 1 1 10 12.7 1.72 8,830 43.0
26 18-Apr-2014 "917183 23 0 2 19:00:00 08:00:00 1 0 00:45:00 4 0 2 0  1 20 14.4 10.00 13,200 33.4
36 09-Mar-2013 "422518 53 0 2 19:00:00 04:00:00 1 0 09:00:00 0 0 2 0 1 1 13 14.6 1.18 15,300 29.5
40 28-Jun-2014 "910578 29 1 4 04:00:00 23:00:00 1 0 19:00:00 8 0 2 2 0 1 16 9.3 1.59 19,659 46.7
45 04-Apr-2013 "441438 41 1 4 19:30:00 00:00:00 1 0 06:00:00 0 1 2 2 1 1 10 13.4 10.00 23,000 180.0
50 02-Aug-2012 "258893 44 0 1 14:00:00 15:30:00 1 0 01:00:00 0 1  2  1 8 12.9 10.00 19,900 180.0
52 18-Jul-2013 "967043 75 1 1 07:00:00 06:00:00 1 0 03:00:00 20 1 2 0  0 0 11.0 1.69 18,200 31.6
85 10-May-2014 "904721 29 1 4 11:00:00 16:00:00 1 0 02:00:00 10 1 2   1 8 10.7 1.39 17,400 31.1
89 03-Jun-2012 "308741 50 0 2 07:00:00 09:00:00 1 0 02:00:00 2 1 2 1  1 6 13.0 10.00 19,400 180.0
91 08-Apr-2015 "950201 38 0 2 23:00:00 00:00:00 3 0 02:00:00 20 1 2 0 2 1 6 16.5 1.26 16,700 51.3
92 31-May-2015 "958933 44 0 1 08:00:00 07:00:00 1 0 01:00:00 6 1 2 2 2 1 10 16.6 2.17 8,300 33.3
93 03-Sep-2014 "836672 43 0 2 04:30:00 16:00:00 1 0 01:00:00 6 1 0 2  1 14 14.8 10.00 4,300 180.0
94 28-Aug-2013 "639728 29 0 1 15:30:00 18:30:00 1 0 04:30:00 0 1 1 2 2 1 10 15.6 7.45 15,700 180.0
98 15-Apr-2013 "448504 46 0 1 21:30:00 08:00:00 1 0 01:00:00 8 1 0 0  1 10 13.3 1.67 20,100 25.0
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PlatB
fibrinog
enb Creatb Nab Kb CPKb V42 ldhd1 tbd1 dbd1 reticsd1 schizd2 hbd2 pltd2 creatd2 ldhd2 tbd2 dbd2 retd2 schzd3 hbd3 pltd3
115,000 172.00 1.16 136.00 4.40 268 1.05 486 0.90 0.10  0.0 13.70 130,000 0.90 680 0.60 0.20     
139,000 35.00 0.92 141.00 3.50 229 0.78 760 0.70 0.24             
260,000 20.00 1.35 141.00 3.60 768 1.35 755 1.61 0.36  0.0 11.90 130,000 1.17 851 1.80 0.25  0.0 10.50 111,000
158,000 98.00 1.07 138.00 3.90 628 1.02 410 0.74 0.25  0.0 12.60 137,000 1.00 460 0.70 0.22     
154,000 180.00 1.14 139.00 4.40 2,071 1.14 2,057 2.33 0.10  0.0 11.90 133,000 0.78 980 1.00 0.10     
153,000 167.00 1.40 139.00 4.30 2,842 1.40 1,501 1.60 0.20  0.0 13.70 117,000 1.44 1,064 1.40 0.10  0.0 12.80 105,000
109,000 114.00 0.80 138.00 3.20 559 0.80 560 1.50 0.60  0.0 12.20 217,000 0.98 622 1.00 0.52  0.0 11.30 224,000
145,000 90.00 1.31 139.00 3.70 496 1.31 980 0.60 0.20  0.0 9.90 120,000 1.17 978 0.40 0.16  0.0 10.50 80,000
24,000  0.88 136.00 3.40 138 0.88  0.90 0.20             
17,000  0.73 138.00 3.70                  
16,000  0.51 136.00 3.60 3,156 0.54 2,196 1.80 0.40    138,000 0.71        
11,000  1.18 139.00 3.30         128,000         
9,000  0.92                    
8,000  1.17 134.00 3.10 2,737                 
37,000 14.60 0.67 138.00 3.10 303 0.67  1.10 0.10  0.5 10.70 189,000 0.67     0.0 10.40 153,000
114,000  0.97 136.00 3.20 363 0.97  1.30 0.30   14.70 209,000         
83,000  0.83 143.00 3.70 21,719 0.83 1,570 2.20 1.10   7.10 67,000 0.65  1.20 0.70  0.0 6.40 67,000
131,000  1.13 135.00 3.70  0.91  1.30 0.30             
125,000  1.22 139.00 3.30  0.96  2.90 0.90             
129,000 0.00 0.95 139.00 3.20 209 0.62  0.90 0.20  0.0 13.60 389,000 0.61        
135,000  0.76 134.00 3.40 297 0.76  1.00 0.40             
930,000  1.12 141.00 3.90                  
127,000  1.34 145.00 3.10 702 0.80  1.10 0.50  0.0 10.20  0.81        
420,000  0.70 134.00 3.50 1,526 0.70  0.90 0.10  0.0 13.50 298,000 0.65     0.0 12.50 238,000
67,000  1.14 133.00 3.00 160 0.82  0.40 0.20  0.0 7.70 187,000 0.94       262,000
48,000  1.14 137.00 3.10  1.17                
28,000  0.57 137.00 2.70 563 1.13  0.90 0.20  0.0 13.40 220,000 0.55        
37,000  1.39 138.00 2.40 324 0.75  0.60 0.10    261,000 0.68        
36,000  0.88 133.00 3.10  0.80      8.70 75,000        128,000
34,000  0.67 132.00 3.50  0.67  0.40 0.20  0.0 8.90 214,000 0.81        
27,000  1.28 136.00 4.70 960 1.28  2.40 0.90  0.0  151,000 1.15      12.10 111,900
52,000  1.32 146.00 4.00 2,108 0.91 712       1.12        
59,000 121.00 0.83 136.00 2.80 142 0.83  0.45 0.10   12.60 312,000 0.56        
64,000  0.87 139.00 3.50 2,118 0.87  3.30 0.30  0.0 13.20 84,000 1.13      13.80 110,000
67,000  1.15 133.00 3.80 160 1.15  0.40 0.20  0.0 9.50 175,000 0.82     0.0 7.70 187,000
77,000  1.03 139.00 3.40 146 1.03  1.70 0.40  0.0 14.40 165,000 0.90        
83,000  0.93 137.00 3.60  0.50  0.80 0.20  0.0  96,000      0.0  116,000
87,000  1.30 133.00 4.30 120 1.30     0.0 12.50 85,000 1.20        
93,000 249.00 0.65 136.00 3.30 2,813 0.65  3.55 0.50  0.0 9.10 55,000 0.59     0.0 9.80 30,000
94,000  0.90 137.00 3.20  0.90     0.0 6.20 80,000         
99,000  1.12 137.00 2.90  1.12  2.60 1.10             
99,000  1.28 136.00 3.90 128 1.28  1.40 0.20  0.0 12.40 148,000 1.10     0.0 11.90 139,000
101,000 44.10 1.20 127.00 4.40  1.20  3.20 1.10             
102,000 267.00 1.18 147.00 3.10 951 1.18  0.38 0.20  0.0  79,000 0.66     0.0 11.60 88,000
109,000  0.84 139.00 3.40 455 0.84 1,200 1.20 0.70  0.0 10.80 83,000 0.90        
114,000  1.16 135.00 4.30                  
119,000  1.33 136.00 3.50  1.33  3.40 1.00     1.03        
120,000  0.99 137.00 3.20 252 0.99  1.20 0.50  0.0 12.20 134,000 0.92        
121,000  1.11 138.00 3.60 270 1.11  3.57 0.30  0.0 12.60 94,000 1.03        
122,000  0.93 134.00 3.30  0.93  1.10 0.20  0.0 13.00 130,000 0.54     0.0 12.10 105,000
123,000 320.00 1.14 147.00 3.70 11,380 1.12 1,230 7.70 0.20  0.0 10.00    6.40 0.20  0.0 10.20 320,000
126,000  0.90 140.00 3.60  0.90     0.0 14.10 120,000 0.94  2.80 1.00  0.0 11.80 114,000
14,200  1.19 142.00 3.70                  
143,000  0.83 137.00 3.30 2,189 0.75                
143,000  1.20 132.00 3.80                  
144,000  0.95 136.00 3.40  0.89 667       0.52        
144,000  1.32 139.00 3.90                  
145,000 77.90 0.82 136.00 3.70  0.67 342 2.70 0.40  0.0 11.20 100,000 0.57        
133,000  0.67 132.00 3.20                  
130,000  1.69 140.00 3.10                  
130,000  1.23 142.00 3.30  0.89 834 2.90 1.00  0.0 13.50 108,000 0.81 294 1.50 0.60     
128,000  1.14 133.00 4.20  0.94 768 1.48 1.10             
128,000  0.80 132.00 3.20 10,134 0.66 1,234 0.80 0.10  0.0 14.10 100,000      0.0 14.60 367,000
128,000  1.02 142.00 3.40 617 0.80 682               
127,000 49.40 0.97 138.00 3.80  0.97  3.40 0.50  0.0 10.30 148,000   0.70 0.20     
41,000 150.00 1.00 137.00 4.10 540 1.00 1,241 3.38 0.50  0.0 11.50 236,000 0.98 780 1.12 0.50     
110,000 245.00 3.23 144.00 5.10 12,133 3.78 4,600 4.69 0.12  0.0 10.30 93,000 5.25 4,117 3.20 0.24  0.0 10.00 69,000
28,000 0.00 0.70 140.00 3.60 303 0.71     0.0   0.69      12.30 200,000
114,000  1.13 135.00 3.80 208 1.13 693 2.50 0.40  0.0 13.20 161,000 0.90        
114,000  0.84 135.00 3.60 321 0.84  4.80 0.50  0.0 14.00 72,000 0.76 756    0.0 12.50 94,000
139,000 109.00 0.88 139.00 4.40 1,320 0.88  0.30 0.10     1.05      10.00  
199,000 140.00 0.82 138.00 4.00 1,683 1.54 746 0.70 0.24  0.5 12.60 118,000 1.14 733 0.59 0.20  0.8 13.00 120,000
73,000 33.10 0.89 139.00 3.70 805 1.05  4.00 1.00  0.4 10.00 64,000 0.60  1.20 0.60  0.8 10.70 48,000
102,000  1.02 137.00 3.00 301 1.02  1.90 0.20  0.1 15.80          
39,000 160.00 1.20 136.00 3.70 4,930 1.19 2,343 1.40 0.30  1.0 12.90 213,000 1.21        
101,000 251.00 3.13 133.00 5.20 206 3.13 2,956 0.67 0.40 2.94 1.0 7.60 55,000 1.67 3,881 0.92 0.25  0.5 7.90 33,000
35,000 190.00 3.79 137.00 4.50 7,295 3.79 4,271 2.92 1.71 1.18 0.8 7.90 18,000 4.84 3,313 2.76 0.90  2.0 7.50 21,000
74,000 108.00 2.00 138.00 3.70 138 2.00 3,780 4.96 0.25 1.29 2.0 10.60 36,000 2.39 2,603 5.94 0.34  2.0 9.20 32,000
100,000 0.00 1.31 141.00 3.50 1,415 1.31 1,310 6.99 1.14  0.3 11.90 89,000 1.64 1,007 4.58 0.60  0.5 13.00 100,000
129,000 152.00 3.25 138.00 4.20 2,459 7.83 1,514 1.50 0.46  0.5 12.60 176,000 8.54 1,310    0.3 12.00 186,000
172,000 32.00 2.89 126.00 4.60 302 4.76 8,892 7.58 0.68  0.5 10.10 24,000 7.10 10,993 3.68 0.90  1.2 9.30 14,000
243,000  0.59 138.00 3.80 193 0.59 62,486 2.40 0.50  0.5 12.40 46,000 4.02 5,225 1.58 0.35  0.8 11.10 22,000
9,000 155.00 7.50 127.00 5.50 4,930 7.46 14,749 2.21 0.16  5.0 7.50 16,000 8.44 11,821 1.98 0.40  4.0 7.10 8,000
57,400 107.00 1.83 137.00 5.20 1,596 2.76  1.00 0.30  1.0 8.70 9,000   1.80 0.90  0.5 7.80 14,000
148,000 104.90 2.34 142.00 5.60 363   1.20 0.40   11.50 75,000 1.65      9.10 60,000
77,000  2.80 139.00 3.50 83 2.81 611 1.20 0.80  0.0 11.20 45,000 4.12     0.0 10.00 60,000
18,000  1.84 135.00 3.40 989 2.49 1,893 2.80 0.20  1.0 9.30 8,000 4.97 2,808 2.10 0.70  1.0 8.30 14,000
144,000 188.00 2.32 139.00 5.20 20,111 2.32 1,891 7.20 0.70  1.2 10.60 62,000 2.00 2,234    2.0 9.20 54,000
36,000 173.00 3.19 132.00 3.90 1,532 3.88 1,822 1.71 0.40  0.2 6.70 22,000 5.96 2,145 7.90 6.20  1.0 8.30 14,000
43,000  0.99 135.00 3.70  3.00 980 0.30 0.10  0.3 6.20 151,000 5.56 1,031 0.40 0.10  0.2 5.40 133,000
43,000 116.00 3.65 139.00 3.40  3.60 3,404 14.00 1.90  1.2 12.70 11,000 4.20 4,310       
43,000 410.00 1.59 138.00 2.60 14,847 1.09 2,923 3.30 1.30  1.0 13.30 30,000 0.90 1,202    1.0 10.10 29,000
50,000 118.00 0.96 136.00 3.10 434 1.00 762 0.77 0.20  0.0 9.70 92,000 1.90     0.2 8.70 83,000
9,000 325.00 4.12 133.00 4.00 3,206 4.57 1,540 0.40 0.10  0.0 10.70 8,000 2.43 1,750 0.70 0.10  0.4 9.60 35,000
59,000  0.98 136.00 3.40 157 2.24  0.80 0.10  0.6 11.80 132,000 3.91     0.3 11.60 140,000
60,000  4.01 137.00 4.40 7,237 2.70 3,493 8.50 3.20 1.21 1.0 9.30 10,000 4.00 2,989    2.0 8.60 25,000
74,000 403.00 4.69 140.00 4.40 853 4.68 1,370 2.10 0.10  1.6 11.20 49,000 4.25 979    1.8 10.00 31,000
148,000 104.90 2.34 142.00 5.60  1.65 2,324 1.20 0.40  1.0 11.50 75,000 1.68     1.0 9.10 60,000
13,000 107.00 1.83 137.00 5.20 1,596 2.76 5,737 1.00 0.30  1.4 8.70 9,000 3.26 5,218 1.80 0.90  2.0 7.80 14,000
110,000  2.79 137.00 4.20 3,801 2.79 5,899 2.70 0.20  0.2 8.20 47,000 3.92 5,690    0.4 7.90 54,000
102,000 293.00 2.90 140.00 3.90  2.90 2,490 0.80 0.20  2.0 9.70 49,000 5.30 3,129 1.00 0.50  1.0 7.70 26,000
108,000 22.60 2.43 137.00 4.30 207 2.43 2,890 4.20 0.20  2.0 8.60 108,600 4.70 2,459 1.90 0.50  2.0 8.30 109,000
75,000  2.70 137.00 3.70 1,533 4.25 1,039 2.60 1.00  0.3 11.20 71,200 5.87 1,340    0.5 11.50 74,000
143,000  2.40 141.00 3.50 2,097 3.00 1,365 1.20 0.40  1.2 9.90 120,000 2.10 954    0.0 12.00 127,000
140,000  4.06 142.00 3.80 23,200 4.06 5,200 4.50 0.60  0.2 8.50 32,000 6.13 4,620    0.8 9.40 33,000
30,000 0.00 1.79 129.00 4.50 339 2.87  4.20 0.20  0.0 13.30 110,000 5.36     0.0 13.80 99,000
650,000 69.50 1.06 140.00 3.00 375 1.24  1.50 0.20   13.60 150,000 1.67        
46,000 48.00 1.87 147.00 2.80 220 1.40  1.27 0.90    24,000 0.88       39,000
42,000  1.70 138.00 3.00 489 1.70  0.70 0.20  0.0 12.00 87,000 1.71        
67,000  1.40 139.00 3.20 776 1.60     0.0 14.20 139,000 1.76     0.0 13.10 342,000
87,000 238.00 1.54 138.00 3.00 4,152 1.54     0.0 10.90 68,000 2.25        
99,000  1.31 131.00 3.50 2,397 1.31  3.50 0.40  0.0  318,000 2.55  10.90   0.0  248,000
102,000  1.52 140.00 4.00  1.52                
112,000  2.11 139.00 4.10  2.11  0.52 0.20  0.0 11.00 83,000 1.37     0.0 11.00 317,000
144,000  1.32 135.00 4.10 2,662 1.89 944 3.31 0.20  0.0 10.40  1.73      9.50  
139,000  1.55 145.00 3.50  1.58                
138,000 169.40 1.96 147.00 3.70 1,546 1.96 1,011 0.80 0.30  0.0 12.10 61,000 1.84     0.0 11.70 54,000
137,000 67.20 1.61 136.00 3.90 610 2.50  2.70 0.30  0.0 11.50 122,000 1.57     0.0 11.50 83,000
134,000 152.60 1.47 141.00 3.00                  
133,000 0.00 1.29 134.00 2.90 681 1.29  1.30 0.20  0.0 10.90 78,000 1.17 2,060    0.0 11.20 71,000
129,000  1.89 139.00 4.20 541 1.44 824               
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creatd3 ldhd3 tbd3 dbd3 retd3 schzd4 hbd4 pltd4 creatd4 ldhd4 tbd4 dbd4 retd4 schzd5 hbd5 pltd5 creatd5 ldhd5 tbd5 dbd5 retd5 schzd6 hbd6 pltd6
                        
                        
1.12 960 1.96 0.80  0.0 10.10 160,000 1.05 850 2.12 0.60  0.0 11.20 380,000 1.04 480 1.82 0.60  0.0 13.30 282,000
                        
                        
1.45 960 1.22 0.28  0.0 12.80 110,000 1.06 960 1.00 0.50  0.0 11.30 101,000 1.04 940 1.00 0.56  0.0 11.60 136,000
0.91 480 0.86 0.24  0.0 12.30 260,000 0.80 410 0.75 0.24             
0.96 731 0.52 0.24  0.0 11.30 56,000 0.80 640 0.50 0.20  0.0 11.90 78,000 0.77 560 0.56 0.24  0.0 12.60 124,000
                        
                        
                        
                        
                        
                        
0.51     0.0 11.40 169,000 0.51     0.0 11.50 181,000 0.62        
0.89      14.20  1.08                
0.53      6.70 53,000 0.52      6.90 71,000 0.57      7.00 116,000
                        
                        
                        
                        
                        
                        
0.66     0.0 11.90 437,000 0.60                
1.36                        
                        
                        
                        
                        
                        
1.08   11.00 1.09   369,000 0.89                
                        
0.51                        
0.84                        
0.94 0    0.0 9.00 262,000 1.36                
                        
0.65                        
                        
0.55     0.0 8.40 33,000 0.55     0.0 8.20 66,000 0.43     0.0 9.10 133,000
                        
                        
1.00                        
                        
      11.60       0.0 12.00 90,000 0.50        
                        
                        
                        
                        
                        
0.74                        
0.80                        
0.58     0.0  145,000 0.62     0.0   0.93  0.50 0.20  0.0 12.40 146,000
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
5.54 3,810 2.10 0.76  0.0 9.50 72,000 5.99 3,100 1.27 0.54  0.0 8.20 108,000 5.81 2,680 0.80 0.50  0.0 8.10 112,000
0.81 1,385 7.80 0.40   11.60 154,000 0.71 1,042 2.60 0.40             
                        
0.66  1.80 0.50                     
1.09                        
1.09 782 0.50 0.25                     
0.67     0.0 10.60 44,000 0.69  0.42 0.20             
0.50        0.49     0.2 14.20 385,000 0.65  2.00 0.40     
                        
3.02 4,865 0.75 0.20  1.2 8.30 33,000 4.42 4,685 0.76 0.24  1.0 7.20 30,000 3.16 4,480 0.80 0.50  1.0 8.30 77,000
3.39 2,331 1.90 0.86  2.0 7.30 36,000 3.59 2,110 1.30 0.76  1.4 6.50 31,000 5.02 1,798 0.92 0.36  1.0 7.30 66,000
3.51 2,006 3.19 0.54  1.8 8.10 30,000 3.81 1,476 3.18 0.34  6.0 10.20 34,000 3.28 1,278 3.00 0.32  3.5 6.80 75,000
1.23 960 2.26 0.75  0.0 13.50 110,000 0.83 860 1.70 0.30             
10.76 1,210 1.00 0.50  1.0 11.50 225,000 11.10 982    0.8 11.20 256,000 12.65 980 0.52 0.24  0.8 10.50 310,000
7.40 6,832 2.10 0.74  2.0 7.40 17,000 7.75 5,830 1.02 0.69  3.0 6.50 170,000 7.09 4,320 0.90 0.20  4.0 8.60 27,000
4.99 3,014 1.20 0.50  1.0 8.60 11,000 4.97 1,784 1.00 0.60  0.8 7.10 19,000 5.66 1,320 1.00 0.50  1.2 8.60 46,000
5.90 9,541 1.76 0.42  6.0 6.50 33,000 5.52 7,360 1.46 0.50  4.0 7.90 53,000 7.53 4,564 1.24 0.56  3.2 7.30 20,000
3.26 5,737 2.83 1.60  2.0 10.10 41,000 4.19     2.0 9.30 7,000 3.79     5.0 8.30 16,000
3.43      7.90 77,000 5.94       120,000 6.26        
4.36        3.08                
7.36 2,280    2.0 7.90 25,000 4.55 1,155    2.0 7.00 48,000 3.95 1,239    1.0 6.20 64,000
2.93     2.0 8.70 43,000 3.81 2,498 3.50 1.00  2.0 7.20 32,000 5.60 2,978    1.0 7.00 37,000
6.23 2,144    1.0 7.70 4,000 3.69 1,476    1.2 6.90 8,000 3.82 1,428    0.0 6.80 12,000
5.57 1,023    1.0 8.10 148,000 6.50 1,041 0.50 0.10  0.0 8.60 253,000 7.47     0.0 8.10 234,000
                        
0.94     0.2 11.40 51,000 0.68     0.0 13.40 91,000 0.48        
1.65     1.0 8.10 219,000 1.42     0.0 9.80 220,000 1.19        
3.11 1,644 0.70 0.10  0.8 8.50 26,000 5.43 1,623 0.60 0.30  1.0 7.90 13,000 6.44 1,502 0.60 0.30  1.2 8.30 25,000
5.25     0.0 10.80 144,000 6.23        6.56        
8.98 2,279 1.00 0.40  1.0 8.40 23,000 6.76 2,218 1.00 0.40  2.0 8.40 23,000 8.98     0.8 7.40 36,000
5.84 980    1.8 10.20 35,000 4.07 988    1.0 10.40 56,000 8.28     2.0 10.00 94,000
3.43     2.2 7.90 77,000 4.69     3.0 8.30 121,000 5.94     3.0 8.30 312,000
4.19 4,310 2.82 1.00 3.79 5.0 10.10 7,000 5.47 3,401    4.0 8.30 16,000 3.28 2,702 2.70 1.80  4.0 8.10 13,000
3.36     0.5 8.00 45,500 3.36     0.0 8.20 55,000 6.64     0.0 6.90 40,000
6.50     0.8 6.40 18,000 8.69     0.4 6.10 35,000 9.66 2,976 1.60 0.80  0.0 5.60 50,000
5.64     3.0 7.00 86,000 7.09 2,234    3.0 6.60 92,000 6.43     4.0 6.10 124,000
5.57     0.0 10.70 66,000 7.25 980    0.0 10.00 107,000 7.80     0.0 10.00 173,000
0.89                        
6.10 3,142    1.0 8.80 30,000 6.08 2,428 2.80 2.20  0.8 8.40 33,000 6.94 1,634    1.0 6.00 58,000
6.57 1,570    0.0 13.60 59,000 7.42     0.0 13.60 127,000 8.13     0.0  169,000
1.45                        
0.61       67,000 0.99                
0.69                        
1.51                        
                        
3.87     0.0 10.20 290,000 4.02 1,520    0.0 9.80 292,000 3.81      11.00  
                        
1.03                        
1.33 961 0.40 0.20   12.20  0.91                
                        
1.21     0.0 12.40 73,000 1.00     0.0 12.21 103,000 0.86      13.20 163,000
1.32     0.0 11.60 87,000 1.30                
                        
1.65                        
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creatd6 ldhd6 tbd6 dbd6 retd6 schzd7 hbd7 pltd7 creatd7 ldhd7 tbd7 dbd7 retd7 schzd8 hbd8 pltd8 creatd8 ldhd8 tbd8 dbd8 retd8 schzd9 hbd9 pltd9
                        
                        
1.13 460 1.02 0.50                     
                        
                        
0.89 826 0.90 0.60  0.0 11.20 210,000 0.90 761 0.80 0.24  0.0 10.20 202,000 0.76 680 0.82 0.32     
                        
0.76 482 0.50 0.20                     
                        
                        
                        
                        
                        
                        
                        
                        
       216,000 0.68                
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
0.40      9.80 269,000 0.40                
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
0.83                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
6.02 1,898 0.45 0.34  0.0 7.80 110,000 9.32 1,489 0.45 0.34  0.0 7.80 176,000 8.26 0 0.32 0.12     
                        
                        
                        
                        
                        
                        
     0.0 14.00 320,000 0.70  1.90 0.40     0.76     0.0 14.70  
                        
5.39 4,572 0.76 0.26  1.0 6.90 77,000 4.10 2,100 0.82 0.34  0.2 7.00 155,000 6.12 2,120 0.81 0.26  0.0 6.50 190,000
4.49 1,477 0.86 0.50  2.0 7.80 108,000 5.54 1,467 0.92 0.50  1.2 8.50 142,000 2.95 1,271 0.76 0.24  0.1 9.10 242,000
2.58 810 2.30 0.24  0.8 6.60 189,000 1.64 481 1.60 0.20  2.5 6.60 210,000 1.38 649 1.00 0.20  2.0 6.60 193,000
                        
10.94 813    0.0 10.40 381,000 6.99 740 0.46 0.24  0.0 10.40  2.06 462       
7.25 1,810 0.75 0.25  1.2 8.30 184,000 8.41 1,740 0.54 0.39  1.0 7.40 292,000 6.89 1,161 0.70 0.25  0.0 7.20 483,000
5.70 675 0.90 0.50  0.6 7.60 86,000 7.35 680 0.80 0.40  0.2 7.80 132,000 10.57 779 0.60 0.32  0.2 8.20 194,000
9.50 3,462 1.49 0.50  5.0 6.70 55,000 9.90     4.0 6.10 102,000 13.10 2,714 1.25 0.50  4.0 7.30 138,000
5.47     4.0 7.80 13,000 3.28  2.70 1.80  4.0 8.10 18,000 4.02        
6.44      8.30 312,000 6.44     3.0 9.60  6.29      9.70  
                        
4.14 980      90,000 3.14                
6.40 2,989 1.90 1.10  1.0 8.00 54,000 7.65 2,322    0.0 7.00 94,000 7.59 2,223    0.0 6.30 118,000
2.87 1,699    0.8 7.90 21,000 8.98 1,051    1.0 6.70 32,000 5.70 1,051    0.0 5.90 48,000
5.60     0.0 8.60 310,000 5.14     0.0 8.90 323,000 3.61     0.0 8.50  
                        
                        
                        
7.86 1,422    1.0 10.50 31,000 3.87     0.8 10.50 15,000 4.35 1,625 5.20 2.70  1.0 9.10 8,000
6.90        6.08        5.71        
8.35     0.0 6.60 78,000 11.11     0.0 7.20 116,000 8.50     0.0 7.60 142,000
10.70     0.8 10.20 301,100 11.20                
6.26     3.0 9.60 311,000 5.80     2.2 9.70  6.29     3.0 9.10  
4.02     4.0 8.10 18,000 4.02                
8.22     0.0 5.50 109,000 5.94     0.0 8.00 121,000 8.12     0.0 7.70 151,000
5.39 2,380    0.0 7.00 88,600 4.90 1,290    0.0 6.60 130,000 5.23     0.0 6.50 142,000
7.95  0.57 0.34  1.0 10.30 154,000 7.96     0.8 9.50 231,000 9.43     0.0 9.10 242,000
7.33 708                       
                        
7.50     0.0 7.40 179,000 8.30     0.0   10.36     0.0   
6.21      16.00 169,000 4.99        3.20        
                        
                        
                        
                        
                        
3.72                        
                        
                        
                        
                        
0.87  0.70 0.40                     
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creatd9 ldhd9 tbd9 dbd9 retd9 schzd10 hbd10 pltd10 creatd10 ldhd10 tbd10 dbd10 retd10 schzd11 hbd11 pltd11 creatd11 ldhd11 tbd11 dbd11 retd11 schzd12
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
0.71  0.70 0.40                   
                      
4.15 2,715 0.76 0.28  0.0 6.80 203,000 3.17 2,384 0.72 0.24  0.0 7.00 261,000 5.05 1,892 0.72 0.24  0.0
3.15 1,113 0.50 0.24  1.0 7.90 263,000 6.56 948 0.50 0.26  1.0 8.50 332,000 5.27 642 0.52 0.24  0.0
1.36 660    4.0 6.70 193,000 1.03 690             
                      
                      
8.24 1,142    0.0 6.60 692,000 5.24 1,112    0.0 6.80 690,000 6.28 1,106    0.0
7.58 786 0.37 0.19  0.2 9.00 176,000 10.55 726 0.30 0.10           
14.26     3.0 7.90 298,000 11.60 2,128 1.00 0.50  4.0 7.30 371,000 7.50     2.0
                      
5.28        5.40        3.43      
                      
                      
7.69 1,594    0.0 8.50 173,000 7.69 1,176    0.0 9.30 207,000 7.13     0.0
7.05     1.0 8.50 85,000 7.05     0.0 7.20 237,000 6.22     0.0
2.67  0.20 0.10                   
                      
                      
                      
3.12     1.0 7.70 32,000 2.25     0.0 7.70 32,000 2.21     0.0
                      
7.40  1.00 0.40  0.0 7.60 200,000 7.33     0.0 8.60 228,000 6.81     0.0
                      
5.40        3.43        3.09      
                      
7.74                      
7.11 560    0.0 6.60 182,000 8.85     0.0 6.80 242,000 10.31     0.0
7.25     0.0 10.00 264,000 8.35     0.0 10.10 291,000 6.94     0.0
                      
                      
9.59     0.0   6.92              
1.57                      
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hbd12 pltd12 creatd12 ldhd12 tbd12 dbd12 retd12 lrd1 cnsd1 renald1 coagd1 lrd2 cnsd2 renald2 coagd2 lrd3 cnsd3 renald3 coagd3 lrd4 cnsd4 renald4 coagd4
       1 2 2 1 1 2 2 2         
       1 1 2 1 1 1 2 2         
       1 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2
       1 2 2 1 1 2 2 1         
       1 1 2 1 1 1 2 2         
       2 1 1 2 2 1 1 2 2 1 1 2 2 1 2 2
       1 2 2 1 1 2 2 2 1 2 2 2 1 2 2 2
       1 2 2 1 1 2 2 2 1 2 2 2 1 2 2 2
       1 1 2 1             
       1 1 2 1             
       1 1 2 1 1 1 2 1         
       1 2 2 1 1 2 2 2         
       1 1 2 1             
       1 1 2 1             
       1 1 2 1 1 1 2 1 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 2 1 1 2 2 2         
       1 2 2 1 1 2 2 2         
                       
       1 2 2 2 2 2 2 2         
                       
       1 1 2 2 1 1 2 2         
       1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1             
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 2 2 1 1 2 2 2 1 2 2 2     
       1 2 2 1 1 2 2 2         
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 2 1 1 2 2 2         
       1 2 2 1 1 2 2 2 1 2 2 2 1 2 2 2
       1 1 2 1 1 1 2 2 1 1 2 2     
       2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2 1 2 2 2
       1 2 2 1 1 2 2 2         
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 2 1 1 2 2 2 1 2 2 2     
       1 2 2 1 2 2 2 2         
       1 2 2 1 1 2 2 2 1 2 2 2     
       1 2 2 1 1 2 2 2         
       1 2 2 1 1 2 2 2 1 2 2 2     
       1 2 2 1 1 2 2 2         
       1 2 2 1             
       1 1 2 1 1 1 2 2         
       1 2 2 1 1 2 2 2 2 2 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 2 1 1 2 2 2         
       1 2 2 1             
       1 2 2 1             
       1 2 2 1 2 2 2 1         
       1 1 2 1 1 1 2 2         
       1 2 2 1 1 2 2 1 1 2 2 2     
       1 2 2 1 1 2 2 1         
       1 2 2 1             
       1 2 2 1 1 2 2 2         
       1 2 2 1 1 2 2 2         
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 2 1 1 2 2 2         
       1 2 2 1 1 2 2 2         
       1 1 2 1 1 1 2 2 1 1 2 2     
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 2 1 1 1 2 2 1 1 2 2 2 2 2 2
       2 2 2 1 2 2 2 2 2 2 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2 1 2 2 2
       1 1 1 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 1 2 1 2 2 2 1 2 2 2     
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 2 1 1 1 2 2 1 1 2 2     
6.50 318,000 7.27 1,613 0.70 0.25  1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2
9.10 445,000 7.26 480 0.52 0.24  1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
       1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
       1 1 1 1 1 1 1 2 1 1 2 2 1 1 2 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
6.50 623,000 7.39 927    1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2
       1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
8.60 483,000 7.95 1,273 0.40 0.22  1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2
       1 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2
  3.09     1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 2 1 1 2 2 1 1 2 2 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
8.70 215,000 6.12 986 0.60 0.50  1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
8.20 323,000 3.43     1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2         
       1 1 1 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 2 2
7.10 89,000 3.31     1 1 1 1 1 1 1 2  1 1 2 1 1 1 2
       2 2 1 1 2 2 1 1 2 2 1 2 2 2 1 2
8.60 367,000 4.48     1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
6.90 284,000 8.87     1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
10.20 320,000 3.66     1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2
       1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 2 1 1 1 2 1 2 2 2 1 2
       1 1 1 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 1 1 1 1 1 2 2 1 1 2 2 1 1 2 2
       1 2 1 1 1 2 1 2 1 2 2 2 1 2 2 2
       1 1 1 2 1 1 1 2 1 1 1 2     
       1 1 1 1 1 1 1 2         
       1 1 1 1 1 1 1 2 1 1 1 2 1 2 1 2
       2 2 2 1 2 2 2 2         
       2 2 2 1 2 2 2 2 2 2 2 2     
       1 2 1 1 1 2 1 2 1 2 2 2     
       1 2 1 1 1 2 2 2         
       1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2
       1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 2
       1 2 1 1 1 2 2 2         
       1 1 2 1 1 1 1 1 1 1 1 1     
       1 2 1 1 1 2 2 2         
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lrd5 cnsd5 renald5 coagd5 lrd6 cnsd6 renald6 coagd6 ldr7 cnsd7 renald7 coagd7 lrd8 cnsd8 renald8 coagd8 lrd9 cnsd9 renald9 coagd9 lrd10 cnsd10 renald10
                       
                       
2 2 2 2 2 2 2 2                
                       
                       
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2        
                       
1 2 2 2                    
                       
                       
                       
                       
                       
                       
1 1 2 2 1 1 2 2 1 2 2 2 2 2 2 2        
                       
1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2        
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
1 1 2 2                    
                       
                       
                       
                       
                       
                       
                       
1 1 2 2 1 1 2 2 1 2 2 2 2 2 2 2        
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
1 2 2 2 1 2 2 2                
1 2 2 2 1 2 2 2 2 2 2 2            
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
1 1 1 2 2 1 1 2 2 2 1 2 2 2 1 2        
                       
                       
                       
                       
                       
1 2 2 2 2 2 2 2                
1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2    
                       
1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 2
                       
1 1 1 2 1 2 1 2 2 2 1 2 2 2 1 2        
1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1
2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2        
1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
                       
1 1 1 2 1 2 1 2 2 2 1 2            
1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2    
                       
1 2 2 2 1 2 2 2                
1 1 2 2                    
1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 2 2 1
2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 2 1 1 2 2 2 1 2            
1 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2        
1 1 1 2 1 1 1 2 1 1 1 2 1 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 1
1 2 1 2 1 2 1 2                
2 2 2 2                    
1 1 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1
2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 1 2    
                       
                       
                       
                       
                       
1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2        
                       
                       
                       
                       
1 1 1 2 1 2 1 2 1 2 1 2 2 2 1 2 2 2 1 2    
1 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2        
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coagd10 lrd11 cnsd11 renald11 coagd11 lrd12 cnsd12 renald12 coagd12 TMA envensynd snake trans VICC cyro FFP PRC prbc Dialysis Plasmap stay ICUd outcome ASVTotal
         1 3 1 2 1     2 2 2 0 1 10.00
         1 5 1 2 1     2 2 2 0 1 14.00
         1 7 2 2 1  2   2 2 6 2 1 20.00
         1 3 1 2 1     2 2 2 0 1 10.00
         1 5 1 2 1     2 2 2 0 1 14.00
         1 5 1 2 1     2 2 8 3 1 20.00
         1 3 1 2 1     2 2 4 0 1 16.00
         1 3 1 2 1     2 2 5 0 1 20.00
         1 5 1 1 1 0 4 0 0 2 2 2 0 1 26.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 10.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 28.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 9.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 18.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 27.00
         1 5 1 2 1 0 0 0 0 2 2 7 0 1 24.00
         1 5 1 2 2 0 0 0 0 2 2 4 0 1 20.00
         1 5 1 2 1 0 0 0 0 2 2 8 0 1 70.00
         1 2 1 2 1 0 0 0 0 2 2 2 0 1 24.00
         1 2 1 2 1 0 0 0 0 2 2 2 0 1 12.00
         1 5 1 1 1 6 4 0 0 2 2 4 0 1 20.00
         1 5 1 2 2 0 0 0 0 2 2 2 0 1 14.00
         1 5 1 2 1 0 0 0 0 2 2 1 0 1 14.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 24.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 18.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 10.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 12.00
         1 5 1 2 1 0 0 0 0 2 2 3 0 1 18.00
         1 5 1 2 2 0 0 0 0 2 2 3 0 1 18.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 10.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 17.00
         1 5 1 2 1 0 0 0 0 2 2 5 0 1 24.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 12.00
         1 3 1 2 1 0 0 0 0 2 2 4 0 1 20.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 12.00
         1 5 1 2 1 0 0 0 0 2 2 4 1 1 15.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 18.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 20.00
         1 2 1 2 1 0 0 0 0 2 2 2 0 1 18.00
         1 5 1 2 2 0 0 0 0 2 2 8 2 1 18.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 8.00
         1 7 2 2 1 0 0 0 0 2 2 2 0 1 24.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 10.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 12.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 12.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 17.00
         1 3 1 2 1 0 0 0 0 2 2 1 0 1 6.00
         1 5 1 2 1 0 0 0 0 2 2 2 0 1 12.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 10.00
         1 5 1 2 1 0 0 0 0 2 2 3 0 1 10.00
         1 5 1 2 1 0 0 0 0 2 2 3 0 1 16.00
         1 5 1 2 1 0 0 0 0 2 2 6 0 1 18.00
         1 5 1 2 1 0 0 0 0 2 2 6 2 1 10.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 10.00
         1 3 1 2 2 0 0 0 0 2 2 1 0 1 10.00
         1 3 1 2 1 0 0 0 0 2 2 1 0 1 15.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 10.00
         1 6 1 2 1 0 0 0 0 2 2 2 0 3 12.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 20.00
         1 3 1 2 1 0 0 0 0 2 2 1 0 1 13.00
         1 3 1 2 2 0 0 0 0 2 2 1 0 3 12.00
         1 3 1 2 1 0 0 0 0 2 2 3 0 1 21.00
         1 3 1 2 1 0 0 0 0 2 2 1 0 1 10.00
         1 5 1 2 1 0 0 0 0 2 2 4 0 1 14.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 10.00
         1 3 1 2 1 0 0 0 0 2 2 2 0 1 21.00
         2 5 1 2 2     2 2 3 0 1 20.00
         2 6 1 2 1     2 2 9 0 1 25.00
         2 5 1 2 1 0 0 0 0 2 2 4 0 1 17.00
         2 7 2 2 1 0 0 0 0 2 2 3 0 1 10.00
         2 5 1 2 1 0 0 0 0 2 2 4 0 1 26.00
         2 5 1 2 1 0 0 0 0 2 2 4 0 1 16.00
         3 3 1 2 1     2 2 3 0 1 10.00
         3 5 1 2 1 0 0 0 0 2 2 6 0 1 26.00
         3 5 1 2 1 0 0 0 0 2 2 9 0 1 22.00
         3 5 1 2 1 0 0 0 0 2 2 3 0 1 20.00
2 2 2 1 2 2 2 1 2 4 4 1 1 2  2  2 1 2 12 2 1 20.00
2 2 2 1 2 2 2 1 2 4 4 1 2 2 2  2 1 1 2 12 0 1 18.00
2         4 4 1 1 2  2 2  1 1 10 4 1 26.00
         4 5 1 2 1     2 2 4 2 1 12.00
         4 5 1 1 2  4   2 2 12 3 1 40.00
2 2 2 1 2 2 2 1 2 4 4 1 1 1 16   2 1 1 12 0 1 20.00
2         4 6 1 1 2 40    1 1 14 0 1 0.00
2 1 2 1 2 1 2 1 2 4 6 1 1 2    4 1 2 26 7 1 10.00
         4 4 1 1 1 24 12 12 4 1 2 9 5 2 20.00
2 2 2 1 2 2 2 1 2 4 5 1 2 2 0 0 0 0 1 2 12 2 1 16.00
         4 5 1 2 1 0 0 0 0 2 2 4 0 3 6.00
         4 5 1 1 1 24 0 0 0 1 1 8 0 1 26.00
2 2 2 1 2 2 2 1 2 4 6 1 1 1 0 0 0 8 1 2 13 0 1 26.00
2 2 2 1 2 2 2 1 2 4 6 1 1 1 0 8 10 4 1 2 14 0 1 30.00
         4 6 1 1 1 0 0 0 4 2 2 9 0 1 10.00
         4 6 1 1 1 8 0 9 0 2 2 2 0 3 24.00
         4 5 1 2 2 0 0 0 0 2 2 6 2 2 47.00
         4 6 1 1 1 8 0 0 0 2 2 5 0 1 20.00
2 2 2 1 2 2 2 1 2 4 6 1 1 2 0 0 0 0 1 2 16 3 1 20.00
2 2 2 1 2 2 2 1 2 4 4 1 2 1 0 0 0 0 1 2 12 0 1 20.00
2 2 2 1 2 2 2 1 2 4 6 1 1 1 0 12 0 4 1 2 16 2 1 15.00
         4 6 1 2 2 0 0 0 0 1 2 8 0 3 16.00
2 2 2 1 2     4 6 1 2 2 0 0 0 0 1 2 12 0 1 16.00
         4 6 1 1 2 20 12 40 10 1 1 9 9 2 20.00
2         4 6 1 1 1 0 8 0 0 1 2 12 4 1 21.00
2 2 2 1 2 2 2 1 2 4 6 1 1 1 6 8 0 3 1 1 27 0 1 14.00
2 2 2 1 2 2 2 1 2 4 6 1 1 1 0 0 0 2 1 2 12 0 1 29.00
         4 6 1 2 2 0 0 0 0 1 2 7 0 1 19.00
         4 6 1 2 2 0 0 0 0 2 2 4 0 1 72.00
2 1 2 1 2 1 2 1 2 4 6 1 1 1 6 4 0 2 1 2 20 10 1 16.00
         5 5 1 2 1 0 0 0 0 2 2 9 0 1 16.00
         5 5 1 2 1 0 0 0 0 2 2 4 0 1 10.00
         5 5 1 2 1 0 0 0 0 2 2 4 0 1 25.00
         5 3 1 2 1 0 0 0 0 2 2 3 0 1 24.00
         5 6 1 2 2 0 0 0 0 2 2 3 0 1 13.00
         5 5 1 2 1 0 0 0 0 2 2 2 0 2 24.00
         5 5 1 2 1 0 0 0 0 2 2 8 0 1 10.00
         5 7 1 2 1 0 0 0 0 2 2 2 0 1 8.00
         5 7 2 2 1 0 0 0 0 2 2 2 0 1 20.00
         5 4 1 2 1 0 0 0 0 2 2 4 0 1 18.00
         5 4 1 2 1 0 0 0 0 2 2 2 0 1 8.00
         5 6 1 2 2 0 0 0 0 2 2 8 4 1 26.00
         5 6 1 1 1 8 5 0 0 1 2 5 2 1 16.00
         5 3 1 2 1 0 0 0 0 2 2 2 0 1 20.00
         5 6 1 1 1 6 4 0 0 2 2 2 2 2 10.00
         5 4 1 2 1 0 0 0 0 2 2 2 0 1 18.00
  151 
ANNEXURE 6: Additional Tables 
Table 17 Snake Envenomation correlation with TMA spectrum 
 
 
Envenomation 
Syndrome 
TMA Spectrum(Prospective n=19, Retrospective n=102, Total n=121) 
Thrombocytopenia  
only 
 
Thrombocytopenia + 
MAHA  
 
Thrombocytopenia + 
MAHA + Schistocytes  
 
Thrombocytopenia + 
MAHA + Schistocytes 
+End Organ Damage 
 
Thrombocytopenia 
+ End Organ Damage 
 
 
P(n=6) 
n(%) 
R(n=57) 
n(%) 
T(n=63) 
n(%) 
P(n=1) 
n(%) 
R(n=4) 
n(%) 
T(n=5) 
n(%) 
P(n=1) 
n(%) 
 
R(n=3) 
n(%) 
T(n=4) 
n(%) 
P(n=8) 
n(%) 
 
R(n=22) 
n(%) 
T(n=30) 
n(%) 
P(n=3) 
n(%) 
 
R(n=16) 
n(%) 
T(n=19) 
n(%) 
Local Reaction + 
Hemotoxicity 
 
 
Pure Hemotoxicity 
 
3(50) 
 
 
 
1(16.7) 
 
25(43.9) 
 
 
 
1(1.8) 
 
28(44.5) 
 
 
 
2(3.2) 
 
- 
 
 
 
- 
 
- 
 
 
 
1(25) 
 
- 
 
 
 
1(20) 
 
1(100) 
 
 
 
- 
 
- 
 
 
 
- 
 
1(25) 
 
 
 
- 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
1(33.3) 
 
 
 
- 
 
2(12.5) 
 
 
 
2(12.5) 
 
3(15.8) 
 
 
 
2(10.5) 
 
 
Hemotoxicity + AKI 
 
 
Hemotoxicity + 
Neurotoxicity 
 
 
 
Hemotoxicity + 
Neurotoxicity + 
AKI 
 
 
 
- 
 
 
 
2(33.3) 
 
 
 
- 
 
 
 
 
- 
 
 
 
30(52.6) 
 
 
 
1(1.8) 
 
 
 
 
- 
 
 
 
32(50.8) 
 
 
 
1(1.6) 
 
 
 
 
- 
 
 
 
1(100) 
 
 
 
- 
 
 
 
 
- 
 
 
 
3(75) 
 
 
 
- 
 
 
 
 
- 
 
 
 
4(80) 
 
 
 
- 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 
- 
 
 
 
3(100) 
 
 
 
- 
 
 
 
 
- 
 
 
 
3(75) 
 
 
 
- 
 
 
 
 
4(50) 
 
 
 
2(25) 
 
 
 
2(25) 
 
 
 
 
2(9.1) 
 
 
 
4(18.2) 
 
 
 
16(72.7) 
 
 
 
 
6(20) 
 
 
 
6(20) 
 
 
 
18(60) 
 
 
 
 
- 
 
 
 
1(33.3) 
 
 
 
1(33.3) 
 
 
 
 
3(18.8) 
 
 
 
5(31.3) 
 
 
 
4(25.0) 
 
 
 
 
3(15.8) 
 
 
 
6(31.6) 
 
 
 
5(26.3) 
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ANNEXURE 7: Abstract 
 
OBJECTIVES: 
The study was conducted to determine the prevalence of thrombotic 
microangiopathy in snakebites and to describe the clinical profile of these 
patients, with relation to the envenomation syndrome and venom induced 
consumption coagulopathy(VICC). 
 
METHODS: 
This study was an observational cohort, consisting of a prospective cohort 
(Recruited from June 2017 to July 2018) and a retrospective cohort (April 2012 
to March 2017). All patients above the age of 18 years, presenting with a 
hemotoxic snake bite, with a platelet count <1,50,000/cumm were recruited. 
Patients were observed both clinically and with appropriate investigations daily 
till discharge. Additional information for analysis was obtained from the clinical 
workstation.  Descriptive statistics such as mean, standard deviation were 
analysed using Kruskal Wallis test across TMA spectrum and lab investigations 
and outcomes. Categorical variables like envenomation syndrome, Fisher’s exact 
test was used.  
 
RESULTS: 
TMA is a spectrum disorder that ranges from isolated Thrombocytopenia, 
thrombocytopenia with MAHA, and Thrombocytopenia, MAHA and renal 
failure(full spectrum TMA disorder).  Prevalence of TMA spectrum was 51.35% 
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and full spectrum TMA disorder was 21.6% in the prospective cohort. Majority of 
hemotoxic snakebites had a Russell’s viper like envenomation syndrome 
(69.4%). More importantly all the patients (30 subjects) who had full spectrum 
TMA had a Russell’s viper like envenomation syndrome. Majority of hemotoxic 
snakebites presented with VICC (81%). Patient group who did not have VICC, but 
presented with Thrombocytopenia (19%). 
Treatment outcomes were  noted to be worse in the TMA spectrum with renal 
failure, requiring higher doses of ASV with longer hospital/ICU stay, and with 
73.3% of these patients requiring dialysis. Hence it is clear that patients who 
developed a TMA full spectrum disorder have a more severe illness with worse 
outcomes. 
 
 
